CLINICAL STUDY PROTOCOL
Study Title: A Phase 2, Randomized, Double -Blind, Multicenter Study Evaluating the 
Safety and Efficacy of Filgotinib and GS-9876 in Subjects with Lupus 
Membranous Nephropathy (LMN)
Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
IND Number : 123903
EudraCT Number: Not Applicable
Clinical Trials.gov 
Identifier:[STUDY_ID_REMOVED]
Indication: Lupus Membranous Nephropathy
Protocol ID: GS-US-437-4093
Gilead Clinical Program 
Manager:Name:
Telephone:
Fax:
Email:
Gilead Medical Monitor :Name:
Telephone:
Fax:
Mobile :
Email:
Protocol Version/Date: Original: 09March 2017
Amendment 1: 05 July 2017
Amendment 2: 21March 2018
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly unpublished data, is the property or under 
control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential 
investigator, or consultant, for review by you, your staff, and an applicable Institution al Review Board or 
Independent Ethics Committee. The information is only to be used by you in connection with authorized 
clinical studies of the investigational drug described in the protocol. You will not disclose any of the 
information to others without written authorization from Gilead Sciences, Inc., except to the extent 
necessary to obtain informed consent from those persons to whom the drug may be administered.
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD(rJ GILEAiJ 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 2 21 March 2018TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................................................
........................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 18
1. INTRODUCTION .............................................................................................................................................. 21
1.1. Background ............................................................................................................................................ 21
1.2. Filgotinib ................................................................................................................................................ 23
1.2.1. General Information ............................................................................................................. 23
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 23
1.2.3. Clinical Trials of Filgotinib .................................................................................................. 24
1.3. GS-9876 ................................................................................................................................................. 24
1.3.1. Nonclinical Pharmacology and Toxicology ......................................................................... 24
1.3.2. Clinical Trials of GS -9876 ................................................................................................... 27
1.4. Rationale for This Study ........................................................................................................................ 28
1.4.1. Rationale for Endpoint and Timing ...................................................................................... 29
1.4.2. Rationale for Dose ................................................................................................................ 29
1.5. Risk/Benefit Assessment for the Study .................................................................................................. 30
1.6. Com pliance ............................................................................................................................................ 31
2. OBJECTIVES ..................................................................................................................................................... 32
3. STUDY DESIGN ................................
................................................................................................................ 33
3.1. Endpoints ............................................................................................................................................... 33
3.2. Study Design .......................................................................................................................................... 34
3.3. Study Treatments ................................................................................................................................... 35
3.4. Durat ion of Treatment ............................................................................................................................ 36
3.5. Discontinuation Criteria ......................................................................................................................... 36
3.5.1. Study Drug Interruption Considerations ............................................................................... 36
3.5.2. Study Drug Discontinuation Criteria .................................................................................... 37
3.6. End of Study ........................................................................................................................................... 39
3.7. Post Study Care ...................................................................................................................................... 39
3.8. Biomarker Testing .................................................................................................................................. 39
3.8.1. Biomarker Samples to Address the Study Objectives .......................................................... 39
4. SUBJECT POPULATION .................................................................................................................................. 42
4.1. Number of Subjects and Subject Selection ............................................................................................ 42
4.2. Inclusion Criteria .................................................................................................................................... 42
4.3. Exclusion Criteria ................................................................................................................................... 44
4.4. Screen Failures ....................................................................................................................................... 47
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 48
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 48
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 48
5.2. Description and Handling of GS -9876, PTM GS -9876, Filgotinib and PTM Filgotinib ....................... 48
5.2.1. Form ulation of GS-9876 and PTM GS -9876 ....................................................................... 48
5.2.2. Form ulation of Filgotinib and PTM Filgotinib ..................................................................... 49
5.2.3. Packaging and Labeling of Study Drugs .............................................................................. 49
5.2.4. Storage and Handling of Study Drugs .................................................................................. 49
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 3 21 March 20185.2.5. Dosage and Administration of GS -9876 .............................................................................. 50
5.2.6. Dosage and Administration of Filgotinib ............................................................................. 50
5.3. Prior and Concomitant Medications ....................................................................................................... 50
5.3.1. Allowed Concomitant Medications ...................................................................................... 51
5.3.2. Prohibited Concomitant Medications ................................................................................... 52
5.4. Vaccine Guidelines ................................................................................................................................ 54
5.5. Accountability for Study Drugs ............................................................................................................. 54
5.5.1. Investigational Medicinal Product Return or Disposal ......................................................... 54
6. STUDY PROCEDURES .................................................................................................................................... 55
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 55
6.2. Pretreatment Assessments ...................................................................................................................... 55
6.2.1. Screening Visit ..................................................................................................................... 55
6.2.2. Day 1 Baseline Assessments ................................................................................................ 57
6.3. Randomization ....................................................................................................................................... 59
6.4. Week 1 Assessments .............................................................................................................................. 59
6.5. Weeks 2 through Week 28 Assessments (excluding Week 16) ............................................................. 59
6.6. Week 16 and Week 32 Assessments ...................................................................................................... 60
6.7. Week 36 through Week 48 Assessments ...............................................................
................................. 62
6.8. Week 52 Assessments ............................................................................................................................ 63
6.9. Early Termination Assessments ............................................................................................................. 64
6.10. Final Foll ow-Up Assessments (4 Weeks Post Treatment) ..................................................................... 65
6.11. Unscheduled Visit (exacerbation of LMN) ............................................................................................ 66
6.12. Study Assessments ................................................................................................................................. 66
6.12.1. Priority of Assessments ........................................................................................................ 66
6.12.2. Efficacy ................................................................................................................................ 66
6.12.3. Safety .................................................................................................................................... 68
6.12.4. Clinical Laboratory Evaluations ........................................................................................... 68
6.12.5. Vital Signs ............................................................................................................................ 68
6.12.6. Physical Examination ........................................................................................................... 68
6.12.7. Other Safety Assessments .................................................................................................... 69
6.13. Pharm acokinetics Assessments .............................................................................................................. 69
6.14. Biomarker Assessments ......................................................................................................................... 69
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 70
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Ev ents................................. 70
7.1.1. Adverse Events ..................................................................................................................... 70
7.1.2. Serious Adverse Events ...............................................................
......................................... 70
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 71
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 71
7.2.2. Assessment of Severity ........................................................................................................ 72
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 72
7.4. Gilead Reporting Requirements ............................................................................................................. 74
7.5. Clinical Laboratory Abnormalities ...............................................................
.......................................... 74
7.6. Toxicity Managem ent............................................................................................................................ 75
7.6.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 75
7.6.2. Grades 3 Laboratory Abnormality or Clinical Event ........................................................... 75
7.6.3. Grades 4 Laboratory Abnormality or Clinical Event ........................................................... 75
7.7. Special Situations Reports ...................................................................................................................... 76
7.7.1. Definitions of Special Situations .......................................................................................... 76
7.7.2. Instructions for Reporting Special Situations ....................................................................... 77
CCI-
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 4 21 March 20188. STATISTICAL CONSIDER ATIONS ................................................................................................................ 79
8.1. Analysis Objectives and Endpoints ........................................................................................................ 79
8.1.1. Analysis Objectives .............................................................................................................. 79
8.1.2. Primary Endpoint ................................................................................................................. 79
8.1.3. Secondary Endpoints ............................................................................................................ 79
8.1.4. Exploratory Endpoints .......................................................................................................... 80
8.1.5. Biomarker Endpoints ............................................................................................................ 81
8.2. Analysis Conventions ............................................................................................................................. 81
8.2.1. Analysis Sets ........................................................................................................................ 81
8.3. Data Handling Conventions ................................................................................................................... 82
8.4. Dem ographic Data and Baseline Char acteristics ................................................................................... 82
8.5. Efficacy Analysis ................................................................................................................................... 82
8.5.1. Primary Analysis .................................................................................................................. 82
8.5.2. Secondary Analyses ............................................................................................................. 82
8.5.3. Exploratory Analyses ........................................................................................................... 83
8.6. Safety Analysis ....................................................................................................................................... 83
8.6.1. Extent of Exposure ............................................................................................................... 83
8.6.2. Adverse Events ..................................................................................................................... 83
8.6.3. Laboratory Evaluations ........................................................................................................ 84
8.6.4. Other Safety Evaluations ...................................................................................................... 84
8.7. Pharm acokinetic Analysis ...................................................................................................................... 84
8.8. Biomarker Analysis ..............................................................................................................................
..84
8.9. Sample Size ............................................................................................................................................ 85
8.10. Data Monitoring Committee ...............................................................
................................................... 85
8.11. Analysis Schedule .................................................................................................................................. 85
9. RESPONSIBILITIES ................................
.......................................................................................................... 86
9.1. Investigator Responsibilities .................................................................................................................. 86
9.1.1. Good Clinical Practice .......................................................................................................... 86
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 86
9.1.3. Informed Consent ................................................................................................................. 86
9.1.4. Confidentiality ...................................................................................................................... 87
9.1.5. Study Files and Retention of Records .................................................................................. 87
9.1.6. Case Report Forms ................................................................
............................................... 88
9.1.7. Investigational Me dicinal Product Accountability and Return ............................................. 89
9.1.8. Inspections ............................................................................................................................ 89
9.1.9. Protocol Compliance ............................................................................................................ 89
9.2. Sponsor Responsibilities ........................................................................................................................ 90
9.2.1. Protocol Modifications ......................................................................................................... 90
9.2.2. Study Report and Publications ............................................................................................. 90
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 90
9.3.1. Payment Reporting ............................................................................................................... 90
9.3.2. Access to Information for Monitoring .................................................................................. 91
9.3.3. Access to Information for Auditing or Inspections .............................................................. 91
9.3.4. Study Discontinuation .......................................................................................................... 91
10. REFERENCES ................................................................................................................................................... 92
11. APPENDICES .................................................................................................................................................... 97
Appendix 1. Investigator Signature Page .................................................................................................... 98
Appendix 2. Study Procedures Table .......................................................................................................... 99
Appendix 3. Management of Clinical and Laboratory Adverse Events .................................................... 104
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 5 21 March 2018Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 .................................. 105
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 106
Appendix 6. Clinical Laboratory Assessment Table ................................................................................. 110
Appendix 7. Safety of Estrogens in Lupus Erythematosus National Assessment trial -based 
Systemic Lupus Erythematosus Disease Activity Index (SELENA -SLEDAI) .................... 111
Appendix 8. British I sles Lupus Activity Group (BILAG) Index ............................................................. 112
Appendix 9. Physician’s Global Assessment of Disease Activity ............................................................ 113
Appendix 10. Patient Global Assessment of Disease Activity .................................................................... 114
Appendix 11. 36- Item Short Form Health Survey ...................................................................................... 115
LIST OF IN -TEXT TABLES
Table 1-1. Margins for GS -9876 Based on Systemic Exposure Relative to the Observed 
Human Exp osure at 30 mg once daily (AUC) ...............................................................
......... 26
Table 5-1. Prohibited Medications ........................................................................................................... 52
Table 7
-1. Grading of Adverse Event Severity ........................................................................................ 72
LIST OF IN -TEXT FIGURES
Figure 3-1. Study Schema ......................................................................................................................... 35
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 6 21 March 2018PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: A Phase 2, Randomized, Double- Blind, Multicenter Study  Evaluating 
the Safet y and Efficacy of Filgotinib and GS -9876 in Subjects with 
Lupus Membranous Nephropathy (LMN)
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:123903
Not Applicable
[STUDY_ID_REMOVED]
Study Centers 
Planned:Approximately  20 centers in North America
Objectives: The primary  objective of this study  is:
To evaluate the efficacy  of filgotinib and GS- 9876 in subjects 
with L MN
The secondary  objectives of this study  are: 
To evaluate the safet y and tolerability  of filgotinib and GS -9876 
in subjects with LMN
To evaluate the pharmacokinetics (PK) of filgotinib and GS-9876 
in subjects with LMN
The exploratory  objectives of this study  are:
 
 
 
CCII 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 7 21 March 2018Study Design: This is a Phase 2, randomized, double -blind, multicenter stud y in 
subjects with L MN. Subjects wi ll be randomized in a 1:1 ratio to 
receive once daily  oral doses of the following study  drugs for 
16weeks:
Arm Study Drugs
Filgotinib (n=16) Filgotinib 200mg + PTM GS-9876
GS-9876 (n=16) GS-9876 30 mg + PTM F ilgotinib
PTM = Placebo to match
Randomization will be stratified b y prior treatment with 
cyclophosphamide. 
Urinary  protein excretion will be determined using 2 methods – two 
consecutive morning voids as well as a 24 -hour urine collection. For 
the Baseline (Day  1) assessment, all 3 urine samples will be collected 
prior to Day  1, with the 24- hour urine collection as close to the Day 1 
visit as possible. At Week 16, the primary  study  endpoint will be 
assessed b y urine protein excretion during a 24 -hour urine collection.
Two consecutive morn ing voids prior to the Week 16 visit will be 
used to determine response for subsequent study treatment. A ll 
subjects who achieve a ≥ 35% reduction in urinary  protein excretion 
(using an average of the urine protein creatinine ratio [ UPCR ]from 
2morning voids) from Baseline (Day  1) will continue to receive their 
assigned blinded study  treatment (filgotinib 20 0 mg + PTM 
GS-9876, or GS -9876 30 mg + PTM f ilgotinib) for an additional 
16weeks. Additional details regarding urine collection procedures 
will be specified in the Laboratory  Manual and Subject Procedures 
Manual .
Subjects who do not achieve a ≥ 35% reduction in urinary  protein 
excretion from Baseline (Day  1) to Week 16 will switch study  
treatment for 16 weeks 
in a blinded fashion (ie, those on filgotinib 
will switch to GS -
9876 + PT M filgotinib, while those on GS -9876 
will switch to filgotinib + PTM GS- 9876). 
After 32 weeks of blinded treatment, those who have 
a ≥ 35% reduction in urinary  protein excretion (using an average of 
the UPCR from 2 morning voids) from Day  1(for subjects who 
remained on the randomized study  treatm ent after Week 16) or from 
Week 16 (for subjects who switched treatment at Week 16) will 
continue their assigned blinded treatment for an additional 20 weeks 
in the Extended Blinded Treatment Phase.  
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 8 21 March 2018Subjects that do not achieve a ≥ 35% reduction in urinary  protein 
excretion from Day  1(for subjects who remained on the randomized 
study  treatment after Week 16) or from Week 16 (for subjects who 
switched treatment at Week 16) to Wee k 32 will be allowed to 
continue whichever study treatment led to the greatest reduction in 
urinary  protein excretion ( from Day  1 to Week 16 on initial study  
treatment or from Week 16 to Week 32 on switched treatment) , or 
either study  treatment per the Inv estigator’s discretion (eg, 
differences in tolerability or other non -renal benefits that support 
overriding the treatment assignment according to reduction in urinary  
protein excretion) during the Extended Blinded Treatment Phase.
All subjects, including those who terminate earl y from the study, will 
be required to complete a Final Follow -Up (FU) visit 4 weeks 
(±5days) after the last dose of study  drug.
RANDOMIZATI ON 
1:1 
(N=32) DAYl 
Baseline Blinded Treatment Phase 
WK16 
1° Endpoi nt WK32 Extended Blinded 
Treatment Phase 
Filgotinib200 mg+ 
PTM GS-9876 
GS-9876 30 mg + 
PTM Filgotinib 
GS-9876 30 mg+ 
PTM Filgotinib GS-9876 30 mg + 
PTM Filgotinib 
Filgotinib200 mg+ 
PTMGS-9876 
' T 'f 
WK 16: Subjects w ith a ~ 3556 reduction in WK 32: SubjecGwith a ~ 35%reduction in urinary 
urinary proteine xaetion fromSas.eline (Day 1) protein exretion from Day l (for subjects who 
to Wee k 16wilt continue to recei ve their rem ained on the randomized srud ytraatmentaftar 
assigned blinded study treatment for an Week 16)orfrom Week 16{forsubjects who 
addit ional l6weeks . switched t'fl!atment at Week 16)willcontinueto 
Subj ectsth atdo notadi iew a ~ 3556 redur::tion receivetheirassigned blinded studytreatmentfor 
in urinary protein e,x:retioo will switch study an additional20 weelts. 
Subjectsthatdo notachiew a~ 35% reduction in 
urin ary pratein e xcretion from Day 1 {for subjects 
who remained on the randomized study treatment 
after Week 16}orfrom Week 16{for sl.b,iect.swho 
switched treatment at Week 16)toWeek 32 c:1n 
continuewh idlever treatment led to the gre3test 
reduction in urinary proteinexuet icm (from Day 1 
to Week 16on initial .studytreatmentorfrom 
Week 16 to Week 32 on switdied traatmen t), o r 
either stuOftreatment per the lnve,,"tig:1tor's 
discretion. WK52 WK56 
Follow-Up 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 9 21 March 2018Substudies:
 
 
 
 
 
 
 
 
 
 
Number of Subjects 
Planned:Approximately  32 subjects
Target Population: Male or female subjects between 18 and 75 years of age , inclusive ,
with active lupus membranous nephropath y who are not in partial or 
complete remission in response to treatment with one or more 
anti-inflammatory  or immunosuppressive agents.
Duration of 
Treatment:Subjects will receive a maximum of 52 weeks of study  drug(s).
Diagnosis and Main 
Eligibility  Criteria:For a complete list of study  inclusion and exclusion criteria, 
please refer to Section 4.
Key Inclusion Criteria
1)Male or female between 18 and 75 years of age, inclusive, at the 
time of initial informed consent
2)Kidney  biops y within the 36 months prior to Screening with a 
histologic diagnosis of LMN (International Society of 
Nephrology  [ISN] and the Renal Pathology  Society  [RPS] 2003 
classification of lupus nephritis), either Class V alone, or Class V 
in combination with Class II. If the biops y indicates segmental 
glomerular scarring indicative of prior Class III or IV lesions but 
there is limited or no evidence of current Class III or IV activity , 
the subject would be eligible if the Class V findings are active . 
A cop y of the kidney biopsy pathology report will be obtained 
from each subject and forwarded to the Gilead Medical Monitor 
for review and confirmation of eligibility  prior to randomization 
on Day  1.
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 10 21 March 20183)Urine protein excretion  ≥ 1.5 grams per day  based on 24- hour 
urine sample collected during Screening 
4)Estimated glomerular filtration rate (eGFR MDRD ) 
≥
40mL/min/1.73 m2based on the MDRD formulation at 
Screening 
5)Prior treatment for LMN with at least one immunosuppressive 
therap y for a sufficient duratio n before Screening, including but 
not limited to:
a)Calcineurin inhibitors (cy closporin A, tacrolimus),
b)Alky lating agents (chlorambucil, cy clophosphamide), or
c)Antimetabolite drugs (azathioprine, my cophenolate mofetil) 
d)Other (eg, methotrexate, leflunomide, m oderate -to high- dose 
steroids, etc.)
Prior therap y should be specified on the Prior and Concomitant 
Medication – LMN and SL E eCRF (ie, therapy  name, dose, and 
start/stop dates).
6) Treatment with an angiotensin- converting enz yme inhibitor 
(ACEi) or angiotensin II receptor blocker (ARB) at a dose 
deemed appropriate for the subject per the Investigator for at least 
6weeks prior to and during Screening, with a stably  prescribed 
dose for at least 14 day s prior to Day  1. Enrolled subjects should 
remain on the stabl y prescribed dose of ACEi or ARB treatment 
throughout the stud y.
Subjects who are not taking an y ACEi or ARB may  be screened 
if there is documented intolerance to ACEi and/or ARB.  
7) If a subject is taking oral glucocorticoids, the dose must be 
≤ 20 mg/day  prednisone (or equivalent) and must have been on a 
stably  prescribed dose for at least 28 day s prior to Day  1. Enrolled 
subjects should remain on the stably  prescribed dose of 
prednisone treatment through Week 16 of the study  (after 
assessment of the primary outcome). 
8) If a subject is taking the following agents, they must have been on 
a stably  prescribed dose for at least 28 day s prior to Day  1: 
a)Hydroxy chloroquine ( ≤ 400 mg/day ),
b) Chloroquine ( ≤ 250 mg/day ), or 
c)Quinacrine ( ≤ 100 mg/day )
Enrolle d subjects should remain on the stabl y prescribed dose of 
the above treatments throughout the stud y.  
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 11 21 March 20189)Use of nonsteroidal anti- inflammatory  drugs (NSAIDs) is 
permitted if the dose has been stabl y prescribed for at least 
14days prior to Day  1. Enrolled subjects should remain on the 
stably  prescribed dose of NSAID treatment throughout the study . 
Intermittent use (pro re nata [PRN]) for non- LMN indications 
should be minimized.
10)All disease modify ing anti -rheumatic drugs (DMARDs) or 
immunosuppressive agents ot her than glucocorticoids, 
hydroxychloroquine (as specified above), azathioprine (up to a 
maximum of 2 mg/kg body  weight/day  or 200 mg/day , whichever 
is lower), and methotrexate ( ≤ 20 mg per week ) should be 
withdrawn at least 28 day s prior to Day  1.
11) S ystolic blood pressure (SBP) below 160 mmHg AND diastolic 
blood pressure (DBP) below 90 mmHg will be measured at 
Screening . The Screening blood pressure may  be repeated 
(amaximum of 2 times) as an unscheduled visit prior to Day 1.
12)
Meet the following tuberculos is (TB) Screening criteria: 
a)No evidence of active or latent TB as assessed during 
Screening b y:
A negative QuantiFERON® TB- Gold In- Tube test at 
Screening AND
A chest radiograph (if consistent with local guidelines) 
taken at Screening or within 90 day s prior to Screening 
(with the report or films available for Investigator review) 
without evidence of active or latent TB infection 
b)Subjects previously  treated for latent TB: subject who has 
previously  received an adequate course of therapy  as per local 
standard of care for latent TB (eg, 9 months of isoniazid in a 
location where rates of primary  multi- drug resistant TB 
infections are <5% or an acceptable alternativ e regimen). In 
these cases, no QuantiFERON® TB -Gold In -Tube test 
(orequivalent assay ) need be obtained, but a chest radiograph 
must be obtained if not done so within 90 day s prior to 
Screening (with the report or films available for Investigator 
review). It is the responsibility  of the Investigator to verify  
the adequacy  of previous anti -tuberculosis treatment and 
provide appropriate documentation. Subjects with a history  of 
untreated or inadequately treated latent TB are excluded from 
the study
c)Subjects w ith newly  identified latent TB during Screening are 
excluded from the study .  
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 12 21 March 2018Cases falling under category  “b” need to be approved by  the 
Sponsor prior to enrollment in the study . Subjects with any  
history  of or current active TB (regardless of past or pr esent 
anti-TB treatment) are excluded.
Key Exclusion Criteria
1) Prior treatments as follows:
a)Previous treatment with a JAK i nhibitor within 3 months of 
Day 1
b) Use of rituximab or other selective B ly mphocy te depleting 
agents (including experimental agents) within 6 months of 
Day 1. Enrollment is permitted if the last dose was given 
>
6months and CD19- positive B cells are detectable at 
Screening.
c)Anticipated use of disallowed medications in Section 5.3.2
2)Known hy persensitivity  or allergy  to the stud y drugs 
(filgotinib, GS-9876), their metabolites, or formulation excipients
3)History  of, or current, inflammatory  or autoimmune disease other 
than SL E (e.g., scleroderma, reactive arthritis, rheumatoid 
arthritis, anky losing spondy litis, Ly me disease) that 
will interfere 
with clinical evaluation during the study , per judgment of the 
Investigator. Secondary  Sjogren’s s yndrome or controlled 
thyroiditis is acceptable, per judgment of the I nvestigator .
4) Administration of a live/attenuated vaccine within 30 days prior 
to Day 1, or planned during the study  or through 12 weeks after 
subject’s last dose of study  drug
Study  Procedures/
Frequency :After the screening period and randomization on Day  1, eligible 
subjects will enter the Blinded Treatment Phase and return to the 
study  center at specified visits.
Blinded Treatment Phase
Weeks 1, 2, 4, 8, 12, 16, 18, 20, 24, 28, and 32 
Following completion of 16 weeks of dosing, the primary  endpoint of 
the study  will be evaluated in all subjects. To test their change in 
urinary  protein excretion, subjects will submit 2 consecutive morning 
urine void samples to the study  center approximat ely 7 day s prior to 
the Week 16 visit. These results will inform their treatment 
assignment for the additional 16 weeks. Subjects who achieve a 
≥ 35% reduction in urinary  protein excretion (using an average of the 
UPCR from 2 morning voids) from Baseline ( Day 1) to Week 16 will 
continue to receive their assigned blinded stud y treatment (filgotinib 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 13 21 March 2018200mg + PTM GS -9876 once dail y; or GS -9876 30 mg + PTM 
filgotinib once daily) for an additional 16 weeks. Those subjects who 
do not achieve a ≥35% reduction in urinary  protein excretion from 
Baseline (Day 1) to Week 16 will switch study  treatment for 16 
weeks in a blinded fashion (ie, those on filgotinib 200 mg + PTM 
GS-9876 once daily will switch to GS -9876 30 mg + PTM filgotinib 
once daily, while those on GS -9876 30 mg + PTM filgotinib 200 mg 
once dail y will switch to filgotinib 200 mg + PTM GS
-9876 once 
daily ). The primary  outcome for urinary  protein excretion will be 
determined using a 24 -hour urine collection that is collected 
immediately  prior to the Week 16 visit, or as close to the Week 16 
visit as possible. Additional details regarding urine collection 
procedures will be specified in the Laboratory  Manual and Subject 
Procedures Manual.
After 32 weeks of blinded treatment, those who have received some 
benefit (a ≥ 35 % reduction in urinary  protein excretion using an 
average of the UPCR from 2 morning voids from Day  1 [for subjects 
who remained on the randomized study  treatment after Week 16] or 
from Week 16 [for subjects who switched treatment at Week 16]) 
will continue on their assigned blinded treatment for an additional 
20
weeks in the Extended Blinded Treatment Phase. To test their 
change in urinary  protein excretion, subjects will submit 
2consecutive morning urine void samples to the study  center 
approximately  7days prior to the Week 32 visit. These results will 
inform their treatment assignment for the additional 20 weeks in the 
Extended Blinded Treatment Phase. Subjects will also submit a 
24-hour urine collection that is collected immediately  prior to the 
Week 32 visit, or as close to the Week 32 visit as possible. Subjects 
who do not achieve a ≥35% reduction in urinary  protein excretion 
from Day 1 (for subjects who remained on the randomized study  
treatment after Week 16) or from Week 16 (for su bjects who 
switched treatment at Week 16) to Week 32 will be allowed to 
continue whichever study
 treatment led to the greatest reduction in 
urinary  protein excretion ( from Day 1 to Week 16 on initial study  
treatment or from Week 16 to Week 32 on switched t reatment) , or 
either study  treatment per the Investigator’s discretion 
(eg,differences in tolerability  or other non- renal benefits that support 
overriding the treatment assignment according to reduction in urinary  
protein excretion) during the Extended Bl inded Treatment Phase. 
Extended Blinded Treatment Phase
Weeks 36, 40, 44, 48, and 52 
All subjects who received at least one dose of study  drug and 
discontinue the study  early  will complete an Earl y Termination (ET) 
visit at the time of study  discontinuat ion. 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 14 21 March 2018All subjects, including those who terminate earl y from the study, will 
be required to complete a Final Follow -Up (FU) visit 4 weeks 
(±5days) after the last dose of study  drug. For subjects that complete 
the entire stud y, the Final FU visit will be conducted at Week 56.
Screening Study Assessments:
Complete medical history, complete ph ysical exam (PE) 
(including height and weight), morning urine voids and 24 -hour urine 
collection for protein, urinaly sis (with urine microscopy  and spot 
protein- to-creatinine ratio), vital signs (ie, blood pressure, respiratory  
rate, heart rate, and bod y temperature), clinical laboratory  tests 
(hematology , serum chemistry , and coagulation), hemoglobin A1c 
(HbA 1c), thy roid stimulating hormone (TSH) test, C- reactive protei n 
(CRP), ery throcy te sedimentation rate (ESR), autoantibody  panel and 
complement levels, serum pregnancy  test for females of childbearing 
potential or follicle stimulating hormone (FSH) test for females of 
nonchildbearing potential (as defined in Appendix 5), human 
immunodeficiency  virus ty pe 1 and 2 (HIV -1, HIV -2) test, 
hepatitis B virus (HBV) tests, hepatitis C virus (HCV) test, HCV 
RNA monitoring (if subject is HCV Ab positive), QuantiFERON®
TB-Gold In -Tube Test (if applicable) and chest x
-ray (if one ha s not 
alread y been obtained within 3 months prior to screening), and 
standard 12-lead electrocardiogram (ECG).
Subjects will be screened up to 35 day s prior to randomization 
(Day 1) to determine eligibility  for participation in the study . The 
Screening vis
it will take two separate day s to complete.  In addition, 
Screening Day  2 cannot occur earlier than 3 day s after Screening 
Day 1 due to the timing of the morning urine voids and the 24 hour 
urine collection.  Additional details regarding urine collection 
procedures will be specified in the Laboratory  Manual and Subject 
Procedures Manual.
Day 1 (Baseline) through Final Follow -Up Visit 
Assessments:
At a minimum, the following safet y assessments will be performed at 
every  study  visit (refer to Appendix 2for a complete list of required 
study  assessments for each study  visit):
Urinalysis (with urine microscopy  and spot protein- to-creatinine 
ratio) (except Final FU visit), vital signs (ie, blood pressure, 
respiratory  rate, heart rate, and bod y temperature), clinical laboratory  
tests (hematology , serum chemistry , and coagulation), CRP, ESR, 
HCV RNA monitoring (if applicable) and urine pregnancy  test for 
females of childbearing potential.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 15 21 March 2018Complete PE, sy mptom -driven PE, weight, morning urine voids and 
24-hour urine collection for protein, fasting lipids, quantitative serum 
immunoglobulin test, autoantibody  panel and complement levels, 
Safety  of Estrogens in Lupus Ery thematosus National Assessment 
trial-based SLE Disease Activity  Index (SELENA -SLEDAI), 
BritishIsles Lupus Activity  Group (BILAG) Index, Patient Global 
Assessment of Disease Activity , Phy sician’s Global Assessment of 
Disease Activity , 36-Item Short Form Health Survey , 
standard 12-lead ECG, in -clinic study  drug administration, study  
drug accounta bility , and study  drug dispensation will be performed at 
selected stud y visits (refer to Appendix 2).  
Early Termination Study Assessments:
Complete PE, weight, vital signs (ie, blood pressure, respiratory  rate, 
heart rate, and bod y temperature), clinical laboratory  tests 
(hematology , serum chemistry , and coagulation), CRP, ESR, HCV 
RNA monitoring (if applicable), urine pregnancy  test for females of 
childbearing potential, standard 12-lead ECG, and study  drug 
accountability .
Assessment of adverse events (A Es) and concomitant medications 
will continue throughout the duration of the stud y.
Pharmacokinetic (PK) Assessments:
Blood samples will be collected for plasma PK analy sis of filgotinib 
and its active metabolite GS- 829845, and GS -9876 post dose at 
Weeks 2, 4 and 20 (at least 30 minutes and up to 3 hours after 
dosing), an ytime at Weeks 8 and 24, and within 2 hours prior to 
dosing at Weeks 16 and 32.
Urine PK anal yses may  be performed for filgotinib and its active 
metabolite GS -829845, and GS -9876, using the 24-hour urine 
collection at Week 16.
Biomarker Assessments:
Urine samples will be collected for biomarker assessments at 
Screening, Day 1 (predose), Weeks 2, 16, 32, 52, ET, and at the Final 
FU.  
Blood samples for biomarker assessments (whole blood TBNK 
biomarker, serum and plasma biomarkers, vfPBMC, and PAXgene 
RNA) will be collected at Screening, Day  1 (predose), Weeks 2, 16, 
32, 52, ET, and at the Final FU.  
Concomitant Medication Management:
Stable medications at Day 1 (per Section 5.3.1 ) are to be c ontinued 
during the stud y. Refer to Table 5-1for a list of prohibited 
medications.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 16 21 March 2018Test Product, Dose, 
and Mode of 
Administration:Filgotinib 200 mg (1 200 mg tablet) administered orall y once daily  
in the AM
GS-9876 30 mg (1 30 mg tablet) administere d orally  once daily in 
the AM
Reference Therapy, 
Dose, and Mode of 
Administration:PTM Filgotinib (1 tablet) administered orall y once daily  in the AM
PTM GS -9876 (1 tablet) administered orall y once daily  in the AM
Criteria for 
Evaluation:
Safety : Safety  will be assessed during the study throu gh the reporting of 
AEs, clinical laboratory tests, vital sign assessments, phy sical 
examinations findings , and ECGs. Treatment emergent AEs 
including infection, worsening of proteinuria, or decrease in eGFR 
will be of particular interest.   
Efficacy : Primary  Endpoint
The percent change in urine protein from Baseline (Day 1) to 
Week 16 (assessed b y urine protein excretion during a 2 4-hour 
urine collection). 
Secondary  Endpoints
Change from Baseline (Day  1) in urine protein (assessed by  urine 
protein excretion during a 24 -hour urine collection) at Week 16 
Change from Baseline (Day  1) in eGFR at Week 16
Change from Baseline (Day  1) in UPCR (assessed by  urine 
protein excretion during a 24 -hour urine collection) at Week 16
Proportion of subjects with partial remission (defined as urine 
protein excretion below < 3 g/d and urine protein excretion 
decrease b y ≥ 50% among subjects with Baseline (Day 1) 
nephrotic range proteinur ia [urine protein excretion ≥ 3g/d]; or 
urine protein excretion decrease b y ≥ 50% among subjects with 
subnephrotic range proteinur ia [urine protein excretion < 3g/d]) 
at Week 16
Proportion of subje cts with complete remission (defined as urine 
protein excretion below 0.5 g/day , with no hematuria) at Week 16
Biomarker Endpoints Change in JAK -STAT -, SYK -, and disease -related biomarkers in 
peripheral blood and urine
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 17 21 March 2018Association of changes in peripheral blood and urine biomarkers 
with clinical outcomes
Association of B aseline markers with disease severity  and 
response to filgotinib and GS -9876
Pharmacokinetics: Plasma concentrations of GS -9876, filgotinib and an active filgotinib 
metabolite, GS -829845, will be anal yzed. Urine concentrations of 
GS-
9876, filgotinib, and GS- 829845 may  be analyzed.
Statistical Methods: Analysis Methods:
The primary  endpoint, the percent change from B aseline (Day 1) in 
24-hour proteinuria at Week 16 , will be calculated for each treatment 
group and the 95% confidence interval will be constructed . The 
primary  anal ysis set for efficacy  anal yses will be the Full Anal ysis 
Set (FAS), which includes all randomized subjects who received at 
least one dose of stud y drug . 
All continuous endpoints will be summarized using an 8 -number 
summary  (n, mean, standard deviation [SD], median, 1st quartile 
[Q1], 3rd quartile [Q3], minimum, maximum). All categorical 
endpoints will be summarized by  the number and percentage of 
subjects who meet the endpoint definition. 
Safety  endpoints will be anal yzed by the number and percent of 
subjects with events or abnormalities for categorical values or 
8-number summary  (n, mean, SD, median, Q1, Q3, minimum, 
maximum) for continuous data. 
Efficacy  and sa fety data collected up to Week 16 will be summarized 
by treatment group for all subjects. Data from subjects who do not 
switch treatment will be summarized for the duration of the study  by 
treatment group. Summaries by  the combinations of treatment groups 
may be provided, if applicable.
The sample size was chosen based on the practical considerations and 
to ensure that a clinically meaningful reduction in proteinuria from 
Baseline (Day  1) could be detected in any  of the treatment groups 
(filgotinib or GS -
9876). With 16 subjects per treatment group 
(32subjects total), there is a 80% power to detect a 35% reduction 
from Baseline (Day 1) in proteinuria at Week 16 with a standard 
deviation of 50% and a 2 -sided 0.05 significance level.
This study  will be cond ucted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 18 21 March 2018GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
ACEi angiotensin -converting enzyme inhibitor 
ACR20 American College of Rheumatology 20% improvement
AE adverse event
AhR aryl hydrocarbon receptor
ALT alanine aminotransferase
ANA antinuclear antibody
Anti-dsDNA anti-double stranded DNA
ARB angiotensin II receptor blocker
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the curve
BCR b-cell receptor
BCRP breast cancer resistance protein
bDMARDs biologic disease- modifying antirheumatic drugs
BILAG British Isles Lupus Activity Group Index
BLQ Below  the limit of quantitation
BMI body mass index
Cave average concentration
CD cluster of differentiation
Cis Confidence intervals
CIA collagen -induced arthritis
CLE cutaneous lupus erythematosus
Cmax maximum observed plasma concentration
CNS central nervous system
CRO Contract Research Organization
CYP Cytochrom e
DKD Diabetic kidney disease
DMARDs disease -modifying antirheumatic drugs
DMC data monitoring committee
DNA deoxyribonucleic acid
DSS Dextran sulphate sodium
EC 50 geometric mean half -maximal effective concentration 
ECG Electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
ET early termination
EU European Union
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 19 21 March 2018FACS Fluorescence -activated cell sorting
FAS Full Analysis Set
FceRl Fc epsilon Receptor I alpha
FDA Food and Drug Administration
FFPE formalin -fixed, paraffin -embedded
FSH follicle stimulating hormone
FU Follow -Up
GCP Good Clinical Practice
GGT gamma glutamyl transferase
GI Gastrointestinal
GLPG Galapagos
HBV Hepatitis B virus
HCV hepatitis C virus
HDPE high density polyethylene 
hERG Human ether -a-gogo related gene
HIV human immunodeficiency virus
HR heart rate
IB investigator’s brochure
IC50 half maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonization
IEC Independent Ethics Committee
IFN interferon
Ig immunoglobulin
IL interleukin
IMP investigational medicinal product
INR international normalized ratio
IP interferon gamma- induced protein
IRB Independent Review Board
IWRS interactive web response system
JAK janus kinase
LLOQ lower limit of quantitation
LMN lupus membranous nephropathy
MCV mean corpuscular volume
MDRD The Modification of Diet in Renal Disease Study
MTX Methotrexate
NDA New  Drug Application
NOAEL no-observed -adverse -effect level
NOELs no observed effect levels
NSAID nonsteroidal anti -inflammatory drugs
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 20 21 March 2018NZB/NZW New  Zealand Black / New Zealand White (mouse strain)
OAT organic ion transporter
PBMC Peripheral blood mononuclear cells
PD Pharm acody namics
PE Physical exam
P-gp P-glycoprotein
PK Pharm acokinetics
PT preferred term
PTM Placebo to match
PVE Pharm acovigilance and Epidemiology (formally Drug Safety and Public Health –DSPH)
PXR Pregnane x receptor
QTcF QT interval corrected for heart rate according to Fridericia
RA rheumatoid arthritis
RNA ribonucleic acid
RR respiratory rate
SAE serious adverse event
SAP Statistical Analysis Plan
SD standard deviation
SELENA -SLEDAI Safety of Estrogens in Lupus Erythematosus National Assessment Trial -Based SLE 
Disease Activity Index
SLE Systemic lupus erythematosus
SOC system organ class
STAT signal transduction and activation of transcription
sTNFR2 soluble tumor necrosis factor receptor -2
SYK spleen tyrosine kinase
TB Tuberculosis
TEAEs Treatment emergent adverse events
tmax the time of occurrence of maximum observed plasma concentration
TNF tumor necrosis factor alpha
TYK tyrosine kinase
ULN upper limit of normal
UPCR urine protein to creatinine ratio 
US United States
vfPBMCs Viably frozen peripheral blood mononuclear cells
VL Viral load
WBC white blood cell
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 21 21 March 20181. INTRODUCTION
1.1. Background
Systemic lupus ery thematosus (SL E) is a chronic sy stemic inflammatory  disease that affects 
approximately  1.5 million adults in the United States (US) {Sarpel 2016}. SL E manifests 
principally  as an autoimmune disease characterized by  autoantibodies to nuclear and cy toplasmic 
antigens that leads to protean manifestations that follows a relapsing and remitting course with 
considerable mortality , morbidity , and impact on quality  of life. Although SL E has a variet y of 
signs and s ymptoms, it often affects the joints, skin, brain, lungs, kidney s, and blood vessels. 
Patients with SL E may  experience fat igue, pain or swelling in joints, skin rashes, and fevers. 
Although people of an y age can be affected, the onset of SL E is most frequent between the ages 
of 15 and 44 years, and women are affected 4 -12 times more often than men {Dall'Era 2013}. 
While the cause of SLE is still not completely  understood, genetic, environmental, and hormonal 
factors may  lead to autoreactive B -cells and T -cells, activation of the adaptive immune sy stem, 
and perpetuation of inflammatory  responses that have all been implicated in its pathogenesis.
Kidney  involvement in SLE continues to be a major contributor to morbidity  and mortalit y 
{Danila 2009 }. Up to 50% of SL E patients will have clinicall y evident kidney disease at 
presentation, a nd during follow -up, kidney  involvement may  occur in over 60% of patients, with 
an even greater representation among children and young adults {Waldman 2006 }. The ty pe of 
renal disease can vary  quite widely  from as ymptomatic hematuria and/or proteinuria to nephrotic 
syndrome and rapidly  progressive glomerulonephri tis.  One subty pe of kidney  disease is 
membranous nephropathy, which is a common cau se of nephrotic s yndrome in non
-diabetic 
adults.  When it occurs in SL E patients it is considered to be a secondary  cause of membranous 
nephropath y (class V lupus membranous nephropathy  [LMN]) and occurs in 10- 20% of patients 
with lupus nephritis {Danila 2009 }.  Patients with L MN are at risk for developing end -stage 
renal disease (ESRD) due to protracted nephrotic sy ndrome.  In addition they are predisposed to 
hypercholesterolemia and hy pertension, which contribute to accelerated atherosclerosis, as well 
as hy percoagulability  and an increased risk of infection {Kolasinski 2002 }.
There are limited studies investigating the benefit of disease -modify ing antir heumatic drugs 
(DMARDs) or biologic disease -modify ing antirheumatic drugs (bDMARDs) in the treatment of 
LMN {Austin 2009, Ginzler 2005 , Hallegua 2000 , Karim 2005, Kasitanon 2008, Mok 2004, 
Mok 2009
, Yap 2012 }.  In particular, randomized, controlled trials are lacking.  Prior studies 
support the use of prednisone and azathioprine {Mok 2004
}mycophenolate mofetil {Ginzler 
2005, Karim 2005, Kasitanon 2008}cy clophosphamide {Austin 2009} sequential use of 
prednisone, cy clophosphamide, and azathioprine {Chan 1999} cyclosporine {Austin 2009, 
Hallegua 2000
}, chlorambucil {Moroni 1998}, and plasmapheresis {Sloan 1996 }.  However, 
these studies have been small, have used variable outcome measures, and have not alway s 
reported dose and duration of therap y.  There are no trials directly comparing 
immunosuppression versus non
-immunosuppressive medications, and thus a consensus regarding 
optimal treatment does not exist.  Standard of care for LMN is controversial, but generall y 
includes immunosuppression when high -grade proteinuria exists (> 3.5g/day despite 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 22 21 March 2018non-immunosuppressive therap y) or serum creatinine pr ogressivel y rises. Given the toxicity  and 
variable efficacy  of current immunosuppressive medications used in the treatment of L MN, there 
is an unmet need for a saf er, more effective therapy .
Recent human studies reveal critical roles of Janus kinase (JAK) inhibition in the treatment of 
rheumatoid arthritis {Fleischmann 2012 , Genovese 2016 , Keystone 2015, Lee 2014, van 
Vollenhoven 2012 }and psoriasis {Bachelez 2015 }.  
Filgotinib (GS -6034, formerly  GLPG0634) is a potent and selective oral inhibitor of JAK1 being 
developed b y Gilead Scien
ces, Inc. (Gilead) and Galapagos (GL PG) NV. Filgotinib is effective 
in treating collagen -induced arthritis in rodents {Van Rompaey  2013}, and has demonstrated 
efficacy  in two large Phase 2b 
clinical studies in subjects with RA .Upon activation, 
receptor -associated JAKs phosphory late the intracellular portion of their receptors and provide a 
docking site for transcription factors known as signal transducers and activators of transcription 
(STATs) {O'S hea 2015 }.  Activated STATs dimerize, enter the nucleus, bind DNA, and directl y 
regulate gene expression.  A number of cy tokines, growth factors, and hormones selectivel y act 
as ligands for one of four JAKs, leading to the preferential activation of 1
of 7STATs.  Notably , 
JAK1 is responsible for signaling by inflammatory cytokines that are involved in autoimmune 
diseases, such as IFN-α, IFN -β, IFN-γ, IL -2, IL -6, IL -10, IL -15, and IL -21, amongst others 
{O'Shea 2015}.  
A study  for the treatm
ent of diabetic kidney  disease (DKD) with baricitinib, a JAK1- 2 selective 
inhibitor, indicated a dose -related reduction in albuminuria and inflammatory biomarkers 
involved in DKD progression, such as urinary  interfer on gamma -induced protein -10 (IP -10) and 
plasma soluble tumor necrosis factor receptor -2 (sTNFR2) { Brosius 2015, Tuttle 2015 }.  
Although the exact pathogenesis of lupus, and more specificall y lupus membranous nephropathy, 
are incompletel y understood, it is 
believed that IF N-α {Feng 2006 }, IL - 10 {Houssiau 1995, 
Rahman 2008
}, IL -21 { Bubier 2009 , Sawalha 2008 , Wang 2014}, and IL-6 {Maier -Moore 2014, 
Mao 2014, Sato 2014} play a role in SLE given th eir elevation and association with disease 
activity  in lupus patients.  Signaling of these cy tokines function through JAK 1 in SL E, and thus 
inhibition of this pathway  with filgotinib may  offer a rational therapeutic target.  
GS-9876 is a potent and selec tive oral inhibitor of spleen ty rosine kinase ( SYK ) being developed 
by Gilead for the treatment of inflammatory  diseases. Spleen ty rosine kinase is a cy toplasmic 
tyrosine kinase (TYK) primarily  expressed in cells of the hematopoietic lineage, where it 
functions as a key  signaling molecule mediating immunoreceptor signaling {Woroniecka 2011 }. 
Signaling of these immune complex through SYK in various kidney  diseases, and accumulating 
evidence from pre -clinical and clinical studies suggest a pathogenic role of SYK in proliferative 
glomerulonephritis, including anti- glomerular basement membrane disease, anti -neutrophil 
cytoplasmic antibody -associated glomerulonephritis, immunoglobulin A nephropa thy, and lupus 
nephritis {Crispin 2010, Ma 2016}. Given its central role in immune cell signaling, inhibition of 
SYK is expected to affect multiple steps in the pathogenesis of several autoimmune diseases 
resulting in pleiotropic anti
-inflammatory effects {Ryan 2016 , Smith 2010 }. Thus, inhibition of 
the 
SYK pathway  with GS -9876 may  offer a rational therapeutic target in lupus nephritis.  
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 23 21 March 20181.2. Filgotinib 
1.2.1. General Information
For further information on filgotinib, refer to the current investigator’s brochure (IB).
1.2.2. Preclinical Pharmacology and Toxicology
Filgotinib is a highl y selective, adenosine triphosphate (ATP) -competitive inhibitor of JAK1. I n 
cellular assay s, it inhibits JAK/signal transduction and activator of transcription (STAT) -driven 
processes with half maximal inhibitory  concentration (I C50) values from 179 nM upwards; in 
human whole blood assays, filgotinib exhibits approximately  30-fold selectivity  over JAK2. 
Filgotinib demonstrated significant efficacy  in the rat collagen -induced arthritis (CI A) model as 
well as in the mouse dextran sulphate sodium (DSS) -induced colitis model. Filgotinib’s 
metabolite, GS -829845, exhibits a similar JAK1 selectivity  profile, but is approximately  
10to20-fold less potent than filgotinib.
In rats, filgotinib and GS -829845 had no effects on the respiratory  system and Central Nervous 
System ( CNS )and no relevant effects on cardiovas cular parameters (human ether -
a-gogo related 
gene [hERG] and dog telemetry  studies), apart from a slight non- adverse increase in heart rate 
and arterial pressure with GS -829845, at exposures 7- fold that of the C maxin human subjects 
dosed with filgotinib 200 mg once dail y.
In repeat oral dose toxicity  studies in both rats and dogs, the primary  target tissues identif ied for 
filgotinib were the l ymphoid tissues which are expected based on the pharmacology  of JAK 
inhibition. Additional filgotinib-related findings were observed in the male reproductive organs 
of both species, and in the incisor teeth of rats. Effects on the ly mphoid s ystem were fully  
reversible. Testicular toxicity demonstrated partial reversibility , however sperm counts remained 
low. A dose of 200 mg once dail y of filgotinib results in an estimated mean clinical area under 
the curve (AUC) of 2.80 μg∙h/mL in rheumatoid arthritis (RA) subjects, which represents an 
exposure margin of 2.3, 1.8, and 3.4- fold when considering the mean AUC in male dogs at the 
no-observed -effect -levels (NOELs) in the 26 -week and 39- week chronic toxicity  studies and the 
39-week ta rgeted exposure toxicity  study , respectively . GS-829845-related findings in general 
repeat dose toxicity  studies were similar to those of the parent filgotinib, however no testicular 
toxicity  was noted following administration of GS -829845.
Filgotinib and GS-829845 are non- genotoxic.  
In embry ofetal development studies, filgotinib and GS -829845 caused embry olethalit y and 
teratogenicit y in rats and rabbits at exposures similar to the human expo sure at 200 mg 
once daily of filgotinib in subjects with RA. Administration of filgotinib did not affect female 
fertility ;however, impaired male fertility  was observed in rats at exposures approximately  
15-fold the human exposure at 200 mg of filgotinib in subje cts with RA. The metabolite, 
GS-829845, did not have any  effects on fertility  parameters
.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 24 21 March 20181.2.3. Clinical Trials of Filgotinib
As of April 2017, filgotinib has been taken b y more than 1400 subjects, including more than 
950with RA and more than 150 subjects with Crohn’s disease, and has been generall y safe and 
well tol erated. Clinical trials of filgotinib have not been previousl y undertaken in subjects with 
LMN . A detailed description of all clinical studies can be found in the IB.
In 9Phase 1 studies conducted in healthy subjects (Studie s GPL G0634- CL-101, -102, -103, 
-
104, -105, -106, -107, - 110, and GS -US- 417-3900 ), filgotinib administered at doses of up to 
450mgonce dail y for up to 10 days was safe and well tolerated.
In 2Phase 2a studies in subjects with RA (Study GLPG0634
-CL-201 and -202), dosing with 
filgotini b was well tolerated and achieved maximal efficacy  at a 200 mg daily  dose 
(American College of Rheumatology  20% improvement [ACR20] response of 75 -92% at 
Week 4).
In 2Phase 2b studies, filgotinib at total daily  doses of 50 mg, 100 mg, or 200 mg, administe red 
in addition to background therap y with methotrexate (MTX) (GLPG0634- CL-203) or as 
monotherap y (GLPG0634 -CL-204) was safe and effective in subjects with moderatel y to 
severel y active RA who had an inadequate response to MTX alone.
Safety  data collected across Phase 2 clinical studies in RA and C rohn’s Disease showed no 
dose-dependent trends in the incidence of adverse events (AEs) or serious adverse events 
(SAEs), including infections, or laboratory  abnormalities with the exception of a numerical 
increas e in select gastrointestinal AEs (eg, nausea, vomiting, abdominal pain, and upper 
abdominal pain). This numerical increase was observed in the 200 mg compared to the 100 mg 
dose. However, the overall frequency  was low and clinical relevance is unknown. The safet y 
profile of filgotinib was consistent with that observed for an immunomodulatory compound 
administered to subjects with RA.
1.3. GS-9876 
For further information on GS -9876, refer to the current IB.
1.3.1. Nonclinical Pharmacology and Toxicology
1.3.1.1. Nonclinical Pha rmacology  and Safet y Pharmacology
GS-9876 is a selective and potent ATP -competitive inhibitor of SYK with an I C50 value of 
9.5nM. Overall, GS -9876 is at least 7 -fold more selective biochemically  for SYK relative to all 
other protein kinases assay ed. Funct ionally , GS-9876 inhibited anti -immunoglobulin (Ig) 
M
-induced B -cell receptor (BCR)/SYK -mediated phosphory lation and activation of multiple 
downstream signaling pathway s in primary  human B -cells, suppressed anti -IgM mediated cluster 
of differentiation (CD) 69 and CD86 activation marker expression on B -cells, and proliferation 
of peripheral B cells. GS -9876 inhibited immune -
complex stimulated tumor necrosis factor alpha 
(TNFand IL -1release from primary human monocytes. In human blood, GS -9876 inhibited 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 25 21 March 2018SYK autophosphory lation, anti -IgD/BCR -induced CD69 expression on B -cells, and 
anti-FceRI -stimulated CD63 expression on basophils with geometric mean half -maximal 
effective concentration (EC 50)values ranging from 171 nM to 301 nM.
In a MRL /lpr murine model of lupus, SYK inhibition with GS- 492429, a compound with similar 
selectivel y as GS -
9876, showed a dose -responsive decrease in anti -dsDNA antibody  titers and 
inhibition of proteinuria with an estimated SYK trough target inhibition of 50%. FACS anal ysis 
of splenic ly mphocy te populations at study  termination showed significant changes in 
lymphocy te subsets and activation markers with SYK inhibition including significant reductions 
in the percentage of follicular (CD19+/CD21+/CD23+) and mature (CD19+/IgM-/IgD+) Bcells, as 
well as activated plasma cells (CD19+/CD138+/CD69+). Activated T helper cells (CD4+CD69+) and 
central memory  T cells (CD4+/ CD44+/CD62L+) were also reduced. A trend toward improved 
renal histopathology was observed with SYK inhibition. This confirm edpreviously  published 
data from the stud y of the SYK inhibitor , fostamitinib, in a NZB/NZW murine model andin a
MRL /lpr murine model that demonstrated delay ed onset of proteinuria and azotemia, reduced 
renal pathology  and kidney  infiltrate s in lupus- prone mice {Bahjat 2008 , Deng 2010 }
In 2independent rat CIA models in animals with established disease, GS -9876 caused significant 
and dose -
dependent amelioration of clinical disease and histopathologic signs. Histological 
evaluation of joints d emonstrated that GS -9876 reduced pannus formation, cartilage damage, 
bone resorption, and periosteal bone formation. Significant efficacy  was seen with GS -9876 
doses that produced C aveexposures that were calculated to inhibit SYK phosphorylation b y EC 50. 
GS-9876 was well tolerated at all doses and there were no treatment -related adverse effects on 
body  weight, food and drink intake, in -life observations or clinical pathology  parameters.  
Safety  pharmacology  studies showed no clinicall y-relevant effects on the respiratory, and CNS 
systems after single oral doses up to 300 mg/kg. Cardiovascular effects in telemetered 
cynomolgus monkey s at ≥ 20 mg/kg included prolonged QTc interval from 5 through 25 hours 
postdose, slightly  higher sy stolic, diastolic, and mea n arterial pressure with lower heart rate 
through 6 hours postdose, and higher heart rate from 9 through 25 hours postdose. While 
differences in QTc interval were generall y small, the changes were of sufficient magnitude to be 
considered biologicall y relev ant. There were no inhibitory  effects on the hERG potassium 
current when GS -9876 was tested up to a free drug concentration of 30 μM, which is 
approximately  207- fold above the observed stead y state C maxat a 30 mg once dail y dose. Further, 
no cardiovascula r effects were observed in telemetered cy nomolgus monkey s administered 
GS-9876 for 39weeks at doses up to 15 mg/kg/day . 
1.3.1.2. Nonclinical Toxicology
In repeat -dose studies, toxicity was assessed in rats and monkey s administered GS -9876 orally  
for up to 39 weeks. Dose -dependent effects on l ymphocytes in both rats and monkey s were 
consistent with the expected pharmacology  of SYK inhibition. Effects observed in rats and 
monkey s were increased ery throcy te turnover in rats at 
≥ 10 mg/kg/day , and hemorrhage and 
thrombosis in monkey s at ≥ 20 mg/kg/day . At higher doses in rats (≥ 30 mg/kg/day ), mortality  
associated with bacterial infections was seen, likely resulting from the immunomodulatory  
activity  of GS -9876. Additional findings included ly mphoid depletion in th e thy mus, changes in 
the pancreas, with secondary  effects related to the immunomodulatory  activity  of GS -9876, and 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 26 21 March 2018opportunistic bacterial infection, observed in s everal tissues. The no -observed -adver se-effect 
level (NOAE L) in rats was 10 mg/kg/day  after 2 6 weeks dosing. For the highest proposed 
clinical dose of 30 mg once dail y, estimate d exposure margins are 2.4 -/5.9-fold based on 
exposures at the NOAELs in the 26 week stud y inmale/female rats, respectively .  
In the 28 -day monkey  study , there were no a dverse effects at doses up to 10 mg/kg/day , with 
hemorrhagic/thrombotic effects noted at 20 mg/kg/day . In the 39 -week monkey  study , there was 
no evidence of effects on hemostasis at the high dose of 15 mg/kg/day , and the NOAEL was 
15mg/kg/day , associated with an AUC 0
-24hrof 8040 ng•h/mL. One animal administered 
15mg/kg/day  was sacrificed for humane reasons with persistent fecal changes, weight loss, 
deteriorating clinical condition, and large bowel inflammation. The moribund condition of this 
animal was not considered directly related to GS -9876 administration.  For the 30 mg dose in 
planned Study  GS US -437-4093, the estimated exposure margins is 2.2- fold based on exposures 
at the NOAEL in the 39 -week stud y in monkey s , and 1.2-fold based on exposures at the mid 
dose of 10 mg/kg/day . In clinical studies GS -US-379- 1372 and GS US - 379-1900 no changes in 
platelets numbers, prothrombin time (PT), partial thromboplastin time (PTT), international 
normalized ration (INR) or bleeding time were observed.
In the pivo tal developmental toxicity  studies in pregnant rats and rabbits, there were no fetal 
malformations. At doses associated with significant maternal toxicity  (reduced body  weight gain 
and food consumption in rats and rabbits, and mortality  and one abortion in rabbits), increases in 
post-implantation loss and late resorptions, reduced fetal bod y weights and fetal variations 
(delay ed ossification) were noted in rats, with reduced fetal body  weights in rabbits. In rats, the 
maternal NOAEL and embry o-fetal develop ment NOEL was 30 mg/kg/day . In rabbits, the 
maternal NOAEL was not determined < 10 mg/kg/day and the embryo -fetal development NOEL 
was 10 mg/kg/day . For the 30 mg dose in planned Study  GS
-US-437- 4093 , estimated exposure 
margins are 23 -and 1.0
-fold compared to exposures at the fetal NOELs in rats and rabbits, 
respectivel y.GS-9876 was negative in the bacterial reverse mutation (Ames) assay , in vitro 
chromosomal aberration assay , and in vivo rat micronucleus assay  and is therefore considered to 
be nongenotox ic. In the in vitro chromosome aberration assay  in human l ymphocytes, slight, but 
statistically  significant increases in the number of poly ploid cells was observed at the highest 
GS-9876 dose level evaluated. GS -9876 did not induce structural chromosome br eakage when 
evaluated in the in vitro assay . 
Table 1-1. Margins for GS - 9876 Based on Systemic Exposure Relative to the 
Observed Human Exposure at 30 mg once daily (AUC)
Species Duration RouteNOAEL
(mg/kg/day )AUC 0-24
(
ng•h/mL)aMarginb
Rat Once daily 
x26weeksOral 10 8,800/21,800
(male/female)2.4/5.9
(male/female)
Cynomolgus Monkey Once daily 
x39weeksOral 15 8,040 2.2
NOAEL = no observed adverse effect level. 
a Week 26 male and female rat AUC and week 39 Cynomolgus monkey AUC (combined sex)
b Margins of exposure were calculated using observed steady -state exposure (AUC tau) in human s of 3708 ng•h/mL at 30 mg 
once daily in study GS -US-379- 1900
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 27 21 March 20181.3.1.3. Nonclinical Drug Metabolism and Pharmacokinetics
GS-9876 exhibi ts high absorption in rats, dogs and monkeys. Plasma protein binding is moderate 
in all species with the mean free fraction in humans of 20.4%.
After oral dosing to albino and pigmented rats, recovery  of [14C]GS -9876- derived radioactivity 
was high ( ≥ 97.8%) and the main route of elimination of GS
-9876 was hepatobiliary  with 
≤ 5.1% orally  dosed radioactivity  found in urine and 69.4% in bile.
In vitro, GS -9876 exhibits high metabolic stability with human hepatocy tes, liver fractions and 
individual metabolizing enzy mes. GS -9876 had little inhibitory  effect on the activities of the 
major human drug metabolizing CYP enzy mes and was a weak inhibitor of human UGT1A1. 
GS-
9876 is a weak inhibitor of P- glycoprotein (P -gp) and breast cancer resistance protein 
(BCR P) and is a substrate for those efflux transports. It is a weak inhibitor of the hepatic uptake 
transporters organic ion transporter (OATP1B1 and OATP1B3) but is a substrate for neither. 
Drug -drug interactions in vivo are unlikely through inhibition of human CYP enzy mes, 
UGT1A1, or efflux or uptake transporters. The potential of GS -9876 to cause drug -drug 
interactions through induction is low as there is little activation of pregnane x receptor (PXR) or 
aryl hydrocarbon receptor (AhR) in vitro.
1.3.2. Clinical Tri als of GS -9876
As of February  2016, 62 healthy  volunteers have been dosed with GS -9876 in two clinical 
studies.
1.3.2.1. Completed Clinical Trial
GS-US-379-1372: This was a first -in-human, Phase 1, single -dose ranging study  of GS -9876 in 
healthy  adult volunteers to evaluate the safet y, tolerability , PK, pharmacod ynamics (PD), food 
effect, and drug -drug interaction potential using omeprazole. No risks were identified and no 
grade 3 or 4 AEs were reported. There were no clinically  significant changes in vital signs, 
physical findings, laboratory  parameters, or ECGs.
GS-US-
379-1900: This was a single -and multiple -dose Phase 1 stud y of GS -9876 in healthy  
volunteers to evaluate the safet y, tolerability , PK and PD of GS -
9876. N o risks were identified;
all AEs were Grade 1 in severit y. No dose relationships were observed between GS -9876 and 
any AE. No AE was assessed by  the investigator as related to study  drug. There were no 
clinically  significant changes in vital signs, phy sical findings, laboratory  parameters, or ECGs. 
1.3.2.2. Ongoing Clinical Trials
GS-US-
379-1582: This is a 12 week proof of concept trial of GS -9876 in patients with RA to 
evaluate efficacy , safet y, tolerability , and PK of GS -9876.
GS-US-379-1932: This is a Phase 1, open -label, parallel -group, adaptive, single - dose, 
multi
-center, PKstudy  in subjects with renal impairment and matched healthy  controls.
Preliminary  PK results showed no change in GS -9876 PK by  moderate renal impairment. 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 28 21 March 2018GS-US-445- 4189: This is a 48 week proof of concept trial of GS -9876 in patients with Sjogren’s 
syndrome to evaluate efficacy , safet y, tolerability , and PK of GS -9876.
1.4. Rationale for This Study
Although patients with LMN are at increased risk for end -stage renal disease, thromboembolic 
events and transition to proliferative lupus nephr itis, therapeutic options for LMN are limited 
{Swan 2011}. There are very  limited clinical trial data in L MN for the various newer biologic 
and sy nthetic DMARDs that have been approved for other indications. Prior studies support the 
use of prednisone and azathioprine {Mok 2004, Mok 2009}, my cophenolate mofetil {Ginzler 
2005, Karim 2005, Kasitanon 2008}, cy clophosphamide {Austin 2009} sequential use of 
prednisone, cy clophosphamide, and azathioprine {Chan 1999}, cy clo sporine {Austin 2009, 
Hallegua 2000}, chlorambucil {Moroni 1998}, and plasmapheresis {Sloan 1996 }.  However, 
these investigations have been sma ll, have used variable outcome measures, and have not alway s 
reported dose and duration of therap y. In addition, some individuals with LMN have an 
inadequate response or intolerance to available therapies. Thus, there is an unmet need for orall y 
administer ed therapies with novel and targeted mechanisms of action that can safel y and 
effectivel y improve the disease.
Filgotinib is an orall y administered, small molecule inhibitor of JAK1, an intracellular TYK 
dysregulated in subjects with inflammatory  disorders . Filgotinib has demonstrated clinical 
activity  and a favorable safet y and tolerability profile in Phase 2 studies in subjects with 
moderatel y to severel y active RA. J AK
1 activation is required for type I interferon (IFN) 
signaling, which is thought to be central to both s ystemic lupus and lupus nephritis. Although in 
vivo studies using a JAK inhibitor attenuated the progression of renal inflammation in the 
MRL /lpr mouse model of lupus using AG490 (JAK 2 inhibitor) {Wang 2010}, as well as the 
NZB/WF1 mouse model of lupus using CP
-690,550 (JAK3 inhibitor) {Ripoll 2016 },there are no 
published data regarding JAK1 inhibition. However, preclinical studies at Gil
ead in MRL /lpr 
mice suggest mild reduction in proteinuria with JAK1/3 inhibition, and even greater 
effectiveness when combined with a SYK inhibitor.  
Given its central role in immune cell signaling, inhibition of SYK is expected to have pleiotropic 
anti-inflammatory  effects and affect multiple steps in lupus nephritis pathogenesis. Compared 
with normal T cells, T cells obtained from lupus patients demonstrated substantially  higher SYK
expression and activity  {Krishnan 2008 }In addition, B cells have been implicated in the 
pathogenesis of lupus nephritis, and B cell depletion demonstrates an effect in individuals with 
certain t ypes of LMN {Ulinski 2014 }. As a critical mediator of BCR signaling, SYK inhibition 
suppresses BCR -stimulated proliferation, co- stimulatory  molecule expression, and autoantibody  
production 
{Braselmann 2006 , Coffey  2012}. Further, inhibiting SYK in vitro delay s the onset 
of proteinuria and azotemia, reduced renal pathology  and kidney  infiltrates and significantly  
prolonged survival in lupus prone NZB/NZW mice {Bahjat 2008 }. In MRL/lpr mice, inhibiting 
SYK prevented the development of renal disease and reduced proteinuria in established disease 
{Deng 2010 }
The data suggest that inhibition of 
SYK or of JAK1 may  decrease several processes implicated 
in LMN pathoph ysiology including B -cell and T -cell activation.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 29 21 March 20181.4.1. Rationale for Endpoint and Timing
Change in proteinuria will be the primary  measure of efficacy . Proteinuria has long been used as 
a surrogate endpoint because it correlates well with kidney  function, and it has been implicated 
in the pathogenesis of chronic kidney  disease. In LMN it is as sociated with thromboembolic 
events, as well as cardiovascular events. Proteinuria is a standardized outcome measure of lupus 
nephritis, and an attractive choice because following an intervention, the change in proteinuria is 
often earlier and larger than the observed change in kidney  function. It might be useful therefore 
in slowly  progressive or earl y stages of disease. A magnitude of 35% or greater reduction in 
proteinuria was selected based on response rates observed during other trials of lupus nephrit is 
{Borchers 2012}, including LMN {Swan 2011 }.
Secondary  measures will include additional measures of kid ney structure and function 
(eg,proteinuria and glomerular filtration rate) at various time points, as well as measures of 
lupus activity . Validated scales will be used for lupus, including the Safety
 of Estrogens in Lupus 
Erythematosus National Assessment trial -based SLE Disease Activity  Index 
(SEL ENA -SLEDAI) and the British Isles Lupus Activity  Group (BILAG). 
The selection of the 16 -week time point is based on prior studies of LMN and lupus nephritis 
more broadl y, as well as the speed of action of filgotinib (approximately  80-90% of total clinical 
benefit achieved b y week 12), as demonstrated in Phase 2b studies of subjects with active RA 
(protocols GL PG0634 -CL-203 and GLPG0634 -CL-204). Review of the published information 
on prior randomized studies in lupus nephritis 
{Borchers 2012 }including LMN {Swan 2011}, 
demonstrates a range of drug administration duration between 10 weeks for cy clophosphamide 
and 6 months for azathioprine and m ycophenolic acid, supporting the idea that a 16 -week 
primary  endp oint is both clinically  and ethicall y appropriate and allows an acceptable time to 
assess initial response to therap y.
1.4.2. Rationale for Dose
Enrolled subjects will be randomized to receive once dail y oral filgotinib (200 mg)orGS-9876 
(30mg)with matched pl acebo tablets. The planned treatment of filgotinib and GS -9876 is based 
on safet y data from clinical studies and supported by
 non- clinical safety  data. Clinical efficacy  
data in RA further support the filgotinib dose.
Results from Phase 2a studies (GL PG0634- CL-201 and GL PG0634 -CL-202) and Phase 2b 
studies (GL PG0634- CL-203 and GL PG0634- CL-204) showed that 200 mg once dail y filgotinib 
was well tolerated and demonstrated clinical efficacy (ACR20/50/70 and DAS28[CRP]) in 
subjects with RA. Exposure
-response anal ysis of data from P hase 2 studies indicated a 
dose-dependent increase in efficacy , with a plateau at the 200 mg total daily  dose on the 
dose-response curve. These results are consistent with the relationship observed between 
filgotinib exposures and pSTAT1 activation (ex -vivo) following single and multiple filgotinib 
doses, where maximal inhibition of pSTAT1 (~78%) w as achieved at or above the 200 mg total 
daily  dose { Namour 2015}. Safety  data collected across Pha se 2 clinical studies showed no 
dose-dependent trends in the incidence of AEs or SAEs. Based on the overall risk -benefit 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 30 21 March 2018observed in Phase 2b studies, as well as some clinical similarities of RA and sy stemic lupus 
erythematosus, 200 mg once daily filgotini b is expected to be a safe dose to evaluate efficacy  in 
subjects with L MN.
A 30 mg once dail y dose of GS -9876 will be investigated in this study . In the multiple ascending 
dose study  (GS-US-379- 1900), GS -9876 doses of up to 50 mg once daily  for 7 day s were well 
tolerated in health
y volunteers. A trial of GS -9876 30 mg once dail y is also under investigation 
in subjects with RA (GS -US-379- 1582). Based on the similarity  in risk -benefit profiles between 
RAand sy stemic lupus er ythematosus, a 30 mg once dail y dose is expected to have an 
acceptable safet y profile and have the potential to be efficacious in LMN.
The totality  of available data support the use of filgotinib 200 mg once daily  and GS -9876 30 mg 
once dail y for Phase 2 evaluation.
1.5. Risk/Benefit Assessme nt for the Study
Based on the clinical data to date, as well as the data from nonclinical efficacy  and mechanistic 
studies, there is a positive benefit-risk ratio for the development of filgotinib and GS- 9876 in this 
underserved disease. It is proposed to study  filgotinib in L MN at a dose of 200 mg once dail y, a 
dose at which maximal clinical benefit has been observed for subjects with active RA.
Filgotinib has been administered in large Phase 2b studies of subjects with RA and C rohn’s 
Disease at daily  dose s ranging from 50 -200 mg.
In general, filgotinib has been safe and well -tolerated in all populations studied. No clinicall y 
relevant impact on cardiovascular parameters (including vital signs and ECGs), respiratory  or 
neurologic function was observed in Ph ase 1 and 2 trials of filgotinib.
In the Phase 2b studies in RA, the most common AEs were in the infections and infestations 
system organ class (SOC), and infections were reported more commonl y in the filgotinib groups. 
Pneumonia is an identified risk and serious infection is considered an important potential risk for 
filgotinib. Reference is made to the IB for further information about clinical infection findings.
As filgotinib is an immunomodulating agent, malignancy  is closel y monitored in clinical studi es 
with filgotinib. Although an association of NHL and other malignancies with filgotinib has not 
been established, “NHL and other malignancies” is considered to be an important potential risk 
for filgotinib. Reference is made to the IB for further informa tion about clinical malignancy  
findings, carcinoma, and nonmelanoma skin cancers. All reported malignancies occurred in 
subjects with RA. 
Nonclinical studies in rats and dogs identified l ymphoid tissues and testes as target organs for 
filgotinib in long -term repeat- dose toxicity  studies. Although decreased l ymphocyte numbers 
observed in nonclinical studies have not been seen in clinical studies, hematological assessments 
will be performed throughout the present study  to ensure this potential risk is appropriatel y 
monitored. I n both rats and dogs, microscopic findings in the testes included germ cell depletion 
and degeneration with reduced sperm content and increased cell debris in the epididy mis, and 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 31 21 March 2018reduced fertility  in male rats. When using the AUC at the NOELs for dogs in the 26 and 39 -week 
chronic toxicity  studies, and in the 39- week targeted exposure toxicity  study , the exposure 
margins compared with the proposed clinical dose of 200 mg once dail y are 2.3, 1.8, and 
3.4-fold, respectivel y.The clinical relevance of nonclinical testicular findings in rats and dogs is 
unknown. A male safet y study  is planned to assess the effects, if an y, of filgotinib on semen 
parameters in males with inflammatory  diseases. Until the definit ive results of this study  are 
available, all males will be informed about this potential toxicity  in the informed consent form 
and only  men understanding and accepting the potential risk for loss of fertility  will be enrolled. 
In addition, SLE is a disease of female predominance and although this may  vary  across some
study  population s,the ratio of those affected is approximately  9 fold higher in females than 
males .
Reference is made to the IB for further information about nonclinical and clinical 
testicular findings.
GS-9876 is a highl y selective SYK inhibitor with once dail y dosing. Nonclinical studies show 
that SYK inhibition may  have therapeutic value in the treatment of multiple autoimmune 
diseases such as RA, SLE, autoimmune cy topenias, as well as allergic and autoinflammatory  
disease s. Clinical experience with GS -9876 is limited.
In repeat dose toxicity  studies of GS -9876 (in rats for up to 26 weeks and in cy nomolgus 
monkey s for up to 39 weeks), the primary  observed effects were reversible, dose -dependent 
decreases in circulating lymp hocy tes, and decreased ly mphocy tes in various tissues 
(spleen, lymph nodes, thy mus, and/or bone marrow), consistent with the expected pharmacology  
of SYK inhibition {Barr 2012 }. Additionally , effec ts on ery throcy te turnover were seen in rats, 
and effects on hemostasis (hemorrhage and thrombosis) were seen in monkey s. In clinical studies 
of GS -9876 in health y volunteers, no safety signals were identified and no grade 3 or4 AEs were 
reported. There w ere no clinically  significant changes in vital signs, phy sical findings, laboratory  
parameters, or ECGs. Given the role of SYK in platelet activation and aggregation, bleeding time 
was evaluated in the study subjects; no clinically  relevant prolongation wa s noted. 
Filgotinib is contraindicated in pregnancy ; highl y effective contraception is to be used across all 
clinical studies to mitigate this risk. Based on available non -clinical findings, GS -9876 is not 
contraindicated in pregn ancy , although pregnancy  in GS-9876 trials should be avoided. 
Measures to minimize other potential risks to subjects will include site/investigator training 
regarding monitoring for infection. 
Preclinical and clinical data support the further clinical development of GS -9876 and f ilgotinib 
due to their potential benefit as novel therapies in lupus nephritis, with an acceptable level of risk 
consistent with immunomodulation in this patient population. Controlled trials will be utilized to 
minimize risk to subjects, while gaining und erstanding of drug efficacy . The development of 
GS-
9876 and filgotinib are expected to provide valuable alternatives to existing treatments for 
lupus nephritis and related diseases.
1.6. Compliance
This study  will be conducted in compliance with this protocol, GCP, and all applicable 
regulatory  requirements.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 32 21 March 20182. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of filgotinib and GS- 9876 in subjects with L MN
The secondary  objectives of this study  are: 
To evaluate the safet y and tolerability  of filgotinib and GS- 9876 in subjects with L MN
To evaluate the PK of filgotinib and GS -9876 in subjects with L MN
The exploratory  objective sof this study  are:
 
 
CCII 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 33 21 March 20183. STUDY  DESIGN
3.1. Endpoints
The primary  endpoint of this stu dy is:
The percent change in urine protein from Baseline (Day  1) to Week 16 (assessed by urine 
protein excretion during a 24 -hour urine collection )
The secondary  endpoints of this study  are:
Change from Baseline (Day  1)in urine protein (assessed by  urine protein excretion during a 
24-hour urine collection) at Week 16
Change from Baseline (Day  1)in eGFR 
at Week 16
Change from Baseline (Day  1)in UPCR (assessed by  urine protein excretion during a 
24-hour urine collection) at Week 16
Proportion of subjects with partial remission (defined as urine protein excretion below 
<
3g/d and urine protein excretion decrease b y ≥ 50% among subjects with Baseline (Day 1) 
nephrotic range proteinuria [urine protein excretion ≥ 3 g/d]; or urine protein excretion 
decrease by ≥ 50% among subjects with subnephrotic range proteinuria [urine protein 
excretion < 3 g/d]) at Week 16
Proportion of subjects with complete remission (defined as ur ine protein excretion below 
0.5g/day , with no hematuria) at Week 16
The exploratory  endp oints of this study  are:
 
 
   
 
 
 
 
 
CCII 
I 
I 
I 
I I 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 34 21 March 2018 
 
 
 
 
 
 
 
The biomarker endp oints of this study  are:
Change in JAK -STAT -, SYK -, and disease -related biomarkers in peripheral blood and urine
Association of changes in peripheral blood and urine biomarkers with clinical outcomes
Association of B aseline markers with disease severity  and response to filgotinib and 
GS-9876
3.2. Study Design
This is a Phase 2, randomized, double -blind, multicenter stud y to evaluate the safet y and efficacy 
of filgotinib and GS -9876 in subjects with active LMN who are not in partial or complete 
remission in respo nse to treatment with one or more anti -inflammatory  or immunosuppressive 
agents .
A schematic of this stud y is provided in Figure 3-1.
CCII 
I I 
I 
I 
I 
I 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 35 21 March 2018Figure 3-1. Study Schema
3.3. Study Treatments
Eligible subjects will be randomized in a 1:1 ra tio to receive once daily  oral doses of the 
following stud y drugs for 16 weeks:
Arm Study Drugs
Filgotinib (n=16) Filgotinib 200mg + PTM GS-9876
GS-9876 (n=16) GS-9876 30 mg + PTM F ilgotinib
PTM = Placebo to match
Randomization will be stratified b y prior treatment with cyclophosphamide. 
Urinary  protein excretion will be determined using 2 methods – two consecutive morning voids 
as well as a 24 -hour urine collection. For the Day  1 assessment, all 3 urine samples will be 
collected prior to Day  1, with the 24
-hour urine collection as close to the Day  1 visit as possible. 
At Week 16, the primary  study  endpoi nt will be assessed by  urine protein excretion during a 
RAND OMIZATION 
1:1 
(N=32) DAY1 
Basefine Blinded Treatment Phase 
WK16 
1• Endpoint 
Gs-9876 30 mg+ 
PTM Filgotinib 
I 
' I " 
WK 16: S.ul>jectsw ith a23556 reduction in 
urinary protein excretion from Baseline (Day l j 
to \Ve.e. 16will continue to rec.eiv.e their 
as, s ign ed l>li nd ed study tre3tmen t for an 
additional 16wceks . 
Sul>j ects th 3tdo notach ieve a 2 3 556 reduction 
in urinary prote in - e.m:.ratioo w i II S1.vitch study 
treatment Extended Blinded 
Treatment Phase WK32 
'f Filgotinib200 mg+ 
PTM GS-9876 
GS-9876 30 mg + 
PTM Filgotinib 
GS-9876 30 mg+ 
PTM Filgotinib 
Filgotinib200 mg+ 
PTM GS-9876 
WK 32: Sul>jectsw ith a 2 3556 reduction in urinary 
protein ,e>e:retion from Dayl [forsul>jects who 
remained on the r.andommed studytr:eatm.entaft 2r 
Week 16) or from Week 16 {for su l>jects who 
switc.hed trc3tmentatWeek l6j willcontinueto 
receiv.eth eirassigned blinded studytreatmentfor 
an additi::in31 20w ee·ks. 
S .ub-jectst.hatdo notachieve al 35% reduction in 
urinary J>roteine xcretion from Day 1 {for subjects 
who r2m3ined on the ranclomiz-ecl studytr.e3tment 
aft.2r't;'•'.eek 16)orfrom 'llleek 16{fors.Libject.swho 
5witc.hed tre3tment atWeek 16jtoW eek 32 can 
cont: in uewh ichever tre.atment led to the gre3test 
reduction in urinary p-rotein.e xcrettcln [from Dav 1 
to'W e,ek 1£.on initial studytr:Eatmentorfrom 
We€k 16toWeek32 on switched treatment! , or 
eit:h.er study treatment p.erth.e lnve::i""t igamr's 
d iscretion. WK52 WK56 
Follow -Up 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 36 21 March 201824-hour urine collection. Two consecutive morning voids prior to the Week 16 visit will be used 
to determine response for subsequent study  treatment. A ll subjects who achieve a 
≥
35% reduction in urin ary protein excretion (usin g an average of the UPCR from 2 morning 
voids) from Day 1 will continue to receive their assigned blinded study  treatment
(filgotinib 200mg+PTM GS -9876, or GS -9876 30 mg + PTM f ilgotinib) for an additional 
16weeks. Additional details regarding urine collection procedures will be specified in the 
Laboratory  Manual and Subject Procedures Manual .
Subjects who do not achieve a ≥ 35% reduction in urinary  protein excretion from Day 1 to 
Week 16 will switch 
study  treatment for 16 wee ks in a blinded fashion (ie, those on filgotinib 
will switch to GS -9876 + PTM filgotinib, while those on GS -9876 will switch to 
filgotinib +PTM GS -9876). 
After 32 weeks of blinded treatment, those who have a ≥ 35% reduction in urinary  protein 
excretion (using an average of the UPCR from 2 morning voids) from Day 1(for subjects who
remained on the randomized study  treatment after Week 16) or from Week 16 ( for subjects who 
switched treatment at Week 16)
will continue their assigned blinded treatment for an additional 
20weeks in the Extended Blinded Treatment Phase.  Subjects that do not achieve a 
≥ 35% reduction in urinary  protein excretion from Day  1 (for subjects who remained on the 
randomized study  treatment after Week 16) or from Week 16 ( for subjects who switched 
treatment at Week 16)to Week 32 will be allowed to continue whichever treatment led to the 
greatest reduction in urinary  protein excretion (from Day  1 to Week 16 on initial study  treatment 
or from Week 16 to Week 32 on switched treatment), or either study  treatment per the 
Investigator’s discretion (eg, differences in tolerability  or other non
-renal benefits that support 
overriding the treatment assignment according to reduction in urinary  protein excretion) during 
the Extended Blinded Treatme nt Phase.
3.4. Duration of Treatment
Eligible subjects will receive a maximum of 52 weeks of stud y drug.
3.5. Discontinuation Criteria
3.5.1. Study Drug Interruption Considerations
The Gilead Sciences, Inc. (Gilead) Medical Monitor should be consulted prior to study  drug 
interruption when medically  feasible.
Study  drug interruption should be considered in the following circumstances; prior to resumption 
of study drug, the investigator should discuss the case with the Gilead Medical Monitor :
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree
Subject is scheduled for elective or emergency  surgery  (excluding minor skin procedures 
under local or no anesthesia); timing of study  drug pausing should be determined in 
consultation with the Gilead Medical Monitor
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 37 21 March 2018If the subject has an y signs or symptoms suggestive of infection (regardless of severit y), 
study  drug dosing should be immediately  interrupted, and the medical monitor notified. Any  
subject who d evelops a new infection during the study  should undergo prompt and complete 
diagnostic testing appropriate for an immunocompromised individual, and the subject should 
be closel y monitored. Study drug should continue to be paused until the subject’s event h as 
resolved, per judgment of the investigator.
Refer to Section 7.5for details on study  drug interruption due to AEs that are related to the study  
drug(s) .
NOTE: During the time of study drug interruption for any of the above, the subject may continue 
to have study visits and to take part in procedures and assessments, if deemed medically 
appropriate by the investigator.
3.5.2. Study Drug Discontinuation Criteria
The Gile ad Medical Monitor should be consulted prior to study  drug discontinuation when 
medically  feasible. 
Study  drug should be permanently  discontinued in the following instances:
Any opportunistic infection
Any serious infection that requires antimicrobial therap y or hospitalization, or an y infection 
that meets Serious Adverse Event (SAE) reporting cr iteria
Complicated herpes zoster infection (with multi
-dermatoma l, disseminated, ophthalmic, 
orCNS involvement)
Evidence of active HCV during the stud y, as evidenced b y HCV ribonucleic acid (RNA) 
positivity
Evidence of active HBV during the stud y, as evid enced b y HBV deox yribonucleic acid 
(DNA) positivity or HBV core antibody  positivity
Unacceptable toxicity , or toxicity  that, in the judgment of the investigator, compromises the 
subject’s ability  to continue study -specific procedures or is considered to no t be in the 
subject’s best interest
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Section 7.7.2.1
Discontinuation of the study  at the request of Gilead, a regulatory  agency  or an institutional 
review board (IRB)
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 38 21 March 2018Subject use of prohibited concurrent therap y may trigger study  drug discontinuation; 
consultation should be made with the Gilead Medical Monitor.
Subjects who require concomitant medications at doses and/or frequencies that are higher 
than their Day  1 dose for ≥ 14 consecutive day sare to be withdrawn from study  drug for lack 
of efficacy  but may  continue with study  visits per investigator judgment ; refer to 
Section 5.3.1.1
Laboratory  Criteria: After becoming aware of any  of the following abnormal laboratory  
values, an unscheduled visit (ie, sequential visit) should occur to retest within 3 to 7 days 
(except creatinine, which should be retested 7 to 14
days apart). Retest may be obtained 
sooner if medicall y indicated per investigator judgme nt. If the laboratory  abnormality  is 
confirmed b y the retest, then study drug should be discontinued and further care of the 
subject should be directed per the investigator.
a)Neutrophil s < 1.0  103cells/mm3(SI: <1.0  109cells/L )
b)Hemoglobin < 8.0 g/dL (SI: < 80 g/L)
c)Platelet s< 75.0103cells/mm3 (SI:
<75.0109cells/L )
d) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the 
upper limit of normal range (ULN) AND total bilirubin > 2 ULN or accompanied by  
symptoms consistent with hepatic injury1
e)AST and/or ALT elevations > 3 ULN accompanied by  elevated international 
normalized ratio (INR)1
f)AST or ALT > 5 ULN1
g)Estimated glomerular filtration rate (eGFR MDRD ) <40 mL /min/1.73 m2based on the 
MDRD formula
Subjects who discontinue study  drug dosing at an y time may  continue with study  visits, 
procedures, and assessments, if deemed medically appropriate b y the investigator, but will not be 
eligible for entering the 20 -week Extended Blinded 
Treatment Phase . Subjects who per manently  
discontinue study  medication for any  reason will not be replaced.  Subjects withdrawing from the 
study  should complete the earl y termination (ET) and Final FU visits. Subjects are free to 
withdraw from the stud y at an y time without providing reason(s) for withdrawal and without 
prejudice to further treatment. The reason(s) for withdrawal will be documented in the electronic 
case report form (eCRF). 
                                                
1In each case, there is a need for additional investigations, such as review of ethanol, recreational drug and dietary 
supplement consumption; testing for acute hepatitis A, B or C infection and biliary tract imaging should be promptly 
discussed with the st udy medical monitor .
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 39 21 March 2018Reasonable efforts will be made to contact subjects who are lost to follow -up. All contacts and 
contact attempts must be documented in the subject’s file.
The sponsor has the right to terminate the study  at any  time in case of safet y concerns or if 
special circumstances concerning the stud y medication or the compan y itself occur, making 
further treatment of subjects impossible. I n this event, the investigator(s) and relevant authorities 
will be informed of the reason for stud y termination.
3.6. End of Study
End of Study  is defined as when the last subject has completed 52 weeks of dosing plus the 
follow -up visit 4 weeks (± 5days) after the last dose of study  drug (ie, Week 56 ).
3.7. Post Study Care
The long- term care of sub jects post -study will remain the responsibility  of their primary  treating 
physician.
3.8. Biomarker Testing
3.8.1. Biomarker Samples to Address the Study Objectives
The following biological specimens will be collected in this study  and will be used to evaluate 
the association of exploratory s ystemic and/or tissue specific biomarkers with study  drug 
response, including efficacy  and/or AEs, and events and to help inform the mechanism of action
and mechanisms of resistance to filgotinib and GS -9876 in lupus nephritis .The specific anal yses 
may include, but will not be limited to, the assay s listed below.  
The biomarker anal yses may  include the following:
Measuring the expression and phosphory lation state of STAT and SYK proteins
Characterization of tissue ly mphocy te subsets
Plasma and serum samples for analy sis of circulating factors including but not limited to 
cytokines, microRNA, and metabolites.
Urine s amples for anal ysis of excreted biomarkers associated with nephritis.
PBMC samples to assess cell phenot ype.
PAXgene blood samples for leukocy te gene expression analy sis.
The biomarker sample collection schedule is described in the Study  Procedures Table 
(Appendix 2). Because biomarker science is a rapidly  evolving area of investigation, and AEs in 
particular are difficult to predict, it is not possible to specify  prospectively  all tests that will be 
done on the specimens collected. The testing outlined abo ve is based upon the current state of 
scientific knowledge. It may  be modified during or after the end of the study  to remove tests no 
longer indicated and/or to add new tests based upon the growing state of art knowledge. 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 40 21 March 2018Specimens will be collected from all subjects. The biomarker samples will be destroy ed no later 
than 15 y ears after the end of study . For sampling procedures, storage conditions, and shipment 
instructions, see the Laboratory Manual.
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI-
-
-
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 41 21 March 2018 
 
 
 
 
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 42 21 March 20184. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
A sufficient number of subjects will be screened to enroll approximately  32subjects with LMN.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)Able and willing to sign the informed consent as approved b y the Institutional Review Board 
(IRB). Written consent must be provided before initiating any  screening evaluations. 
Subjects must have read and understood the informed consent form (I CF), must fully  
understand the r equirements of the study , and must be willing to comply  with all study  visits 
and assessments; subjects who cannot read or understand the ICF may  not be enrolled by  a 
guardian or an y other individual
2)Male or female between 18 and 75 y ears of age, inclusive , at the time of initial informed 
consent
3)Kidney  biops y within the 36 months prior to Screening with a histologic diagnosis of LMN 
(International Societ y of Nephrology  [ISN] and the Renal Pathology  Society  [RPS] 2003 
classification of lupus nephritis), either Class V alone, or Class V in combination with
Class II. If the biops y indicates segmental glomerular sca rring indicative of prior Class III or 
IV lesions but there is limited or no evidence of current Class III or IV activity , the subject 
would be elig ible if the Class V findings are active. 
A cop y of the kidney biopsy path ology  report will be obtained from each subject and 
forwarded to the Gilead Medical Monitor for review and confirmation of eligibility  prior to 
randomization on Day  1.
4)Urine protein excretion ≥ 1.5 
grams per day  based on 24 -hour urine sample collected during 
Screening
5)Estimated glomerular filtration rate (eGFR MDRD ) ≥ 40 mL /min/1.73 m2based on the MDRD 
formulation at Screening 
6)
Prior treatment for LMN with at least one immunosuppres sive therap yfor a sufficient 
duration before Screening , including but not limited to :
a)Calcineurin inhibitors (cy closporin A, tacrolimus), 
b)Alky lating agents (chlorambucil, cy clophosphamide), or
c)Antimetabolite drugs (azathioprine, my cophenolate mofetil) 
d) O ther (eg, methotrexate, leflunomide, moderate- to high- dose steroids, etc .)
A brief Investigator summary  of prior therapy  should be provided (ie, therapy name , 
duration/dates, and response).
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 43 21 March 20187)Treatment with an ACEi or ARB at a dose deemed appropriate for the subject per the 
Investigator for at least 6 weeks prior to and during Screening, with a stably  prescribed dose
for at least 14 day s prior to Day  1. Enrolled subjects should remain on the stably  prescribed 
dose of ACEi or ARB treatment throughout the study .
Subjects who are not taking any ACEi or ARB 
may be screened if there is documented 
intolerance to ACEi and/or ARB  
8)If a subject is taking oral glucocorticoids, the dose must be ≤ 20 mg/day  prednisone 
(orequivalent) and must have been on a stabl y prescribed dose for at least 28 days prior to 
Day 1. Enrolled subjects should remain on the stably  prescribed dose of prednisone treatment 
through Week 16 of the study  (after assessment of the primary  outcome) . 
9)If a subject is taking the following agents, they  must have been on a stabl y prescribed dose
for at least 28 day s prior to Day  1:
a)Hydroxychloroquine (
≤ 400 mg/day ),
b)Chloroquine (≤ 250 mg/da y), or
c)Quinacrine (≤ 100 mg/day )
Enrolled subjects should remain on the stabl y prescribed dose of the above treatment s
throughout the stud y.  
10)Use of NSAIDs is permitted if the dose has been stably  prescribed for at least 14 day s prior 
to Day  1. Enrolled subjects should remain on the stably  prescribed dose of NSAID treatment 
throughout the stud
y. Intermittent use (PRN) for non -LMN indications should be minimized.
11)All DMARDs or immunosuppressive agents other than glucocorticoids , hydroxychloroquine
(as specified above), azathioprine (up to a maximum of 2mg/kg bod y weight/day or 
200mg/day , whichever is lower), and methotrexate ( ≤ 20 mg per week )should be withdrawn 
at least 28 day s prior to Day  1.
12)
Systolic blood pressure (SBP) below 160 mmHg AND diastolic blood pressure (DBP) below 
90 mmHg will be measured at Screening . The Screening blood pressure may  be repeated (a 
maximum of 2 times) as an unscheduled visit prior to Day 1.
13)Females of childbearing potential (as defined in Appendix 5) must have a negative pregnancy 
test at S creening , Day  1 and throughout the stud y at each stud y visit .
14)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 5. Specifically , female subjects must agree to refrain from attempting conception, 
egg donation or harvest from the time of signing consent through 3 6days following the last 
dose of study  drug. Male subjects must agree to refrain from attempting conception, or sperm 
donation from the time of signing consent through 90 day s following the last dose of study  
drug.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 44 21 March 201815)Subjects must agree to re frain from blood donation from S creening through at least 30 days 
following the last dose of study  drug .
16) Lactating female subjects must agree to discontinue nursing from Screening through at least 
36days following the last dose of study  drug .
17)Meet the following TBScreening criteria: 
a)No evidence of active or latent TB as assessed during Screening b y:
A nega tive QuantiFERON®TB-Gold In -
Tube test at Screening AND
A chest radiograph (if consistent with local guidelines) taken at Screening or within 
the 90 day s prior to Screening (with the report or films available for investigator 
review) without evidence of ac tive or latent TB infection 
b)Subjects previously  treated for latent TB: subject who has previousl y received an 
adequate course of therapy  as per local standard of care for latent TB (eg, 9 months of 
isoniazid in a location where rates of primary  multi- drug resistant TB infections are 
<5% or an acceptable alternative regimen). In these ca ses, no QuantiFERON®TB-Gold 
In-Tube test (or equivalent assay) need be obtained, but a chest radiograph must be 
obtained if not done so within 90 day s prior to Screening (w ith the report or films 
available for I nvestigator review). It is the responsibility  of the Investigator to verify  the 
adequacy  of previous anti -tuberculosis treatment and provide appropriate documentation.  
Subjects with a history  of untreated or inadequa tely treated latent TB are excluded from 
the study .
c)Subjects with newly  identified latent TB during Screening are excluded from the study .  
Cases falling under category  “b” need to be approved by  the Sponsor prior to  enrollment in 
the study . Subjects wit h any  history  of or current active TB (regardless of past or present 
anti-TB treatment) are excluded. 
18)In the judgment of the investigator, participation in the study  offers an acceptable benefit/risk 
ratio when considering current lupus membranous nephrop athy disease status, medical 
condition, and the potential benefits and risks of alternative treatments for lupus membranous 
nephropath y
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)Prior treatments as follows:
a)Previous treatment with a JAK inhibitor within 3 months of Day  1
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 45 21 March 2018b) Use of rituximab or other selective B ly mphoc yte depleting agents 
(including experimental agents) within 6 months of Day  1. Enrollment is permitted if the 
lastdose wa s given > 6 months and CD19 -positive B cell sare detectable at Screening .
c)Anticipated use of disallowed medications in Section 5.3.2
2)Known hy persensitivity  or allergy  to the study  drugs (filgotinib, GS- 9876), their metabolites, 
or formulation excipients 
3) H istory  of, or current, inflammatory  or autoimmun e disease other than SLE 
(e.g., scleroderma, reactive arthritis, rheumatoid arthritis, anky losing spondy litis, 
Lym edisease) that will interfere with clinical evaluation during the study , per judgment of 
the Investigator. Secondary  Sjogren’s Sy ndrome or controlled thy roiditis is acceptable, per 
judgment of I nvestigator
4)Administration of a live/attenuated vaccine within 30 day s prior to Day 1, or planned during 
the study  or through 12 weeks after subject’s last dose of study  drug
5)Participation in any  clinical study  of an investigational drug/ device within 4 weeks or 
5half-
lives prior to Screening, whichever is longer. Exposure to investigational biologics 
shoul d be discussed with the Sponsor
6)End stage renal disease (ESRD; peritoneal dialy sis, hemodialy sis, or status post -renal 
transplantation) 
7)History  of lymphoproliferative disease or current ly mphoproliferative disease 
8)History  of organ or bone marrow transplant
9)Positive serology  for human immunodeficiency  virus (HIV) 1 or 2 at Screening
10)Evidence of active HCV infection. S ubjects with positive HCV Ab at S creening, require 
reflex testing for HCV RNA. Subjects with positiv e HCV RNA viral load (VL) at S creening 
will be excluded. Subjects with positive HCV Ab, but negative HCV RNA VL  are eligible 
per investigator judgment, but require ongoing monitoring as outlined in the schedule of 
assessments. Subjects with active HCV during the study , as evidenced b y RNA positivity , 
will be discontinued from study  drug as outli ned in the protocol.
11)Evidence of active or prior HBV infection. Subjects with positive HBV surface antigen 
(HBsAg) at S creening are excluded from the study . Subjects with positive HBV DNA or 
HBV core Ab are excluded from the stud y.
12)History  of opportunistic infection, or immunodeficiency  syndrome, which would put the 
subject at risk, as per investigator judgment.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 46 21 March 201813)Active infection that is clinically  significant, as per judgment of the investigator, or any  
infection requiring hospitalization or treatment with intravenous anti -infectives within 
60days of Day 1; or any  infection requiring oral anti ‑infective therap y within 30 days of 
Day 1.  
14)Currently  on any  treatment or prophy laxis for chronic infection (such as pneumocy stis, 
cytomegalovirus, herpes zoster, an
d aty pical m ycobacteria). Past history  of disseminated 
Staphy lococcus aureus or disseminated Herpes simplex infection. 
15)History  of symptomatic herpes zoster infection within 12 weeks prior to Screening or history 
of disseminated/complicated herpes zoster i nfection (multi -dermatomal involvement, 
ophthalmic zoster, central nervous sy stem involvement or postherpetic neuralgia)
16)Known bleeding disorder or hypercoagulable state; antiphospholipid antibody  (APL A) 
syndrome with prior clinically significant event (pe r judgment of investigator); or on chronic 
anticoagulation/anti -platelet therap y such as warfarin, heparin, etc. , as outlined in 
Section 5.3.2  (NOTE: stably  prescribed chronic aspirin therapy  ≤ 325 mg/day  for 
cardiovascular proph ylaxis is allowed) .
17)Histor y of an infected joint prosthesis or other implanted device with retention of the 
prosthesis or device in situ
18)Current drug or alcohol abuse, per investigator judgment
19)History  of or current moderate to severe congestive heart failure (New York Heart 
Associ ation [NYHA] class III or IV), OR within the last 6 months, a cerebrovascular 
accident, m yocardial infarction, unstable angina, unstable arrh ythmia, OR new or significant 
ECG finding at Screening, or an
y other cardiovascular condition which, in the opinion of the 
investigator, would put the subject at risk b y participation in the study.
20)History  of malignancy  within the past 5 years prior to Screening (except for adequatel y 
treated basal cell carcinoma or non -metastatic squamous cell carcinoma of the skin or
cervical carcinoma in situ, with no evidence of recurrence). 
21)Significant blood loss (> 450mL) or transfusion of any  blood product within 12 weeks prior 
to Day 1.
22)Tests performed at the central laboratory  at Screening that meet any  of the criteria below 
(outof range lab values that are believed to be in error m ay be rechecked one time, after 
consultation with the sponsor or its designee, before subject is considered a screen failure):
a)Hemoglobin < 8.0 g/dL (International S ystem of Units [SI ]: <80g/L);
b)Neutrophils < 1.5103cells/mm3(SI: <1.5109cells/L );
c)Platelets < 100103cells/mm3(SI: <100109cells/L );
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 47 21 March 2018d)Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5ULN;
e)Total bilirubin level ≥ 2 ULN unless the subject has b een diagnosed with Gilbert’s 
disease and this is clearly documented;
4.4. Screen Failures
Subjects who do not meet eligibility  criteria for study  entry  (“screen failures”) may  be rescreened 
one time in select cases. For example,
To adequatel y washout a concomit ant medication
Administrative reasons (eg, exceeding the screening window due to issues with appointment 
scheduling or obtaining results of laboratory  data)
Written approval must be obtained from the sponsor prior to rescreening. Rescreening may  not 
be use d to recheck a subject who is likely  unsuitable for the study  (for example, to check whether 
a chronically  abnormal laboratory  test is closer to normal range). 
Subjects who are permitted to rescreen must repeat the informed consent process and sign a new 
informed consent form. A new screening number will be assigned. The following 
tests/procedures will not need to be repeated (unless required per investigator judgment) if 
results are available within the appropriate timeframe:
Chest x -ray, if performed wit hin 3 months prior to the rescreening visit
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 48 21 March 20185. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
An Interactive Web Response Sy stem (IWRS) will be employ ed to manage subject 
randomization and treatment assignments. It is the responsibility  of the investigator to ensure that 
the subject is eligible for the study  prior to enrollment. Subjects will be assigned a screening 
number at the time of consent. 
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment directly  from the I WRS sy stem 
for that subject. Gilead recommends but does not require that the i nvestigator contact the 
Gilead Medical M onitor before breaking the blind. Treatment assignment should remain blinded 
unless that knowledge is necessary  to determine emergency  medical care for the subject . The 
rationale for unblinding must be clearl y explained in source documentation and on the case 
report form/ electronic case report form (eCRF), along with the date on which the treatment 
assignment was unbli nded .The investigator is requested to co ntact the Gilead Medical M onitor 
promptly  in case of an y treatment unblinding.
Blinding of stud y treatment is critical to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued.
Gilead 
Pharmacovigilance and Epidemiology (PVE ) may  indepe ndently  unblind cases for 
expedited reporting of suspected unexpected serious adverse reactions (SUSARs).
5.2. Description and Handling of GS-9876, PTM GS - 9876, Filgotinib and PTM 
Filgotinib
5.2.1. Formulation
of GS -9876 and PTM GS -9876
GS-9876 will be supplied as 30 mg tablets that are round, plain- faced and film -coated blue. Each 
tablet contains 30 mg of GS -9876 free base as the succinate form (GS -9876 -02). The G S-9876 
tablets contain commonly used excipients including microcry stalline cellulose, mannitol, 
croscarmel lose sodium, magnesium stearate, pol yviny l alcohol, pol yethylene gl ycol, titanium 
dioxide, talc, and FD&C blue #2/indigo carmine aluminum lake. 
Matching placebo tablets will be supplied that are identical in phy sical appearance to the 30 mg 
GS-9876 tablet s and contain the following inactive ingredients: microcry stalline cellulose, 
lactose monohy drate ,croscarmellose sodium , magnesium stearate, pol yvinyl alcohol, 
polyethylene gly col, titanium dioxide, talc, and FD&C blue #2/indigo carmine aluminum lake.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 49 21 March 20185.2.2. Formulation of Filgotinib and PTM Filgotinib
Filgotinib will be provided as 200 mg tablets that are capsule -shaped, and film -coated beige 
debossed with “GSI” on one side and “200” on the other. Each tablet contains the equivalent of 
200mg filgotinib free base in the form of filgotinib maleate. In addition to the active ingredient, 
filgotinib tablets contain the following inactive ingredients: microcry stalline cellulose, lactose 
monohy drate, fumaric acid, pregelatinized starch, silicon dioxide, magnesium stear ate, 
macrogol/PEG 3350, polyvin yl alcohol, talc, titanium dioxide, iron oxide yellow, and iron oxide 
red.
PTM filgotinib tablets are identical in appearance to the active filgotinib tablets. PTM filgotinib 
tablets contain the following inactive ingredients : microcry stalline cellulose, lactose 
monohy drate, croscarmellose sodium, magnesium stearate, macrogol/PEG 3350, poly vinyl 
alcohol, talc, titanium dioxide, iron oxide y ellow, and iron oxide red.
5.2.3. Packaging and Labeling of Study Drugs
GS-9876 tablets, 30 mg, filgotinib tablets, 200 mg, and PTM tablets are packaged in white, 
high-densit y pol yethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant 
and poly ester packing material. Each bottle is enclosed with a white, continuous thread, 
child-resistant poly propylene screw cap with a n induction -
sealed and aluminum- faced liner.
Study  drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Dr ug Administration 
(FDA) and/or other local regulations.
5.2.4. Storage and Handling of Study Drugs
GS-9876 tablets, filgotinib tablets, and PTM tablets should be stored at a controlled room 
temperature of 25 ºC (77 ºF); excursions are permitted between 15 ºC and 30 ºC (59 ºF and 
86 ºF). Storage conditions are specified on the label. Until dispensed to the subjects, all bottles of 
study  drugs should be stored in a securel y locked area, accessible only to authorized site 
personnel.
To ensure the stabilit y and proper identification, study  drugs should not be stored in a container 
other than the container in which they  were supplied.  Keep the container tightl y closed to 
protect from moisture.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure when handling.  
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 50 21 March 20185.2.5. Dosage and Administration of GS -9876
GS-9876 30 mg (1 30 mg tablet), or GS-9876 PTM (1 tablet) will be provided by  Gilead 
Sciences, Inc. and are to be administered orally  once dail y with water. The study drug should be 
swallowed whole. GS -9876 or GS -9876 PTM 
may be taken with or without food. Each subject 
will be given instructions to maintain approximatel y the same daily dosing interval between 
study  drug doses. Subjects will be instructed to take study  drug at approximately  the same time 
each morning. At Weeks 2, 4 and 20, subjects will be instructed to take their study  drug in clinic 
as the first study  procedure prior to an
y others scheduled for that visit. At Weeks 16 and 
32subjects will be instructed to take their stud y drug after predose assessments have been 
completed (eg, PK sample collection).
For missed dose(s) of study  medication, subject should be instructed to take the missed dose(s) 
of study  medication, as soon as possible, during the same day . If more than 8 hours has elapsed 
since the scheduled time of the missed dose, the subject should be instructed to wait and take the 
next dose at the reg ularly scheduled time. Subjects should be cautioned never to double the next 
dose with a missed dose of study  drug under an y circumstances. 
5.2.6. Dosage and Administration of Filgotinib
Filgotinib 200 mg tablets and PTM filgotinib 200 mg ta blets will be administered once daily 
with or without food. Each subject should be given instructions to maintain approximately  the 
same daily  time of administration to ensure a similar dosing interval between study  drug doses. 
At Weeks 2, 4 and 20, subjects will be instructed to take their st udy drug in clinic as the 
firststudy  procedure prior to any  others scheduled for that visit. At Weeks 16 and 32 subjects 
will be instructed to take their study  drug after predose assessments have been completed (eg, PK 
sample collection).
For missed dose(s) of study  medication, subjects should be instructed to take the missed dose(s) 
of study  medication as soon as possible during the same day. If more than 8 hours has elapsed 
since the scheduled time of the missed dose, the subject should be instructed to wait and take the 
next dose at the regularl y scheduled time. If the missed dose is not taken on the original day , 
subjects should be cautioned not to double the next dose with the missed dose of study  drug 
under an y circumstances. I n those cases, the missed dose should be returned to the study  drug 
bottle.
5.3. Prior and Concomitant Medications
All medications taken for the treatment of lupus and lupus nephritis will be recorded in the 
source documents and on the eCRF. All other medications (for non- SLE indications) taken up to 
30 day s prior to the screening visit through the end of th e study  (4weeks after the last dose of 
study  drug) will be recorded in the source documents and on the eCRF. At each study  visit, the 
study  center will capture any and all medications taken b y the subject since the last visit or 
during the visit (as applicable). Concomitant medicatio ns include prescription and 
non-prescription medications, dietary  supplements, vitamins, and minerals.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 51 21 March 2018Effective current therapies should not be discontinued for the sole purpose of participating in this 
study . Subjects may  receive medications to treat AEs as deemed necessary  by the investigator or 
the subject’s health care providers. Should subjects have a need to initiate treatment with any  
excluded concomitant medication, the Gilead Medical Monitor should be consulted prior to 
initiation of the new medication, where possible. In instances where an excluded medication is 
initiated prior to di scussion with the sponsor, the I nvestigator must notify  Gilead as soon as 
he/she is aware of the use of the excluded medication, and instruct subjects to hold study  drug 
administration while taking an excluded medication.
5.3.1. Allowed Concomitant Medications 
5.3.1.1. Concomitant Medications for LMN
The allowed concomitant medication(s) for LMN should be maintained, as much as possible, at 
stable doses (defined as no change in prescription) 28 day s prior to Day  1 through Week 16:
Oral corticosteroids for SLE ≤ 20 mg pre dnisone/day  (or equivalent). Subjects who are not 
planning to continue oral corticosteroids during the study  must have discontinued them at 
least 28 day s prior to Day 1
Oral antimalarials (eg, chloroquine ≤ 250 mg/day , hydroxychloroquine ≤ 400mg/day , or 
quinacrine ≤ 100 mg/day) for SLE (administered per investigator judgment). Subjects who 
are not planning to continue oral antimalarials during the stud y must have discontinued them 
at least 28 day s prior to Day 1  
Oral or injectable MTX 
≤ 20 mg per week (subjects on MTX should also be on folic acid 
supplementation [or equivalent], per local standard of care). All local standard -of-care 
practices for the administration of MTX, including laboratory  testing, follow -up care, and 
contraindications should be perf ormed throughout the study . The concomitant use of 
medicines which may  increase the risk of hepatotoxicity  and/or nephrotoxicity  with MTX 
(such as NSAIDs, salicy lates, or other folate antagonists) should be avoided, as much as 
possible, in accordance with clinical practice
Oral azathioprine ( ≤2 mg/kg body weight/day  or 200 mg/day , whichever is lower) for SL E or 
lupus nephritis (administered per investigator judgment). Subjects who are not planning to 
continue oral azathioprine during the study  must hav e discontinued them at least 28 days 
prior to Day 1  
After completion of the Week 16 visit, the dose and/or frequency  of these medications may  be 
reduced one or more times per investigator judgment. I n these cases, the dose and/or frequency  
may be increased ag ain as needed, but should not exceed the subject’s Day  1 dose and frequency .
Subjects who require concomitant medications at doses and/or frequencies that are higher than 
their Day  1 dose for 
≥ 14 consecutive day sare to be withdrawn from study drug for la ck of 
efficacy  but may  continue with study  visits per investigator judgment.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 52 21 March 2018Dose adjustment for toxicity  management is allowed at any  time. A toxicity  requiring dose 
adjustment should be reported as an AE or SAE and managed as outlined in Section 7.5. 
5.3.1.2. Other Concomitant Medications
The following concomitant medications should be maintained, as much as possible, at stable 
doses 28 day s prior to Day  1 and throughout the duration of the study .
Vitamins, minerals, and herbal supplements
Hormonal contraceptives or male or female hormone replacement therap y
Other chronic therapies including, but not limited to, antihy pertensives, thyroid replacement, 
analgesics, dail y aspirin for cardiovascular proph ylaxis ( ≤ 325 mg/day ), and chronic 
nonsteroidal anti-inflammatory  drugs (NSAIDs) or other analgesics
5.3.2.
Prohibited Concomitant Me dications 
Examples of prohibited medications are provided below. This list does not include medications 
such as anti -HIV agents that would be contraindicated based on other excl usion criteria.
Table 5-1. Prohibited Medications
Drug Class Agents Disallowed Prohibited Period
Biologic Immunomodulator Anti-tumor necrosis factor drugs infliximab, 
adalimumab, belimumab, golimumab, 
certolizumab, rituximab, dupilumab, or 
biosimilar agent (if applicable)90 day s prior to screening through the 
end of study  participation (6months 
for rituximab and demonstration of 
CD19+ B cell presence )
Any other investigational immunomodulatory  
biologic agent or biosimilar (if applicable)90 day s or 5 half -lives prior to 
screening (whichever is longer) 
through the end of study  participation
Prohibited SLE Medications
Corticosteroids Oral corticosteroids > 20 mg prednisone 
equivalent/day28 day sprior to Day 1 through the end 
of study  participation
Injectable corticosteroids 14 day s prior to Day 1 through the end 
of study  participation
Non-biologic 
ImmunomodulatorAzathioprine (> 2mg/kg body weight/day  or 
200mg/day, whichever is lower), colchicine, 
cyclosporine, cy clophosphamide, tacrolimus 
(oral or topical), gold salts, leflunomide,
minocycline, MTX > 20mg/week (subcutaneous 
or oral), mycophenolate, penicillamine, 
sirolimus ,  everolimus, temsirolimus, or other 
immunomodulatory /immunosup pressive 
therapies (with the exception of oral 
antimalarials as permitted in Section 5.3.1.1 )28 day s prior to Day 1 through the end 
of study  participation
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 53 21 March 2018Drug Class Agents Disallowed Prohibited Period
Strong P -gp Inducersa
Anticonvulsants Phenobarbital, pheny toin, or carbamazepine 21 day s prior to Day 1 through the end 
of study  participationAntimycobacterials Rifabutin, rifapentine, rifampin
Herbal/Natural Supplements St. John’s wort or danshen (salvia miltiorrhiza)
CYP3A4 Inhibitorsb
Strong CYP3A4 Inhibitors Clarithromycin, conivaptan, itraconazole, 
ketoconazole, nefazodone, posaconazole, 
telithromycin, voriconazole, telaprevir, 
boceprevir, grapefruit juice, idelalisib, Viekira 
Pak (ombitasvir, paritaprevir, ritonavir, 
dasabuvir), troleandomy cin, or mibefradil14 day s prior to Day 1 through the end 
of study  participation
Moderate CYP3A4 
InhibitorsFluconazole, erythromycin, diltiazem, 
dronedarone, aprepitant, casopitant, imatinib, 
verapamil, tofisopam, ciprofloxacin, cimetidine, 
cyclosporine, Schisandra sphenanthera, 
crizotinib, netupitant, nilotinib, or isavuconazole14 day s prior to Day 1 through the end 
of study  participation
CYP3A4 Inducersc
Strong CYP3A4 Inducers Carbamazepine, pheny toin, rifampin, 
fospheny toin, pentobarbital, primidone, 
rifabutin, rifapentine, phenobarbital, mitotane, 
avasimibe, St. John’s Wort, enzalutamide14 day s prior to Day 1 through the end 
of study  participation
Moderate CYP3A4 InducersBosentan, thioridazine, nafcillin, modafinil, 
semagacestat, genistein14 day s prior to Day 1 through t he end 
of study  participation
Other
JAK Inhibitor Ruxolitinib or tofacitinib (or investigational) 3 months prior to screening through 
the end of study  participation
SYK Inhibitor Fostamatinib , entospletinib ,orother 
investigational3 months prior to screening through 
the end of study  participation
Anti-platelet Adenosine diphosphate (ADP) receptor 
inhibitors, phosphodiesterase inhibitors, PAR -1 
antagonists, gly coprotein 2b/3a inhibitorsOne y ear prior to screening through 
the end of study  participation
Aspirin > 325 mg/day 14 day s prior to Day 1 through the end 
of study  participation
Anti-coagulant Warfarin, any  Vitamin K antagonist, any  novel 
oral anticoagulant, any  heparin or low molecular 
heparins, or inhibitors of factor XaOne y ear prior to screening through 
the end of study  participation
a May result in a decrease in the concentrations of filgotinib . Filgotinib is a P-gp substrate. A single dose of 200 mg 
itraconazole (a potent P -gp inhibitor) increased filgotinib C maxby 63.9% and AUC infby 44.6% but had no effect on the 
major, active metabolite GS -829845.
b May result in an increase in the concentrations of GS -9876
c May result in a decrease in the concentrations of GS-9876
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 54 21 March 20185.4. Vaccine Guidelines
Prior to study  participat ion, it is recommended that the subject’s vaccinations be brought up to 
date according to local vaccination standards.
Live or attenuated vaccines (including, but not limited to varicella and inhaled flu vaccine) are 
prohibited within 30 days of Day  1, thr oughout the study , and for 12 weeks after the last dose of 
study  drug.
Subjects should be advised to avoid routine household contact with persons vaccinated with 
live/attenuated vaccine components. General guidelines suggest that a study subject’s exposure
to household contacts should be avoided for the below stated time periods:
Varicella or attenuated typhoid fever vaccination – avoid contact for 4 weeks following 
vaccination
Oral polio vaccination - avoid contact for 6 weeks following vaccination
Attenua ted rotavirus vaccine - avoid contact for 10 day s following vaccination
Inhaled flu vaccine - avoid contact for 1 week following vaccination
Inactivated vaccines (such as inactivated flu vaccines) should be administered according to local 
vaccination standards whenever medicall y appropriate; however, there are no available data on 
the concurrent use of filgotinib or GS- 9876 and their impact on immune responses following 
vaccination.
5.5. Accountability for Study Drugs
The investigator is responsible for en suring adequate accountability  of all used and unused study  
drug. This includes acknowledgement of receipt of each shipment of stud y drug (quantity  and 
condition). All used and unused study  drug dispensed to subjects must be returned to the site.
Study  drug accountability records will be provided to each stud y site to:
Record the date received and quantity  of study  drug
Record the date, subject number, subject initials, the study  drug number dispensed
Record the date, quantity of used and unused study drug returned, along with the initials of 
the person recording the information. Dispensing records will include the initials of the 
person dispensing the study drug or supplies
5.5.1. I nvestigational M edicinal Product Return or Disposal
For additional information about study  drug accountability , return, and disposal refer to 
Section 9.1.7.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 55 21 March 20186. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. Additional details regarding 
urine collection procedures will be specified in the L aboratory  Manual and Subject Procedures 
Manual .
Subject -reported outcomes will be administered, where available, and should be completed
before an y other stud y procedures. Invasive stud y procedures such as blood draws should be 
done at the end of a study  visit, unless otherwise specified. Investigator 
questionnaires/assessments will be administered, where available, and should be performed prior 
to reviewing subject -reported outcomes for that visit, as much as possible. 
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
Subject eligibility  will be esta blished at the conclusion of the screening evaluations. The 
screening number and subject ID will be assigned for each subject b y IWRS. 
It is the responsibility  of the investigator to ensure that each subject is eligible for the study  
before randomization. A subject will be considered enrolled once they have been randomized.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened up to 35days prior to randomization (Day  1) to determine eligibility  
for participation in the study . The Screening visit will take two separate day s to complete. In 
addition, Screening Day  2 cannot occur 
earlier than 3 day s after Screening Day  1 due to the 
timing of the morning urine voids and the 24 hour urine collection. Additional details regarding 
urine collection procedures will be specified in the L aboratory  Manual and Subject Procedures 
Manual.
The following will be performed and documented at S creening:
Obtain written informed consent
 
Obtain medical history , including a cop y of the kidney biops y pathology  report with a 
histologic diagnosis of LMN performed within the 36 months prior to Screening. The report 
will be forwarded to the Gilead Medical Monitor for review and confirmation of eligibility  
prior to randomization on Day  1.
CCII 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 56 21 March 2018Review inclusion and exclusion criteria
Height and weight
Complete PE
Obtain urine samples for:
Urinary  protein excretion will be determin ed using 2 consecutive morning voids as well 
as a 24 -hour urine collection. 
Urinaly sis (with urine microscop y and spot protein- to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for active urine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria], or 
red cell casts in the absence of infection or other causes). In such circumstances,
investigators may  ask patients to return for another screening visit.
Urine biomarker sample
Vital signs
Standard 12- lead ECG
Obtain blood samples for:
Clinical Laboratory Tests ( hematology , serum chemistry , and coagulation )
HbA 1cand TSH
CRP and ESR
Autoantibod y panel and complement levels
Serum Pregnancy  Test (for females of childbearing potential) or FSH test (for females of 
nonchildbearing potential)
Virology  Tests (HIV - 1 , HIV -2, HBV, and HCV)
HCV RNA VL (if subject is HCV Ab positive)
QuantiFERON®TB Gold in Tube Test (if applicable)
Biomarker Samples ( whole blood TBNK biomarker sample
, serum and plasma biomarker 
sample s, vfPBMC 
sample, and PAXgene RNA sample)
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 57 21 March 2018Chest x -ray (if one has not alread y been obtained within 3 months prior to screening)
Record an y serious adverse events and all adverse event s related to protocol mandated 
procedures occurring after signing of the consent form
Record an yconcomitant medication in the medical history
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 35days after screening for randomization into the study on Day  1.
Subjects who do not meet the eligibility  criteria will be excluded from randomization and may  be 
considered for rescreening one time for the study  in consultation with the Sponsor or its 
designee. Refer to Section 4.4for additional details.
A single retest of screening labs is permitted only
 if there is reason to believe the retest value will 
be within accepted parameters, or if the initial value was either due to a sample processing error 
or an extenuating circumstance.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all concomitant medication, serious adverse events (SAEs), as well as 
any adverse events related to protocol-mandated procedures on the adverse events case report 
form (eCRF). All other untoward medical occurrences observed during the screening period, 
including exacerbation or changes in medical hi story are to be captured on the medical history  
eCRF. See Section 7Adverse Events and Toxicity  Management for additional details.
6.2.2. Day 1 Baseline Assessments
The following will be performed and documented prior to dosing:
Updates to medical history  (if applicable)
Review inclusion and exclusion criteria
Weight
Symptom -driven PE 
Obtain urine samples for:
Urinary  protein excretion will be determined using 2 consecutive morning voids as well 
as a 24 -hour urine collection. All 3 urine samples will be collected prior to Day 1, with 
the 24- hour urine collection as close to the Day  1 visit as possible. 
Urinaly sis (with urine microscop y and spot protein- to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or no t the patient is 
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for active urine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria], or 
red cell casts in the absence of infection or other causes). 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 58 21 March 2018Urine pregnancy  test (for females of childbearing potential)
Urine biomarker sample
SELENA -SLEDAI
BILAG
Patient Global Assessment of Disease activity
Physician Global Assessment of Disease activity
36-Item Short Form Health Survey
Vital signs
Standard 12
-lead ECG
Obtain predose blood samples for:
Fasting Clinical Laboratory Tests (hematology , serum chemistry with lipid assessments , 
and coagulation )
CRP and ESR
Quantitative serum immunoglobulin test
Autoantibod y panel and complement levels
HCV RNA VL (if subjec t was HCV Ab positive at Screening )
Biomarker Samples ( whole blood TBNK biomarker sample
, serum and plasma biomarker 
samples, vfPBMC sample, and PAXgene RNA sample)
Study  drug dispensin g
Review and record all AEs and concomitant medications
Following the completion of the above assessments, the subject will be randomized and 
administered study  drug.   
 
 
 
CCI
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 59 21 March 20186.3. Randomization
Subjects may  not be randomized until the Gilead Medical Monitor has reviewed the kidney  
biopsy  pathology  report and has confirm ed that a subject is eligible. Upon qualification for the 
study , subjects will be randomized in a 1:1 ratio using a computerized I WRS sy stem. 
For each subject at each visit, the clinic will contact the I WRS sy stem and for the appropriate 
bottle number to be dispensed. The bottle will contain the relevant study  drug for the period until 
the next dispensation visit.
Refer to Sections 3.3and 6.1for additional details.
6.4. Week 1 Assessments
Weight
Symptom -driven PE 
Obtain urine samples for:
Urinaly sis (with urine microscop y and spot protein- to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is 
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for act ive urine sediment (any  of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria], or 
red cell casts in the absence of infection or other causes). 
Urine pregnancy  test (for females of childbearing potential)
Vital signs
Obtain blood samples for:
Clinical Laboratory Tests (hematology , serum chemistry , and coagulation)
CRP and ESR
HCV RNA VL (if subject was HCV Ab positive at Screening)
Study  drug accountability
Review and record all AEs and concomitant medications
6.5. Weeks 2 through Week 28 Assessments (exclud ing Week 16)
At Weeks 
2, 4, and 20, subjects will be instructed to take their study  drug in the clinic as the 
firststudy procedure prior to any others scheduled for those visits.
Weight
Symptom -driven PE 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 60 21 March 2018Obtain urine samples for:
Urinaly sis (with urine microscop y and spot protein- to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is 
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for active u rine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria], or 
red cell casts in the absence of infection or other causes). 
Urine pregnancy  test (for females of childbearing potential)
Urine biomarker sample (Week 2 only )
SELENA -SLEDAI
Vital si gns
Obtain blood samples for:
Clinical Laboratory Tests (hematology ,serum chemistry , and coagulation)
CRP and ESR
Quantitative serum immunoglobulin test (Weeks 8 and 24 only )
Autoantibod y panel and complement levels 
(Weeks 2, 4, and 8 only )
HCV RNA VL (if subject was HCV Ab positive at Screening)
Plasma PK samples ( Weeks 2, 4, and 20 [ at least 30 minutes and up to 3 hours after 
dosing ] and an ytime at Weeks 8 and 24)
Biomarker Samples (Week 2 only  [whole blood TBNK biomarker sample , serum and 
plasma biomark er samples, vfPBMC sample, and PAXgene RNA sample])
Study  drug accountability
Study  drug dispensing (Weeks 4, 8, 12, 20, 24, and 28 only )
Review and record all AEand concomitant medications
6.6. Week 16 and Week 32 Assessments
At Weeks 16 and 32 subjects will be instructed to take their stud y drug after predose assessments 
have been completed (eg, up to 2 hours after PK sample collection) . The following will be 
performed and documented prior to dosing:
Weight
Symptom -driven PE 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 61 21 March 2018Obtain urine samples for:
For Week 16, subjects will submit 2 consecutive morning urine void samples to the study  
center approximately  7days prior to the Week 16 visit to test their change in urinary  
protein excretion.  Subjects will also submit a 24 -
hour urine collection that is collected 
immediately  prior to the Week 16 visit, or as close to the Week 16 visit as possible. 
These results will inform their treatment a ssignment for the additional 16 weeks.
For Week 32, subjects will submit 2 consecutive morn ing urine void samples to the study  
center approximately  7days prior to the Week 32 visit to test their change in urinary  
protein excretion.  Subjects will also submit a 24 -hour urine collection that is collected 
immediately  prior to the Week 32 visit, or as close to the Week 32 visit as possible. 
These results will inform their treatment assignment for the additional 20 weeks in the 
Extended Blinded Treatment Phase.
Urinaly sis (with urine microscop y and spot protein
-to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is 
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for active urine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria ], or 
red cell casts in the absence of infection or other causes). 
Urine pregnancy  test (for females of childbearing potential)
Urine PK sample (Week 16 only )
Urine biomarker sample
SELENA -SLEDAI
BILAG
Patient Global Assessment of Disease activity
Physician Global Assessment of Disease activity
36-Item Short Form Health Survey
Vital signs
Standard 12
-lead ECG
Obtain predose blood samples for:
Fasting Clinical Laboratory Tests (hematology , serum chemistry  with lipid assessments , 
and coagulation )
CRP and ESR
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 62 21 March 2018Autoantibod y panel and complement levels
HCV RNA VL (if subject was HCV Ab positive at Screening)
Plasma PK sample ( within 2 hours prior to dosing)
Biomarker Samples ( whole blood TBNK biomarker sample, serum and plasma biomarker 
samples, vfPBMC sample, and PAXgene RNA sample)
Study  drug accountability
Study  drug dispensing
Review and record all AEs and concomitant medications
6.7. Week 36 through Week 48 Assessments
Weight
Symptom -driven PE 
Obtain urine samples for:
Urinaly sis (with urine microscop y and spot protein- to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is 
menstruating will be recorded on the CRF; microscopic urine exam ination will evaluate 
for active urine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria], or 
red cell casts in the absence of infection or other causes). 
Urine pregnancy  test (for females of childbearing potential)
SELENA -SLEDAI
Vital signs
Obtain blood samples for:
Clinical Laboratory Tests (hematology , serum chemistry , and coagulation)
CRP and ESR
Quantitative serum immunoglobulin test (Week 48 only )
HCV RNA VL (if subject was HCV Ab positive at Screening)
Study  drug accountability
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 63 21 March 2018Study  drug dispensing
Review and record all AEs and concomitant medications
6.8. Week 52 Assessments
Weight
Symptom -driven PE 
Obtain urine samples for:
Morning voids and 24 -hour Urine Collection for Urin e Protein. Urine samples from 
3consecutive day s will be collec ted to evaluate urine protein, including morning voids 
during 2 consecutive days prior to each 24 -
hour urine collection (on the 3rdconsecutive 
day).
Urinaly sis (with urine microscop y and spot protein
-to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is 
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for active urine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/hpf [hematuria], or 
red cel l casts in the absence of infection or other causes). 
Urine pregnancy  test (for females of childbearing potential)
Urine biomarker sample
SELENA -SLEDAI
BILAG
Patient Global Assessment of Disease activity
Physician Global Assessment of Disease activity
36-Item Short Form Health Survey
Vital signs
Standard 12
-lead ECG
Obtain blood samples for:
Clinical Laboratory Tests (hematology , serum chemistry , and coagulation)
CRP and ESR
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 64 21 March 2018Autoantibod y panel and complement levels
HCV RNA VL (if subject was HCV Ab positive at Screening)
Biomarker Samples ( whole blood TBNK biomarker sample, serum and plasma biomarker 
samples, vfPBMC sample, and PAXgene RNA sample)
Study  drug accountability
Review and record all AEs and concomitant medications
6.9. Early Termination Assessments 
All subjects who received at least one dose of study  drug and discontinue the study  early will 
have the below assessments completed at the time of study  discontinuation:
Weight
Complete PE 
Obtain urine samples for:
Urine pregnancy  test (for females of childbearing potential)
Urine biomarker sample
Vital signs
Standard 12- lead ECG
Obtain blood samples for:
Clinical Laboratory Tests (hematology , serum chemistry , and coagulation)
CRP and ESR
Autoantibod
ypanel and complement levels
HCV RNA VL (if subject was HCV Ab positive at Screening)
Biomarker Samples ( whole blood TBNK biomarker sample, serum and plasma biomarker 
samples, vfPBMC sample, and PAXgene RNA sample)
Study  drug accountability
Review and record all AEs and concomitant medications
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 65 21 March 20186.10. Final Follow -Up Assessments (4 Weeks Post Treatment)
The following procedures will be completed 4 weeks (± 5 day s) after the subject’s last dose of 
study drug.  Subjects that discontinue earl y from the study will be required to complete the FU 
visit.
Weight
Complete PE 
Obtain urine samples for:
Morning voids and 24 -hour Urine Collection for Urin e Protein. Urine samples from 
3consecutive day s will be collected to evaluate urine protein, including morning voids 
during 2 consecutive days prior to each 24 -
hour urine collection (on the 3rdconsecutive 
day).
Urine pregnancy  test (for females of childbearing potential)
Urine biomarker sample
SELENA -SLEDAI
BILAG
Patient Global Assessment of Disease activity
Physician Global Assessment of Disease activity
36-Item Short For m Health Survey
Vital signs
Obtain blood samples for:
Fasting 
Clinical Laboratory Tests (hematology , serum chemistry  with lipid assessment s , 
and coagulation )
CRP and ESR
Autoantibod y panel and complement levels
HCV RNA VL (if subject was HCV Ab positive at Screening)
Biomarker Samples ( whole blood TBNK biomarker sample, serum and plasma biomarker 
samples, vfPBMC sample, and PAXgene RNA sample)
Review and record all AEs and concomitant medications
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 66 21 March 20186.11. Unscheduled Visit (exacerbation of LMN ) 
The following proced ures will be completed at an unscheduled visit for exacerbation of LMN
(worsening of proteinuria, and/or decrease in eGFR) :
Symptom -driven PE 
Obtain urine samples for:
Urinaly sis (with urine microscop y and spot protein- to-creatinine ratio ). As contamination 
by menstrual blood may  interfere with the primary endpoint, whether or not the patient is 
menstruating will be recorded on the CRF; microscopic urine examination will evaluate 
for active urine sediment (an y of:  > 5 WBC/hpf [py uria], > 5 RBC/ hpf [hematuria], or 
red cell casts in the absence of infection or other causes). 
Urine pregnancy  test (for females of childbearing potential)
Vital signs
Review and record all AEs and concomitant medications
6.12. St udy Assessments
6.12.1. Priority of Assessments
Subject -reported outcomes will be administered, where available, and are recommended to be 
completed before an y other study procedures. Invasive study  procedures such as blood draws 
should be done at the end of a study  visit, unless otherwise specified. In vestigator 
questionnaires/assessments will be administered, where available, and should be performed prior 
to reviewing subject -reported outcomes for that visit, as much as possible. 
6.12.2. Efficacy
Efficacy  assessments will be performed at the time points indic ated in the study  procedures table 
(Appendix 2). 
6.12.2.1. Urine Protein Excretion
Several methods exist to assess urine protein excretion. Measurement of protein excretion in a 
24-hour collection period has been the longstanding “gold standard” for the quantitativ e
evaluation of proteinuria, and will be used to assess the primary  outcome. An alternative method 
for quantitative evaluation of proteinuria is measurement of the ratio of protein to creatinine in 
an untimed “spot” urine specimen (UPCR). These ratios corr ect for variations in urinary  
concentration due to hy dration and provide a more convenient method of assessing protein and 
albumin excretion than those requiring timed urine collections, and will be used to provide a 
preliminary  assessment of response prio r to the Week 16 and Week 32 visits .
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 67 21 March 20186.12.2.2. Safety  of Estrogens in Lupus Ery thematosus National Assessment -Systemic Lupus 
Erythematosus Activity Index (SEL ENA -SLEDAI)
The SEL ENA -SLEDAI is an index of SL E flares commonly  used in clinical trials as an 
assessment tool of SL E activity  with scores that range from 0 to 105, with higher scores 
indicating more severe disease activity .
6.12.2.3. British Isles Lupus Activity  Group (BILAG) Index
The BILAG is an index of SL E flares commonly  used in clinical trials as an organ -specif ic 
assessment tool of SL E activity  that includes a 97-question assessment based upon the evaluating 
physician’s intent to treat, which requires an assessment of improved (1), the same (2), worse 
(3), or new (4) over the last month.  Within each of 8 organ systems, multiple manifestations and 
laboratory  tests are combined into a single score for that organ that range from A through E, with 
A representing very  active disease and E indicating that the organ was never involved.
6.12.2.4. Physician’s Global Assessments of Disease Activity
The Phy sician’s Global Assessment of Disease Activity  will be recorded on a 0 to 100 mmvisual 
analogue scale (VAS; Appendix 9), with 0 indicating “no LMNdisease activity ” and 
100indicating “maximum LMNdisease activity ”. It represents the average assessment of a 
patient's disease activity  based on phy sical examination and laboratory  data according to the 
evaluating ph ysician. 
6.12.2.5. Patient’s Global Assessments of Disease Activity
The Patient Global Assessment reflects the patient's perceiv ed overall health and disease activity , 
with disease activit y estimated on a 0 to 100 mm visual analog scale.
6.12.2.6.
36-Item Short Form (SF) Health y Survey (SF-36)
The SF -36 is a health related quality  of life instrument consisting of 36 questions belonging to 
8domains in 2 components and covers a 4 -week recall period:
Physical well -being, 4 domains: phy sical functioning (10 items), role phy sical (4 items), 
bodily  pain (2 items), and general health perceptions (5 items)
Mental well -being, 4 domains: vitality  (4items), social functioning (2 items), role emotional 
(3items), and mental health (5 items).
The remaining item (health transition) is not part of the above domains but is kept separately . 
These scales will be rescaled from 0 to 100 (converting the lowest possible score to 0 and the 
highest possible score to 100), with higher scores indicating a b etter quality  of life. 
The SF -36 is not disease specific and has been validated in numerous health states.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 68 21 March 20186.12.3. Safety 
Safety will be assessed via AEs, concomitant medications, phy sical examinations (complete and 
symptom -driven), vital signs, ECGs, and clinic al laboratory  results.
6.12.4. Clinical Laboratory Evaluations
Alllaboratory  analy ses will be performed at a central laboratory . Reference ranges will be 
supplied by  the central laboratory  and will be used by  the investigator to assess the laboratory  
data for clinical significance and pathological changes.
Blood samples will be collected b y venipuncture (  
 in the arm at the time points indicated in the study  procedures table 
(Appendix 2). In addition, urine sampl es for the clinical laboratory  assessments will be collected. 
Subjects only  need to be fasted on day s were lipid profiling is scheduled. 
Refer to 
Appendix 6for table of c linical laboratory  tests.
The laboratory  values outside the normal range will be fla gged and clinical relevance will be 
assessed b y the investigator. More frequent sampling as well as additional tests may be 
performed as deemed necessary  by the investigator as indicated. 
Note that in the case where clinicall y significant laboratory test results are a potential reason for 
discontinuation from the study drug and withdrawal from the study , retesting of the affected 
parameter(s) should be prompt (within 3 to 7 days) after the investigator has consulted with the 
medical monitor. A decision reg arding subject discontinuation should be made after the results 
from the retest are available (see Section 3.5for additional information).
The details of sample handling and shipment instructions will be provided in a separate 
Laboratory  Manual.  
6.12.5. Vital S igns
Vital signs will be measured at the time points indicated in the study  procedures table 
(Appendix 2). 
Vital signs should be taken after the subject has been resting in the seated or supine position 
for at least 5 minutes and will include pulserate, respiratory  rate, systolic and di astolic blood 
pressure, and temperature.
6.12.6. Physical Examination
A phy sical examination should be performed at the time points indicated in the study  procedures 
table Appendix 2. Any changes from b aseline will be recorded. Height will be measured at 
screening onl y. Subjects should be instructed to remove shoes prior to measurement of height.
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 69 21 March 2018At Screening , a complete phy sical examination will be performed. A complete phy sical 
examination should include source documentation of ge neral appearance and the following body  
systems: head, neck, and thy roid; ey es, ears, nose, throat, mou
th and tongue; chest 
(excluding breasts); respiratory ; cardiovascular; lymph nodes; abdomen; skin, hair, nails; 
musculoskeletal; and neurological. 
Symptom -driven phy sical examinations will be performed at all other visits based on reported 
signs and s ymptoms.
6.12.7. Other Safety Assessments
6.12.7.1. 12-lead Electrocardiogram
A resting 12 -lead ECG will be performed at the time points indicated in the study  procedures
table ( Appendix 2). 
The ECG should be obtained after the subject has been resting in the supine position for at least 
5
minutes and will include heart rate (HR), inter- beat (RR), QRS, uncorrected QT, morphology , 
and rh ythm anal ysis. QT interval corrected for HR according to Fridericia (QTcF) will be 
derived during the statistical anal ysis. Electrocardiograms will be interpreted by  the investigator
(or qualified designee) for clinical significance and results will be entered into the eCRF.
6.13. Pharmacokinetics Assessments
Blood samples will be collected for plasma PK analysis of filgotinib and its active metabolite 
GS-829845, and GS -9876 post dose at Weeks 2, 4, and 20 (at lea st 30 minutes and up to 3 hours 
after dosing), an ytime at Weeks 8 and 24, and 
within 2 hours prior to dosing at Weeks 16 and 32.
Urine PK anal yses may be performed for filgotinib and its active metabolite GS -829845, and 
GS-9876, using the 24- hour urine collection at Week 16.
6.14. Biomarker Assessments
Urine samples will be collected for biomarke r assessments at Screening, Day  1 (predose) , 
Weeks 2, 16, 32, 52, ET, and at the Final FU.  
Blood samples for biomarker assessments ( whole blood TBNK biomarker
, serum and plasma 
biomarkers, vfPBMC, and PAXgene RNA) will be collected at Screening, Day  1 (predose), 
Weeks 2, 16, 32, 52, ET, and at the Final FU.  
 
 
CCI
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 70 21 March 20187. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and
/orunintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the m edicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose, drug abuse/misuse reports , or 
occupational exposure . Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, andtransfusion.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occu rrence has not occurred (eg, hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.7)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol- associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 71 21 March 2018Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reactio n: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercise d to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements .
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessm ents.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP 
treatment using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may have been caused by the 
investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive pr ocedures such as venipuncture) should be 
assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg., venip uncture )
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 72 21 March 20187.2.2. Assessment of Severity
The severit y of AEs will be graded using the modified CTCAE, version 4.03. For each episode, 
the highest grade attained should be reported. For AEs associated with laboratory  abnormalities, 
the event should be graded on the basis of the clinical severity in the context of the underl ying 
conditions; this may  or may  not be in agreement with the grading of the laboratory  abnormality .
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: 
Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life- threatening) or 
Grade 5(fatal) to describe the maximum intensity  of the adverse event. For purpos es of 
consistency  with the CTCAE, these intensity  grades are defined in Table 7-1and Appendix 4.
Table 7-1. Grading of Adverse Event Severity
Grade Adjective Description
Grade 1 Mild Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
Grade 2 Moderate Local or noninvasive intervention indicated; limiting age -appropriate instrumental 
ADL 
Grade 3 Severe Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indi cated; disabling; limiting self -care ADL 
Grade 4 Life-threatening Urgent intervention indicated 
Grade 5 Death Death related AE 
* Activities of Daily Living (ADL) Instrumental ADL refer to opening preparing meals, shopping for groceries or clothes, 
using the telephone, managing money, etc. 
** Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form (CRF/eCRF): all SAEs and adverse events related to 
protocol -mandated procedures.
Adverse Events
Following initiati on of study  medication, all AEs, regardless of cause or relationship, until 
30-days after last administration of study  drug(s) must be reported to the CRF/eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse even t is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 73 21 March 2018Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participa te in the study  (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
CRF/eCRF database and Gilead Pharmacovigila nce and Epidemiology (PVE ) as i nstructed. This 
also includes an y SAEs resulting from protocol-associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30- days of the 
last dose of study  drug(s) , regardless of causality , should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period. 
However, if the investigator learns of any  SAEs that occur after stud y participation has 
concluded and the event is deemed relevant to the use of study  drug(s) , he/she should promptly  
document and report the event to Gilead PVE .
All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline. 
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead PVE within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
Gilead PVE : Fax:
E-mail:
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, 
nofurther action is necessary .
For fatal or life -
threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
PPD
PPD
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 74 21 March 2018Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
7.4. Gilead Reporting Requirements
Depen ding on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may  be require d to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs),
orsuspected unexpected serious adverse reactions (SUSARs). I n accordance with the EU 
Clinical Trials Directive (2001/20/EC), Gilead or a specified desi gnee will notify  worldwide 
regulatory  agencies and the relevant IEC in concerned Member States of applicable SUSARs as 
outlined in current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information spec ified in the investigator’s brochure. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Clinical Laboratory Abnormalities
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , coagulation, and urinal ysis) independent of 
the underl yingmedical condition that require medical or surgical intervent ion or lead to 
investigational medicinal product interruption or discontinuation must be recorded as an AE, as 
well as an SAE, if applicable. In addition, laboratory  or other abnormal assessments 
(eg,electrocardiogram, X -rays, vital signs) that are associ ated with signs and/or sy mptoms must 
be recorded as an AE or SAE if they  meet the definition of an AE (or SAE) as described in 
Sections 7.1.1 and7.1.2. If the laboratory  abnormality  is part of a s yndrome, record the 
syndrome or diagnosis (ie, anemia) not the laboratory  result (ie, decreased hemoglobin).
Severity  should be recorded and graded according to the Common Terminology  Criteria for 
Adverse Events (CTCAE) and Laboratory  Abnormalities. For AEs associated with laboratory  
abnormalities, the event shoul d be graded on the basis of the clinical severity in the context of 
the underl ying conditions; this may  or may not be in agreement with the grading of the 
laboratory  abnormality .
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 75 21 March 20187.6. Toxicity Management 
All clinical and clinicall y significant laboratory toxic ities will be managed according to uniform 
guidelines detailed in Appendix 3and as outlined below.
For stud y-specific interruption and discontinua tion criteria, refer to Section 3.5. Specific toxicity  
discont inuation criteria in Section 
3.5supersede below general toxicity  guidelines, and in 
general, where discrepancy  is present, the more conservative criteria appl y.
The Gilead Medical Monitor should be consulted prior to study drug discontinuation when 
medically  feasible.
7.6.1. Grades 1 and 2 Laboratory Ab normality or Clinical Event
For Grades 1 and 2 laboratory  abnormalities or clinical events not specified in Section 3.5, 
continue study  drug at the discretion of the investigator. 
7.6.2. Grades 3 Laboratory Abnormality or Clinical Event
For Grade 3 laboratory  abnormalities or clinical events not specified in Section 3.5, the following 
toxicity  management guidelines apply :
For a Grade 3 clinicall y significant laboratory  abnormality  or clinical event, I MP may  be 
continued if the event is considered to be unrelated to IMP.
For a Grade 3 clinical event, or clinicall y significant laboratory abnormality confirmed b y 
repeat testing, that is considered to be related to IMP, I
MP should be withheld until the 
toxicity  returns to ≤ Grade 2.
If a laboratory  abnormality  recurs to ≥ Grade 3 following re -challenge with I MP and is 
considered related to IMP, then I MP should be permanently  discontinued and the subject 
managed according to local clinical practice. Recurrence of laboratory  abnormalities 
considered unrelated to IMP may  not require permanent discontinuation and study  drug may  
be continued at the discretion of the investigator.
7.6.3. Grades 4 Laboratory Abnormality or Clinical Event
For Grade 4 laboratory
 abnormalities or clinical events not specified in Section 3.5, the followi ng 
toxicity  management guidelines apply :
For a Grade 4 clinical event or clinicall y significant 
(confirmed) laboratory abnormality ,
study  drug should be permanently  discontinued and the subject managed according to local 
practice. The subject should be fol lowed as clinically indicated until the laboratory  
abnormality  returns to baseline or is otherwise explained, whichever occurs first. A clinically  
significant Grade 4 laboratory  abnormalit y that is not confirmed b y repeat testing should be 
managed accordin g to the algorithm for the new toxicity  grade.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 76 21 March 2018Study  drug may  be continued without dose interruption for a clinicall y non -significant 
Grade 4 laboratory  abnormality  (eg, Grade 4 creatine kinase after strenuous exercise or 
nonfasting trigl yceride elevation that can be medically  managed) or a clinical event 
considered unrelated to the study  drug(s).
Grade 4 t reatment- emergent toxicities will be noted by  the investigator and brought to the 
attention of the Gilead Sciences Medical Monitor, who will discuss with the investigator and 
determine the appropriate course of action. All subjects experiencing AEs must be monitored 
periodicall y until symptoms subside, any abnormal laboratory values have resolved or returned 
to baseline levels or they  are considered irreve rsible, or until there is a satisfactory  explanation 
for the changes observed.
Histologic hemorrhage and thrombosis have been observed in cy nomolgus monkey s that 
received GS -9876 at doses 
≥ 20 mg/kg/day .The clinical relevance of these findings to humans i s 
unknown; these adverse events have not been reported in clinical studies of GS -9876. An y 
treatment -emergent adverse event involving significant bleeding or thrombosis is to be reported 
to the investigator and brought to the attention of the Gilead Scienc es medical monitor ,or 
designee ,to discuss the appropriate course of action .
Any questions regarding toxicity  management should be directed to the Gilead Sciences 
Medical Monitor.
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose , reports 
of AEs associated with product complaints, occupational exposure with an AE, pregnancy  
reports (regardless of an associated AE), and an AE in an infant following potential exposure 
from breastfeeding.
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the d aily dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for th e discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 77 21 March 2018Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
Occupational exposure is defined as exposure to a medicinal product as a result of one's 
professional or non- professional occupation.  
7.7.2. Instructio ns for Reporting Special Situations
7.7.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study drug follow - up 
period, to Gilead PVE the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy .
Refer to S ection 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and will be reported as described in 
Sections 7.1.1 and 7.1.2. Further more, any  SAE occurring as an adverse pregnancy  outcome 
post study  must be reported to Gilead 
PVE .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead using the pregnanc y outcome report form. 
If the end of the pregnancy  occurs after the study  has been completed, the outcome should be 
reported directl y to Gilead PVE . Gilead PVE contact information is as follows: 
Email:  and Fax:  
Pregnancies of female partners of male study  subjects exposed to study  drugs must also be 
reported and relevant information should be submitted to Gilead PVE using the pregnancy  and 
pregnancy  outcome forms within 24 hours. Monitoring of the pregnancy should co ntinue until its 
conclusion. If the end of the pregnancy  occurs after the study  has been completed, the outcome 
should be reported directly  to Gilead PVE ,fax number  or email 
 
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
PPD
PPD
PPD
PPD
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 78 21 March 20187.7.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead PVE within 24 hour s of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMPand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of s
pecial situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 79 21 March 20188. STATISTICAL  CONSIDER ATIONS
Efficacy  and safet y data collected up to Week 16 will be summarized by treatment group for all 
subjects. Data from subjects who do not switch treatment will be summarized for the duratio n of 
the study  by treatment group. Summaries by  the combinations of treatment groups may  be 
provided, if applicable.
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective is:
To evaluate the efficacy  of filgotinib and GS- 9876 in subje cts with L MN
The secondary  objectives are: 
To evaluate the safet y and tolerability  of filgotinib and GS- 9876 in subjects with LMN
To evaluate the PK of filgotinib and GS- 9876 in subjects with LMN
The exploratory  objectives are: 
 
 
8.1.2. Primary Endpoint
The primary  endpoint is the percent change in urine protein from Baseline (Day  1) to Week 16. 
Urine protein is assessed by  urinary  protein excretion during a 24-hour urine collection. 
8.1.3. Secondary Endpoints
Change from Baseline (Day  1)in urine protein (assessed by  urine protein excretion during a 
24-hour urine collection) at Week 16
Change from Baseline (Day  1) in eGFR 
at Week 16
Change from Baseline (Day  1)in UPCR (assessed by  urine protein excretion during a 
24-hour urine collection) at Week 16
CCII 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 80 21 March 2018Proportion of subjects with partial remission (defined as ur ine protein excretion below 
< 3g/d and urine protein excretion decrease b y ≥ 50% among subjects with Baseline (Day 1) 
nephrotic range proteinuria [urine prote in excretion ≥ 3 g/d]; or urine protein excretion 
decrease b y ≥ 50% among subjects with subnephrotic range proteinuria [urine protein 
excretion < 3 g/d]) at Week 16
Proportion of subjects with complete remission (defined as ur ine protein excretion below 
0.5g/day , with no hematuria) at Week 16
8.1.4. Exploratory Endpoints
 
 
   
 
 
 
 
 
 
 
 
 
CCI
CCII 
I 
I I I I 
I 
I I I 
I I 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 81 21 March 2018 
 
 
 
 protein excretion below 
0.5g/day , with no hematuria) at each visit other than Week 16
8.1.5. Biomarker Endpoints
Change in JAK -STAT -, SYK -, and disease -related biomarkers in peripheral blood and urine
Association of changes in peripheral blood and urine biomarkers with clinical outcomes
Association of B aseline markers with diseas e severity  and response to filgotinib and 
GS-9876
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. All Randomized
The all randomized anal ysis set includes all subjects who are randomized in the study. This is the
primary  anal ysis set for by -subject listings.
8.2.1.2. Efficacy
The primary  anal ysis set for efficacy  anal yses will be the Full Anal ysis Set (FAS), which 
includes all randomized subjects who received at least one dose of study  drug.
8.2.1.3. Safety
The primary  anal ysis set for safety anal yses will be the Safet y Analysis Set, wh ich includes all 
subjects who received at least one dose of stud y drug. All data col lected during treatment plus 
30days after the last dose of study  drug will be included in the safety  summaries.
8.2.1.4. Pharmacokinetics
The primary  anal ysis set for PK anal yses will be the PK anal ysis set, which includes all subjects
in the Safety  Anal ysis Set who have at least 1 non- missing PK concentration data for GS- 9876, 
filgotinib or their metabolites. 
CCII 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 82 21 March 20188.2.1.5. Biomarkers 
The primary  anal ysis set for biomarker anal yses will be the Biomarker Analysis Set, which
includes all subjects in the Safet y Anal ysis Set who have at least one evaluable measurement
available at an y time point for a given biomarker of interest.
8.3. Data Handling Conventions
Pharm acokinetic concentration values and PK parameter values below the limit of quantitation
(BLQ) will be presented as “BLQ” in the data listings. BLQ values that occur prior to the 
firstdose will be treated as 0, BLQ values at all other time points will be treated as 1/2 of the 
lower limit of qua ntitation (LLOQ).
Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or
above the upper limit of quantitation will be imputed to the value of the lower or upper limit
minus or plus one significant digit, respectivel y (eg, if the result of a continuous laboratory  test is
< 20, a value of 19 will be assigned; if the result of a continuous laboratory test is < 20.0, a value
of 19.9 will be assigned).
8.4. Demographic Data and Baseline Characteristics
Demographic a nd baseline measurements will be summarized using standard descriptive 
statistics including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and number and percentages of subjects for categorical variables.
Demographic s ummaries will include sex, race/ethnicity , and age.
Baseline characteristics will include and not limited to a r ange of proteinuria (< 3g/d, >= 3g/d), 
histologic diagnosis, prior and current treatment for lupus membranous nephropathy , and 
patient -reported and ph ysician- reported outcome assessments.
8.5. Efficacy Analysis 
Details of the efficacy  analy ses will be described in the Statistical Analy sis Plan (SAP).
8.5.1. Primary Analysis
The primary  endpoint, t he percent change from Baseline (Day  1) in 24- hour proteinuria at 
Week 16,will be calculated and the 95% confidence interval will be constructed for each 
treatment group. 
8.5.2.
Secondary Analyses
All continuous secondary endpoints will be summarized using an 8 -number summary  (n, mean, 
standard deviation [SD], median, 1st quartile [Q1], 3rd quartile [Q3], minimum, maximum) by  
treatment group. All categorical secondary  endpoints will be summarized by  the number and 
percentage of subjects who meet the endpoint definition. The 95% CI  will be provided, as 
appropriate.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 83 21 March 20188.5.3. Explora tory Analyses
 
8.6. Safety Analysis
All safet y anal yses will be performed using the safety  anal ysis set.  Safet y will be evaluated b y 
the assessment of clinical laboratory  tests, phy sical examinations, vi tal signs measurements at 
various time points during the stud y, and b y the documentation of AEs.
All safet y data collected on or after the date that study drug was first dispensed up to the date of 
last dose of study  drug + 30 day s will be included in the safet y analysis .
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug will be generated from the study  drug 
administration page of the eCRF. 
Duration of exposure to study  drug will be summarized as the number of weeks between the 
firstand last dose of the study  drug, inclusive, regardless of temporary  interruptions in study  
drug administration.
8.6.2. Adverse Events
Clinical and laboratory  AEs will be coded using the Medical Dictionary  for Regulatory  
Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term (HLGT), 
High -Level Term (HLT), Preferred Term (PT), and L ower -
Level Term (LLT) will be attached to 
the clinical database.
Treatment -emergent adverse events (TEAEs) are defined as one or both of the following:
Any AEs with an onset date on or after the stud y drug start date and no later than 30 days 
after permanent discontinuation of study  drug.
Any AEs leading to premature discontinuation of study  drug.
Summaries (number and percentage of subjects) of treatment -emergent adverse events (by SOC, 
and PT) will be provided. TEAEs will also be summarized by  relationship to study  drug and 
severit y. 
All observed AEs will be presented in b y-subject listings.
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 84 21 March 20188.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and 
maximum) along with corresponding change s.The incidence of treatment -emergent graded 
laboratory  abnormalities will be summarized similarly .
Graded laboratory  abnormalities will be defined using CTCAE 4.03 gra ding scale inAppendix 4.
Laboratory  abnormalities that occur before the first dose of study  drug or after the subject has 
been discontinued from treatment for at least 30 days will be included in a data listing.
8.6.4.
Other Safety Evaluations
Individual data for ph ysical examination findings, prior and concomitant medications and
medical history  will be provided. Vital signs measurements will be listed by  subject and 
summarized by  incidence of events/abnormalities or descriptive statistics as appropriate.
8.7. Pharmacokinetic Analysis
Plasma concentrations and other PK parameters of filgotinib, the active metabolite of filgotinib 
(GS-829845) and GS -9876 will be listed and summarized using descriptive statistics (eg, sample 
size, arithmetic mean, geometric mean, % coefficient of variation, standard deviation, median, 
minimum, and maximum). Plasma concentrations of other filgotinib or GS -9876 metabolite(s) 
may also be determined and anal yzed.
Urine PK anal yses may be performed for GS -9876, filgotinib and its active me tabolite, 
GS-
829845, using the 24h urine collection at Week 16.
8.8. Biomarker Analysis
 
 
 
 
 
 
For biomarker analy sis, the baseline level and the modulation pattern upon treatment, including 
change over time from baseline level, will be evaluated by  treatment arm. Descriptive statistics 
will be provided at each sampling time, by  treatment arm. Additi onally  graphical summaries, 
eg,mean ± SD, median ± interquartile range (Q1, Q3), box plots, and scatter plots to explore 
correlations between different biomarkers may  also be generated, as needed. These graphs may  
be generated for raw values as well as change s, as appropriate.
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 85 21 March 2018 
 
 
 
 
Biomarker objectives may be further described and updated based on evolving scientific 
knowledge of filgotinib and GS-9876.  
 
8.9. Sample Size
The sample size was chosen based on the practical considerations and to ensure that a clinicall y 
meaningful reduction in proteinuria from Baseline (Day  1) could be detected in any  of the 
treatment groups, filgotinib or GS -9876.  With 16 subjects per treatment group (32 subjects 
total), there is a 80%  power to detect a 35% reduction from Baseline (Day 1) in proteinuria at 
Week 16 with a standard deviation of 50% and a 2 -sided 0.05 significance level.
8.10. Data Monitoring Committee
An external multidisciplinary  DMC will review the progress of the study  and perform interim 
reviews of safet y data and provide recommendation to Gi lead whether the nature, frequency , and 
severit y of adverse effects associated with study treatment warrant the earl y termination of the 
study  in the best interests of the participants, whether the stud y should continue as planned, or 
the study  should cont inue with modifications.
The first DMC data review meeting will be conducted after approximately  50% of planned 
subjects enroll and complete through 16 weeks of study  treatment. The DMC’s specific activities 
will be defined b y a mutually  agreed charter, wh ich will define the DMC’s membership, conduct 
and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on all aspect s of 
the study .
8.11. Analysis Schedule
The primary  and secondary  anal yses will be conducted after all subjects either complete their
Week 16 visit or prematurely  discontinue from the study . The final anal ysis will be performed 
when all subjects complete the stu dy or prematurely  discontinue from the study .
CCI
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 86 21 March 20189. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Council for Harmonisation (ICH) guidelines, or with the 
laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject. 
The investigator will ensure adherence to the basic principles o f Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, and 21 CFR, part 56.
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, providing 
documen
tation of their financial interest or arrangements with Gilead, or proprietary  interests in 
the investigational drug under study . This documentation must be provided prior to the 
investigator’s (and an y subinvestigator’s) participation in the study . The in vestigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to a n IRB . The investigator will not begin an y stud y subject activities until 
approval from the IRB has been docum ented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRB any modifications made to the protocol or any accompan ying material to be provided to 
the subject after initial IRB approval, with the exception of those necessary to reduce immediate 
risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current IRB-approved consent form for documenting written 
informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject or the subject’s legally authorized representative and the person 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 87 21 March 2018conducting the consent discussion, and also by  an impartial witness if required by IRB local 
requir ements.  
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor , IRB,or laboratory . Laboratory  spec imens 
must be labeled in such a way as to protect subject identity  while allowing the results to be 
recorded to the proper subject. Refer to specific laboratory instructions .NOTE :The investiga tor 
must keep a screening log showing codes, names, and addresses for all subjects screened and for 
all subjects enrolled in the trial. Subject data will be processed in accordance with all applicable 
regulations. 
The investigator agrees that all informat ion received from Gilead, including but not limited to the 
investigator brochure, this protocol, CRF /eCRF , the IMP, and an y other study information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This infor mation is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms , IRB 
and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 88 21 March 2018Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results 
of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuati on, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or J apan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorit ies have been notified. Investigators may  be required to retain documents longer if 
specified by  regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records .
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection . When source documents are required for the con tinued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented accordi ng to stud y procedures. eCRF should be 
completed on the day  of the subject visit to enable the sponsor to perform central monitoring of 
safet y data.  The Eligibility  Criteria eCRF should be completed onl y after all data related to 
eligibility  have been re ceived.  Subsequent to data entry , a study  monitor will perform source 
data verification within the EDC sy
stem. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to database lock (or any  interim time points 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 89 21 March 2018as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF c apture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal Gilead staff, 
who routinely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original entry, and providing the reason 
for the update (e.g. data entry  error). At the conclusion of the trial, Gilead will provide the site 
with a read -only archive copy  of the data entered by  that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5 .
9.1.7. Investigational Medicinal Product Accountability and Return
Where possible, IMP should be destro yed at the site. At the start of the study, the stud y monitor 
will evaluate each stud y center’s IMP disposal procedures and provide appropriate instruction for 
disposal or return of unused IMP supplies. If the site has an appropriate standard operating 
procedure (SOP) for drug destruction as determined by  Gilead Sciences, the site may  destroy  
used (empt y or partially empty) and unused IMP supplies as long as performed in accordance 
with the site’s SOP. This can occur onl y after the study  monitor has performed drug 
accountability  during an on -site monitoring visit. 
A cop y of the site’s IMP Disposal SOP or written procedure (signed and dated by  the PI 
or designee) will be obtained for Gilead site files. If the site does not have acceptable 
procedures in place, arrangements will be made between the site and Gilead Scie nces 
(orGilead Sciences’ representative) for return of unused study  drug supplies. 
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP 
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the I MP. Upon study  completion, copies of the 
IMP accountability  records must be filed at the site. Another copy  will be returned to Gilead.
The study  monitor will review IMP supplies and associa ted records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , toIRBs or to regulatory  authorit y or health authority 
inspectors.
9.1.9. Protocol Comp liance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 90 21 March 20189.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB in 
accordance with local requirements and receive documented IRB approval before modifications 
can be implemented.
9.2.2. Study Repor t and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agenc y(ies). Gilead 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the study  in their entiret y have been publicly disclosed by or with the consent 
of Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at 
all study  sites for at least 2 y ears.
The investigator will submit to Gilead any  prop osed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 day s before submission of 
the publication or presentation. 
No such communication, presentation, or publication will include Gi lead’s confidenti al 
information (see Se ction 9.1.4.)
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 day s in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendanc e at I nvestigator's Meetings.  If required under the applicable statutory  
and regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 91 21 March 20189.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF /eCRF .
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistency , and acc uracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of moni toring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 92 21 March 201810. REFERENCES
Austin HA, 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, 
cyclophosphamide, and cy closporine in lupus membranous nephropathy . J Am 
Soc Nephrol 2009;20 (4):901-11.
Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib 
versus etaner cept or placebo in moderate -to-severe chronic plaque psoriasis: a 
phase 3 randomised non -inferiority trial. Lancet 2015;386 (9993):552 -61.
Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally  bioavailable 
spleen ty rosine kinase i nhibitor delay s disease progression and prolongs survival 
in murine lupus. Arthritis Rheum 2008;58 (5):1433-44.
Barr PM, Wei C, Roger J, Schaefer- Cutillo J, Kelly  JL, Rosenberg AF, et al. Sy k inhibition with 
fostamatinib leads to transitional B ly mphocy te depletion. Clin I mmunol 
2012;142 (3):237 -42.
Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. L upus 
nephritis: a critical review. Autoimmunity  reviews 2012;12 (2):174-94.
Braselmann S, Taylor V, Zhao H, Wang S, Sy lvain C, Baluom M, et al. R406, an orall y available 
spleen ty rosine kinase inhibitor blocks fc receptor signaling and reduces immune 
complex -mediated inflammation. J Pharmacol Exp Ther 2006;319 (3):998 -1008.
Brosius FC, Tuttle KR, Adler SG, Kretzler M, Mehta RL , Tumlin JA, et al. Baricitinib in 
Diabetic Kidney  Disease: Biomarker Anal ysis from a Phase 2, Randomized, 
Double- Blind, Placebo- Controlled Study  [Abstract TH -OR034]. American 
Society  of Nephrology  Kidney  Week; 2015 03- 08 November; San Diego, CA. 
Bubier JA, Sproule TJ , Foreman O, Spolski R, Shaffer DJ, Morse HC, 3rd, et al. A critical role 
for IL -21 receptor signaling in the pathogenesis of sy stemic lupus ery thematosus 
in BXSB -
Yaa mice. Proc Natl Acad Sci U S A 2009;106 (5):1518-23.
Chan TM, Li FK, Hao WK, Chan KW, L uiSL, Tang S, et al. Treatment of membranous lupus 
nephritis with nephrotic syndrome b y sequential immunosuppression. L upus 
1999;8 (7):545 -51.
Coffey  G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, et al. Specific inhibition of 
spleen ty rosine kinase s uppresses leukocy te immune function and inflammation in 
animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340 (2):350 -9.
Crispin JC, Ky ttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nature 
reviews. Rheumatology  2010;6 (6):317 -25.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 93 21 March 2018Dall'Era M. Current Diagnosis & Treatment: Rheumatology , Third Edition. Section 111. L upus 
& Related Autoimmune Disorders. Chapter 21. Systemic Lupus Ery thematosus.  
2013:
Danila MI, Pons -Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the 
most important predictor of mortality  within the damage index: data from 
LUM INA LX IV, a multiethnic US cohort. Rheumatology  (Oxford) 2009;48 
(5):542-5.
Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney  disease by  
inhibition of spleen ty rosine kinase in lupus- prone mice. Arthritis Rheum 2010;62 
(7):2086-92.
Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of 
increased interferon -inducible gene expression with disease activity  and lupus 
nephritis in patients with sy stemic lupus ery thematosus. Arthritis Rheum 2006;54 
(9):2951-62.
Fleischmann R, Kremer J, Cush J, Schulze -Koops H, Connell CA, Bradley  JD, et al. Placebo-
controlled trial of tofacitinib monotherapy  in rheumatoid arthritis. N Engl J Med 
2012;367 (6):495 -507.
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in 
Patients with Refractory  Rheumatoid Arthritis. N Engl J Med 2016;374 
(13):1243-52.
Ginzler EM, Dooley  MA, Aranow C, Kim MY, Buy on J, Merrill JT, et al. My cophenolate 
mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 
2005;353 (21):2219-28.
Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cy closporine for lupus 
membranous nephritis: exper ience with ten patients and review of the literature. 
Lupus 2000;9 (4):241 -51.
Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum 
interleukin 10 titers in systemic lupus ery thematosus reflect disease activity. 
Lupus 1995; 4 (5):393 -5.
Karim MY, Pisoni CN, Ferro L, Tungekar MF, Abbs I C, D'Cruz DP, et al. Reduction of 
proteinuria with my cophenolate mofetil in predominantly  membranous lupus 
nephropath y. Rheumatology  (Oxford) 2005;44 (10):1317 -21.
Kasitanon N, Petri M, Haas M, Magder LS, Fine DM. My cophenolate mofetil as the primary  
treatment of membranous lupus nephritis with and without concurrent 
proliferative disease: a retrospective study  of 29 cases. Lupus 2008;17 (1):40 -5.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 94 21 March 2018Keystone EC, Tay lor PC, Drescher E, Schlichting D E, Beattie SD, Berclaz PY, et al. Safet y and 
efficacy  of baricitinib at 24 weeks in patients with rheumatoid arthritis who have 
had an inadequate response to methotrexate. Annals of the rheumatic diseases 
2015;74 (2):333 -40.
Kolasinski SL , Chung JB, Albert DA. What do we know about lupus membranous nephropathy ? 
An anal ytic review. Arthritis Rheum 2002;47 (4):450-5.
Krishnan S, Juang YT, Chowdhury  B, Magilavy  A, Fisher CU, Ngu yen H, et al. Differential 
expression and molecular associations of Sy k in s ystemic lupus ery thematosus T 
cells. J I mmunol 2008;181 (11):8145 -52.
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley  JD, Gruben D, et al. Tofacitinib versus 
methotrexate in rheumatoid arthritis. N Engl J Med 2014;370 (25):2377 -86.
Ma TK, McAdoo SP, Tam FW. S pleen Ty rosine Kinase: A Crucial Play er and Potential 
Therapeutic Target in Renal Disease. Nephron 2016;133 (4):261 -9.
Maier -Moore JS, Horton CG, Mathews SA, Confer AW, L awrence C, Pan Z, et al. IL -6 
Deficiency  Corrects Nephritis, Ly mphocy te Abnormalities, and Secondary  
Sjogren's Features Sle1.Yaa lupus- prone mice. Arthritis Rheumatol 2014;66 
(9):2521-31.
Mao X, Wu Y, Diao H, Hao J, Tian G, Jia Z, et al. I nterleukin -6 promotes sy stemic lupus 
erythematosus progression with Treg suppression approach in a muri ne systemic 
lupus ery thematosus model. Clinical rheumatology 2014;33 (11):1585 -93.
Mok CC, Ying KY, Lau CS, Yim CW, Ng WL , Wong WS, et al. Treatment of pure membranous 
lupus nephropath y with prednisone and azathioprine: an open -label trial. Am J 
Kidney  Dis 2004;43 (2):269 -76.
Mok CC, Ying KY, Yim CW, Ng WL , Wong WS. Very  long -term outcome of pure lupus 
membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 
2009;18 (12):1091 -5.
Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Trea tment of membranous lupus 
nephritis. Am J Kidney  Dis 1998;31 (4):681 -6.
Namour F, Diderichsen PM, Cox E, Vay ssiere B, Van der Aa A, Tasset C, et al. 
Pharmacokinetics and Pharmacokinetic/Pharmacody namic Modeling of Filgotinib 
(GLPG0634), a Selective JAK1 I nhibitor, in Support of Phase IIB Dose Selection. 
Clin Pharmacokinet 2015;54 (8):859
-74.
O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK -STAT 
pathway : impact on human disease and therapeutic intervention. Annu Rev Med 
2015;66:311 -28.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 95 21 March 2018Rahman A, Isenberg DA. Sy stemic lupus ery thematosus. N Engl J Med 2008;358 (9):929 -39.
Ripoll E, de Ramon L , Draibe Bordignon J, Merino A, Bolanos N, Goma M, et al. JAK3-STAT 
pathway  blocking benefits in experimental lupus nephritis. Arthritis res earch & 
therap y 2016;18 (1):134.
Ryan J, Ma FY, Han Y, Ozols E, Kanellis J, Tesch GH, et al. M yeloid cell -mediated renal injury  
in rapidly  progressive glomerulonephritis depends upon spleen ty rosine kinase. 
The Journal of pathology 2016;238 (1):10-20.
Sarpel D, Wasserman I, Trochtenberg A, Bichoupan K, DelBello D, Perumalswami PV, et al. 
Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV 
treatment failure in the real world [Poster P1978]. American Association for the 
Study  of Live r Diseases (AASL D); 2016 11- 15 November; Boston, MA. 
Sato S, L ennard Richard M, Brandon D, Jones Buie JN, Oates JC, Gilkeson GS, et al. A critical 
role of the transcription factor fli- 1 in murine lupus development by  regulation of 
interleukin -6 expression. Arthritis Rheumatol 2014;66 (12):3436-44.
Sawalha AH, Kaufman KM, Kelly  JA, Adler AJ, Aberle T, Kilpatrick J, et al. Genetic 
association of interleukin -21 poly morphisms with sy stemic lupus ery thematosus. 
Annals of the rheumatic diseases 2008;67 (4):458 -61.
Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long- term outcome in s ystemic lupus 
erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative 
Study  Group. J Am Soc Nephrol 1996;7 (2):299-305.
Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, et al. A spleen 
tyrosine kinase inhibitor reduces the severity  of established glomerulonephritis. J 
Am Soc Nephrol 2010;21 (2):231-6.
Swan JT, Riche DM, Riche KD, Majithia V. S ystematic review and meta -analy sis of 
immunosuppressant therapy clinical trials in membranous lupus nephritis. J 
Investig Med 2011;59 (2):246 -58.
Tuttle KR. Baricitinib in Diabetic Kidney  Disease: Results from a Phase 2, Multicenter, 
Randomized, Double -Blind, Placebo -Controlled Study  [Abstract 114- LB].
American Diabetes Association (ADA); 2015 05 -08 July ; Boston, MA. 
Ulinski T, Davourie -Salandre A, Brocheriou I, Aoun B. Immunoadsorption: a new strategy  to 
induce remission in membranous lupus nephritis. Case Rep Nephrol Urol 2014;4 
(1):37-41.
Van Rompae y L, Galien R, van der Aar EM, Clement -Lacroix P, Nelles L, Smets B, et al. 
Preclinical characterization of GL PG0634, a selective inhibitor of JAK1, for the 
treatment of inflammatory diseases. J I mmunol 2013;191 (7):3568-77.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 96 21 March 2018van Vollenhoven RF, Fleischmann R, Cohen S, L ee EB, Garcia Meijide JA, Wagner S, et al. 
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 
2012;367 (6):508 -19.
Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006;70 
(8):1403-12.
Wang L, Zhao P, Ma L, Shan Y, Jiang Z, Wang J, et al. Increased interleukin 21 and follicular 
helper T -like cells and reduced interleukin 10+ B cells in patients with new -onset 
systemic lupus ery thematosus. The Journal of rheumatology  2014;41 (9):1781-92.
Wang S, Yang N, Zhang L, Huang B, Tan H, Liang Y, et al. Jak/STAT signaling is involved in 
the inflammatory  infiltration of the kidney s in MRL/lpr mice. Lupus 2010;19 
(10):1171-80.
Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcrip tome 
analysis of human diabetic kidney  disease. Diabetes 2011;60 (9):2354 -69.
Yap DY, Yu X, Chen XM, L u F, Chen N, Li XW, et al. Pilot 24 month study  to compare 
mycophenolate mofetil and tacrolimus in the treatment of membranous lupus 
nephritis with nephro tic sy ndrome. Nephrology  (Carlton) 2012;17 (4):352- 7.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 97 21 March 201811. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 6. Clinical Laboratory Assessment Table
Appendix 7. Safety of Estrogens in Lupus Erythe matosus National Assessment trial -based 
Systemic Lupus Erythematosus Disease Activity Index (SELENA -SLEDAI)
Appendix 8. British Isles Lupus Activity Group (BILAG) Index
Appendix 9. Physician ’s Global Assessment of Disease Activity
Appendix 10. Patient Global Assessment of Disease Activity
Appendix 11. 36- Item Short Form Health Survey
PPD
PPD
PPDGS-98 7 6/F ilgotinib 
Protocol GS-US-437-4093 Final 
Gilead Sciences, Inc. Amendment 2 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNU\VLEDGEMENT 
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of 
Filgotinib and GS-9876 in Subjects with Lupus Membranous Nephropathy (LMN) 
GS-US-437-4093, AMENDMENT 2, 21 MARCH 2018 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
_____ (Printed) 
Study Director and Medical Monitor 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
infonnation provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator ame (Printed) Signature 
Date Site Number 
CONFIDE TIAL Page 98 21 March 2018 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 99 21 March 2018Appendix 2. Study Procedures Tabl e
Visit Window (Days)Blinded Treatment PhaseExtended Blinded 
Treatm ent PhaseEnd of 
Study
Unscheduled 
Visit 
(exacerbation 
of LMN
)fScreenaD1/
BaselineWeek 
1Weeks 2, 4, 8, 12, 
18, 20, 24, 28Week 
16bWeek 
32cWeeks 36,
40, 44, 48Week
52 F/UdETe
-35 0 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5
Written Informed 
ConsentX
Medical History , 
including kidney biopsy 
reportX
Revie w 
Inclusion/Exclusion 
CriteriaX X
Randomization X
Height X
Weight X X X X X X X X X X
Com plete Physical 
ExaminationX X X
Symptom -driven 
Physical ExaminationgX X X X X X X X
2 Morning voids &
24-hour Urine CollectionhXhXhXhXhXhXh
UrinalysisiX X X X X X X X X
SELENA -SLEDAIj, bbX X X X X X X
BILAGk, bbX X X X X
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 100 21 March 2018Visit Window (Days)Blinded Treatment PhaseExtended Blinded 
Treatm ent PhaseEnd of 
Study
Unscheduled 
Visit 
(exacerbation 
of LMN)fScreenaD1/
BaselineWeek 
1Weeks 2, 4, 8, 12, 
18, 20, 24, 28Week 
16bWeek 
32cWeeks 36,
40, 44, 48Week
52 F/UdETe
-35 0 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5
Patient Global 
Assessment of disease 
activityl, bbX X X X X
Physician Global 
Assessment of disease 
activitym, bbX X X X X
36-Item Short Form 
Health SurveybbX X X X X
Vital SignsnX X X X X X X X X X X
ECG X X X X X X
Hem atology X X X X X X X X X X
Serum Chemistry X X X X X X X X X X
Fasting Lipids X X X X
Coagulation X X X X X X X X X X
HbA 1cand TSH X
CRP and ESR X X X X X X X X X X
Quantitative Serum 
Immunoglobulin TestX XccXdd
Autoantibody Panel & 
Com plement LevelsX X XzX X X X X
Serum Pregnancy TestoX
Urine Pregnancy Testo, pX X X X X X X X X X
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 101 21 March 2018Visit Window (Days)Blinded Treatment PhaseExtended Blinded 
Treatm ent PhaseEnd of 
Study
Unscheduled 
Visit 
(exacerbation 
of LMN)fScreenaD1/
BaselineWeek 
1Weeks 2, 4, 8, 12, 
18, 20, 24, 28Week 
16bWeek 
32cWeeks 36,
40, 44, 48Week
52 F/UdETe
-35 0 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5
FSH TestqX
HIV-1/2, HBV, HCV 
SerologyX
HCV RNA VLrX X X X X X X X X X
QuantiFERON®TB 
Gold in Tube TestsX
Chest X -RaysX
Plasma PK SampletX X X
Urine PK SamplesuX
Whole Blood TBNK 
Biomarker SampleX X XxX X X X X
Serum Biomarker 
SampleX X XxX X X X X
Plasma Biomarker 
SampleX X XxX X X X X
vfPBMC Sample X X XxX X X X X
PAXgene RNA Sample X X XxX X X X X
CCI
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 102 21 March 2018Visit Window (Days)Blinded Treatment PhaseExtended Blinded 
Treatm ent PhaseEnd of 
Study
Unscheduled 
Visit 
(exacerbation 
of LMN)fScreenaD1/
BaselineWeek 
1Weeks 2, 4, 8, 12, 
18, 20, 24, 28Week 
16bWeek 
32cWeeks 36,
40, 44, 48Week
52 F/UdETe
-35 0 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5
Urine Biomarker 
SampleX X XxX X X X X
In-Clinic Study Drug 
AdministrationyX X X X
Study Drug 
AccountabilityX X X X X X X
Study Drug Dispensing X XaaX X X
Revie w AEs & 
Concomitant 
MedicationsX X X X X X X X X X X
a Prospective subjects should be screened no more than 35days prior to the administration of the first dose of study treatment .The Screening visit will take two separate days to 
complete. In addition, Screening Day 2 cannot occur earlier than 3 days after Screening Day 1 due to the timing of the morning urine voids and the 24 hour urine collection. 
b Urinary protein excretion will be determined using 2 methods –2 consecutive morning voids as well as a 24 -hour urine collection. For the Baseline assessment, all 3 urine 
samples will be collected prior to Day 1, with the 24-hour urine collection as close to the Day 1 visit as possible. At Week 16, the primary study endpoint will be assessed by 
urine protein excretion during a 24-hour urine collection. Two consecutive morning voids prior to the Week 16 visit will be used to determine response for subseq uent study 
treatment. A ll subjects who achieve a ≥ 35% reduction in urinary protein excretion (using an average of the UPCR from the morning voids) from Baseline (Day 1) will 
continue to receive their assigned blinded study treatment (filgotinib 200 mg + PTM GS-9876, or GS -9876 30 mg + PTM filgotinib) for an additional 16 weeks. Subjects who 
do not achieve a ≥ 35% reduction in urinary protein excretion from Baseline (Day 1) to Week 16 will switch study treatment for 16 weeks in a blinded fashion (ie, those on 
filgotinib will switch to GS-9876 + PTM filgotinib, while those on GS -9876 will switch to filgotinib + PTM GS -9876)
c After 32 weeks of blinded treatment, those who have a ≥ 35% reduction in urinary protein excretion (using an avera ge of the UPCR from 2 morning voids) from Day 1
(forsubjects who remained on the randomized study treatment after Week 16) or from Week 16 ( for subjects who switched treatment at Week 16) will continue their assigned 
blinded treatment for an additional 20 weeks in the Extended Blinded Treatment Phase.  Subjects that do not achieve a ≥ 35% reduction in urinary protein excretion f rom 
Day 1 (for subjects who remained on the randomized study treatment after Week 16) or from Week 16 (for subjects who switched t reatment at Week 16) to Week 32 will be 
allowed to continue whichever treatment led to the greatest reduction in urinary protein excretion (from Day 1 to Week 16 on initial study tr eatment or from Week 16 to 
Week 32 on switched treatment) , or either study treatment per the Investigator’s discretion during the Extended Blinded Treatment Phase.
d T he Follow -up (FU) Visit as detailed in the End of Study section of the Study Procedures Table will be completed 4 weeks after the last dose of study treatment . For su bjects 
that complete the entire study, the FU visit will be conducte d at Week 56 .
e
Subjects who discontinue from the study for any reason will complete the Early Termination (ET) Visit at the time of study discontinuation . 
f Subjects seen at an unscheduled visit for disease exacerbation (worsening of proteinuria, and/or decrease in eGFR) will complete the Unscheduled Visit assessments.
g Symptom -driven physical examinations will be performed, as needed, based on reported signs and symptoms.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 103 21 March 2018h Urinary protein excr etion will be determined using 2 consecutive morning voids as well as a 24 -hour urine collection. 
-For the Day 1 assessment, all 3 urine samples will be collected prior to Day 1, with the 24- hour urine collection as close to the Day 1 visit as possible. 
-For Week 16, subjects will submit 2 consecutive morning urine void samples to the study center approximately 7days prior to the Week 16 visit to test their change in 
urinary protein excretion.  Subjects will also submit a 24 -hour urine collection that is collected immediately prior to the Week 16 vi sit, or as close to the Week 16 visit as 
possible. These results will inform their treatment assignment for the additional 16 weeks.
-For Week 32, subjects will submit 2 consecutive morning urine void samples to the study center approximately 7days prior to the Week 32 visit to test their change in 
urinary protein excretion.  Subjects will also submit a 24 -hour urine collection that is collected immediately prior to the Week 32 visit, or as close to the Week 32 visit as 
possible. These results will inform their treatment assignment for the additional 20 weeks in the Extended Blinded Treatment Phase.
i The urinalysis will include urine microscopy and spot protein -to-creatinine ratio. As contamination by menstrual blood may interfere with the primary endpoint, whether or 
not the patient is menstruating will be recorded on the CRF; microscopic urine examination will evaluate for active urine sediment (any of:  > 5 WBC/hpf [pyuria], 
>
5 RBC/hpf [hematuria], or red cell casts in the absence of infection or other causes). In such circumstances, investigators may ask patients to return for another screening 
visit.
j Safety of Estrogens in Lupus Erythematosus National Assessment trial-based SLE Disease Activity Index (SELENA-SL EDAI)
k British Isles Lupus Activity Group (BILAG ) 
l Patient global assessment of disease activity 
m Physician global assessment of SLE disease activity 
n Vital signs include resting blood pressure, respiratory rate, heart rate, and body temperature. 
o Females of childbearing potential only.
p If a urine pregnancy test is positive, study drug should be immediately interru pted and the subject should return to the site for a serum pregnanc y test to confirm result.
q Females of nonchildbearing potential only.
r Subjects with positive HCV Ab, but negative HCV RNA VL at Screening are eligible per investigator judgment, but require ongoi ng monitoring during the study.
s Subjects previously treated fo r latent TB or active TB described in Inclusion # 17do not need to have the QuantiFERON®TB-Gold In -Tube test (or equivalent assay) 
obtained, but a chest radiograph must be obtained if not done so within 3 months prior to screening (with the report or films available for investigator review). All other 
subjects must have the QuantiFERON®TB-Gold In -Tube test (or equivalent assay) obtained at screening AND a chest radiograph (views as per local guidelines) taken at 
screening or within the 3 months prior to screening (with the report or films available for investigator review).
t Blood samples wil l be collected for plasma PK analysis of filgotinib and its active metabolite GS -829845, and GS-9876 post dose at Weeks 2, 4 and 20 (at least 30 minutes 
and up to 3 hours after dosing), anytime at Weeks 8 and 24, and within 2 hours prior to dosing at Weeks 16 and 32.
u Urine PK analyses will be collected for GS -9876, filgotinib and its active metabolite, GS -829845, using the 24h urine collection at Week 16.
 
 
  
x Biomarker assessments will be c ollected at Week 2 only.
y At Weeks 2, 4, and 20, subjects will be instructed to take their study drug in clinic as the first study procedure prior to a ny others scheduled for that visit. At Day 1, and 
Weeks 16 and 32 ,subjects will be instructed to take their study drug after predose assessments have been completed (eg, 2 hours afte r PK sample collection at Weeks 16 
and32).
z Autoantibod y panel and complement levels will be collected at Weeks 2, 4, and 8only.
aa Study drug will be not be dispensed at Week s 2and 18 .
bb Questionnaires will be administered where available.
cc Quantitative serum immunoglobulin testing will be performed at Week 8 and 24 only.
dd Quantitative serum immunoglobulin testing will be performed at Week 48 only.
CCII 
I 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 104 21 March 2018Appendix 3. Management of Clinical and Laboratory Adverse Events
* Refer to Sections 3.5and7.6for details
Grade 1 
~-Gr-ade-2 _ I .___I _Gr-ade-3 _____.I .___I --G-ra-de 4 _ _____, 
May continue Repeat lab to 
dosing at the confirm toxicity 
discretion of the grade 
investigator 
, 
If confirmed and possibly and/or probably related to 
investigational medicinal products: 
1. Withhold investigationa l medicinal products until 
:,; Grade 2 
2. Rest.art all investi1rntional medicinal oroducts at full dose 
l 
If Grade 3 or 4 recurrence that is confirmed and possibly or 
probably related to investigational medicinal products, 
discontinue all investigational medicinal products dosing 
oermanentlv l Repeat lab to 
confirm toxicity 
grade 
l 
If c onfirmed and unrelated to 
estigational medicinal inv 
pro 
the ducts, dosing may continue at 
discretion of the investigator If confirmed and 
possibly or probably 
related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently 
and follow at 
periodic intervals at 
least weekly until a 
return to baseline or 
is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all 
invcstigational medicina l products at the same dose at the 
discretion of the investigator 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 105 21 March 2018Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Please refer to the Common Termi nology  Criteria for Adverse Events (CTCAE) Version 4.03, 
which can be found at:
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010
-06-14_QuickReference_8.5x11.pdf 
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
The only  modification to the CTCAE criteria is the addition of a Grade 1 upper respiratory  
infection as f ollows:
CTCAE 
v4.03
Term Grade 1
Grade 2 Grade 3 Grade 4 Grade 5CTCAE v4.03 
AE Ter m 
Definition
Upper 
respiratory 
infectionMild symptoms; 
symptomatic 
relief (eg, cough 
suppressant, 
decongestant)Moderate 
symptoms; 
oral 
intervention 
indicated 
(eg,antibiotic, 
antifungal, 
antiviral)IV antibiotic, 
antifungal, 
orantiviral 
intervention 
indicated; 
radiologic, 
endoscopic, 
oroperative 
intervention 
indicatedLife-
threatening 
consequences; 
urgent 
intervention 
indicatedDeath A disorder 
characterized by 
an infectious 
process 
involving the 
upper respiratory 
tract 
(nose, paranasal 
sinuses, pharynx, 
larynx, 
ortrachea).
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 106 21 March 2018Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
The administration of filgotinib in embry o-fetal animal development studies resulted in 
decreased numbers of viable rat fetuses, increased resorptions, and visceral and skeletal 
malformations. Similar effects were noted in the rabbit. A safet ymargin relative to human 
exposure has not been identified. Therefore, filgotinib iscontraindicated during pregnancy .
Relevant non -clinical reproductive toxicity  studies of GS -
9876 did not have findings that raise a 
strong suspicion 
forhuman teratogenici ty/fetotoxicity .  The re is no data from pregnant women 
who have taken GS -9876.
For participation in this study , the use of highly effective contraception is required as outlined 
below for all subjects of childbearing potential. In addition, women of childbearing potential 
should have a urine pregnancy  test every  4 weeks during the study .
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiatio n of pubert y (Tanner stage 2) until becoming post -menopausal, 
permanentl y sterile or with medically documented ovarian failure. Women who do not meet 
below criteria for being post- menopausal, are not permanentl y sterile, or do not have medicall y 
documented ovarian failure must have pregnancy  testing as outlined by  the protocol. 
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women < 54 years of age with amenorrhea of >12 months may  also be considered 
postmenopausal if their FSH level is in the postmenopausal range and they  are not using 
hormonal contraception or hormonal r eplacement therap y.
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.  Bilateral tubal ligation is not considered 
permanent sterilization.
b)Definition of Male Fertility
For the purposes of this study, a male -born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchiectomy or has medical documentation of 
permanent male infertility. Vasectom y is not considered permanent steriliz ation.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 107 21 March 20182)Contraception for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
Filgotinib is contraindicated in pregnancy as there is a possibility  of human 
teratogenicit y/fetotoxicity  in earl y pregnancy based on non- clinical data. Data from a drug -drug 
interaction study  of filgotinib and hormonal contraceptives demonstrated thatfilgotinib d oesnot 
alter the pharmacokinetics of representative hormonal contraceptives levonorgestrel/ethiny l 
estradiol . 
GS-9876 has not been studied in pre gnant women. There is no evidence of human teratogenicit y 
based on class effects or genotoxic potential. Relevant non -clinical reproductive toxicity  studies 
of GS -9876 did not have findings that raise a strong suspicion for human 
teratogenicit y/fetotoxicit y. In vitro dr
ug interaction assessment of GS -9876 and hormonal 
contraceptives suggests that there is no clinicall y relevant effects that would decrease
contraception efficacy . 
For male subjects, male condom should be used; for their female partners of ch ildbearing 
potential, an accepted contraceptive method should also be considered. Details are outlined 
below.
Please refer to the latest version of the IBs for filgotinib and GS -9876 for additional information.
b)Contraception for Female Subjects of Childbea ring Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. Women of childbearing potential must have a negative serum pregnancy  
test at screening and a negative urine pregnancy  test at the Day  1 visit prior to randomization. 
Pregnancy  tests will be performed at monthly  intervals thereafter. In the event of a delayed 
menstrual period (>
onemonth between menstruations), a pregnancy  test must be performed to 
rule out pregnancy . This i s true even for women with infrequent or irregular periods. Female 
subjects must agree to use one of the following methods from screening until 36 days following 
the last dose of study  drug :
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below: 
Intrauterine device (IUD) with a failu re rate of < 1% per year
Tubal sterilization
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 108 21 March 2018Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or
Female subjects who wish to use a hormonall y based method must use it in conjunction with 
a barrier method, preferably  a male condom.  Female subjects who utilize a hormonal 
contraceptive as one of their birth control methods must have consistently  used th e same 
method for at least three months prior to study  drug dosing.  Hormonall y -based 
contraceptives and barrier methods permitted for use in this protocol are as follows:
Barrier methods (each method must be used with a hormonal method)
■Male condom (with or without spermicide)
■ Female condom (with or without spermicide)
■ Diaphragm with spermicide
■Cervical cap with spermicide
■ Sponge with spermicide
Hormonal methods (each method must be used with a barrier method, preferably  male 
condom)
■Oral contraceptives (e ither combined or progesterone only )
■Injectable progesterone
■Subdermal contraceptive implant
■Transdermal contraceptive patch
■Contraceptive vaginal ring
All female subjects must also refrain from egg donation and in vitro fertilization during the study  
and until 36 day s after the last study  drug dose.
3) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant concentration of study  drug may  be achieved in a 
female partner from exposure to the male subject’s seminal fluid. There fore, male subjects with 
female partners of childbearing potential must use condoms during stud y participation and for 
90days after the last study  drug dose. Female partners of male study  subjects should consider 
using one of the above methods of contrace ption as well. Male subjects must also refrain from 
sperm donation during the study  and until 90 days after the last dose of study  drug.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 109 21 March 20184) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calenda r, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM). Female condom and male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 36 day s of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the s tudy must report the 
information to the investigator and discontinue all study  drugs immediatel y. Male subjects whose 
partner has become pregnant or suspects she is pregnant during the stud y or up to 90 days after 
the last dose of study  drug are to report the information to the investigator immediately .
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section 7.7.2.1.
6)Pregnancy Testing
All females of childbearing potential will have urine pregnancy  testing every  4weeks during the 
study . If a positive urine pregnancy  test is reported, the female subject 
should stop all study  
drugs and return to the clinic for a serum pregnancy  test.
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 110 21 March 2018Appe ndix 6. Clinical Laboratory Assessment Table
Hem atology Chemistry Urin e Other
White blood cell (WBC) 
count
Hem atocrit
Hem oglobin
Red blood cell (RBC) 
count
Red blood cell indices
Platelet count
Differentials (absolute 
and percentage), 
including:
Lymphocytes
Monocytes
Neutrophils
Eosinophils
Basophils
Reticulocyte countAlkaline phosphatase
Aspartate aminotransferase 
(AST)
Alanine aminotransferase 
(ALT)
Gamma -glutamyl 
transpeptidase (GGT)
Total bilirubin
Direct and indirect bilirubin
Total protein
Albumin
Bicarbonate
Blood urea nitrogen (BUN)
Calcium
Chloride
Creatinine
Creatinine clearance1
Glucose
Phosphorus
Magnesium
Potassium
Sodium
Creatine Phosphokinase 
(CPK)
Amylase
Lipase
Uric acid (at screening only)Appearance
Blood
Color
Dipstick
  Glucose
  Specific gravity
  Nitrites
  Leukocyte esterase
  pH
  Protein
  Urobilinogen
Reflex to microscopic 
urinalysis if dipstick result 
is abnormal.
Spot urine protein and 
creatinine (for UPCR)
24-hour urine for protein 
and creatinin eQuantiFERON®TB –
Gold 
In-Tube Analysis (if 
required per inclusion 
criteria; at screening only )
FSH (as applicable ; at 
screening only )
HbA1c (at screening only)
TSH (at screening only)
C-reactive protein (CRP) 
Erythrocyte sedimentation 
rate (ESR)
Quantitative 
immunoglobulins (IgG, 
IgM, and IgA)
Autoantibody panel (ANA2
with reflex ENA3[dsDNA4, 
Sm5, RNP6, SSA, and 
SSB])
Com plement levels (C3, 
C4, and CH50)Virology
Hepatitis B surface antigen 
(HBsAg)
Hepatitis B virus (HBV) 
core antibody
HBV DNA (reflex)
Hepatitis C Virus (HCV) 
Ab (if positive, then reflex 
HCV RNA)
HCV Viral Load (if 
applicable)
Human immunodeficiency 
virus 1 and 2 Ab
Coagulation Fasting Lipids Pregnancy
Activated partial 
thromboplastin time 
(aPTT)
Prothrombin time 
International normalized 
ratio (INR)Total cholesterol
Low-density lipoprotein 
(LDL)
High -density lipoprotein 
(HDL)
TriglyceridesIn females of childbearing 
potential:
Serum pregnancy test
Urine pregnancy test
Estimated glomerular filtration rate based on the MDRD formulation (eGFR MDRD )
ANA = antinuclear antibody 
ENA = extractable nuclear antigen 
dsDNA = double stranded DNA
Sm = Smith antigen
RNP =  ribonucleo protein 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 111 21 March 2018Appendix 7. Safety of Estrogens in Lupus Erythematosus Nat ional Assessment 
trial-based Systemic Lupus Erythematosus Disease Activity Index
(SELENA -SLEDAI)
Hybrid SELENA SLEDAI with SELENA SLEDAI FLARE INDEX and PGA 
(Circle in SLE':DAI Scor e column if desc riptor is presen t at the lime of the visit or in the preced ing 4 weeks) 
Item Check Score Descriptor Definition 
no. if active 
1 8 Seizure Recen t onset , exclude metabolic , infectious or drug causes 
2 8 Psychosis Altered ability to funct ion in normal activity due to seve re disturbance in the 
perception of reality. Include hallucinations , incoherence , marked loose 
associations , impoverished thought content , marked illogical thinking, bizarre , 
disorganized , or cataton ic behavior. Exclude uremia and drug causes 
3 8 Organic Altered mental function with impaired orien tation, memory , or other intellectual 
brain function , with rapid onset and fluctuating clinical featu res, inability to susta in 
syndrome attention to environmen t, plus at least 2 of the follow ing: perceptual 
disturbance , incohere nt speech , insomn ia or daytime drows iness , increased or 
decreased psychomotor activity. Exclude metabo lic, infectious or drug causes 
4 8 Visual Retinal changes of SLE. Include cytoid bodies , retinal hemo rrhages, serous 
disturbance exudates or hemo rrhages in the choroid , or optic neur itis, scleritis or 
episc leritis. Exclude hype rtension, infection, or dr ug causes 
5 8 Cranial nerve New onse t of sensory or motor neuropathy involving cranial nerves 
disorder 
6 8 Lupus Severe, persisten t headache ; may be migrainous , but must be nonresponsive 
headache to narcot ic analgesia THIS WOULD RARELY BE ATTR IBUTED TO 
SLE. .. ALMOST NEVER SCOR ED 
7 8 CVA New onset Cerebrovascu lar accide nt(s). Exclude arteriosclerosis 
8 8 Vasculitis Ulcera tion, gang rene, tender finge r nodu les, periu ngual infarction, splinter 
hemorrhages or biopsy or a ngiogram proof of vascul itis 
9 4 Arthritis > 2 joints with pain and si gns of inflammation (Le. tenderness with swelling or 
effusion) 
10 4 Myos itis Proximal musc le aching/wea kness , assoc iated with elevated creatinine 
phosphokinase (CK)/aldolase, or EMG changes or a biopsy showing myositis 
11 4 Urina ry casts Heme-granu lar or RBC casts 
12 4 Hematur ia > 5 RBC/high power field. Exclude stone , infection or ot her cause 
13 4 Proteinu ria More than 0.5 gm/24 hours . 
14 4 Pyuria > 5 WBC/ high powe r field. Exclude infection 
15 2 Rash Inflamma tory type rash 
16 2 Alopecia Abnorma l, patchy or diff use loss of hair 
17 2 Mucosal Oral or nasa l ulcerations 
ulcers 
18 2 Pleurisy Pleuritic chest pain or pleural rub or effus ion, or pleural thickening (does not 
require an objective component if medica lly conv incing) 
19 2 Pericarditis Classic pericardia! pain and/o r rub, effusion or ECG or echocardiogram 
confi rmation (does not requ ire an objective component if medically convincing) 
20 2 Low Decrease in CH 50, C3 or C4 < lower limit of nl for testing labora tory 
complement 
21 2 Increased Increased DNA binding above normal range for testing laboratory 
DNA bindi ng 
22 1 Feve r > 38°C . Exclude infectio us cause 
23 1 Thrombocyto < 100 x 109 platelet s/L, exclude drug causes 
penia 
24 1 Leukopenia < 3 x 109 WBC/L, exclude drug causes 
Total SCORE 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 112 21 March 2018Appendix 8. British Isles Lupus Activity Group (BILAG) Index
BILAG2004 INDEX 
Only rKord it doc to SU: Diaaa At:Ciritr • 11 
n·ffks (c,ompared mtb the pnrio 
Sccmg: ND ·• DHt l llllprv . 
2 Saa 
3 w ... 
4 
Yes/No OR. Vllat (1rUR illdiafM) 
~= ir aia.JIIIIL~w..lll.lUllU. 
CONSTTIUITO i\l. 
L P,u!m -clDcmm!ll!d :> 37 .SWC 
Weigbr kiss- . . :> ~. 
3. I yrrc,hadf!nnp>dty/5J1 11moJC!lfl,ltly 
ADlllml 
MUCoct.r'TA.l'\'EOUS s. ·!nlpOIIII - ~ 
Ci. • empliaa -Did 
7 .~ --
1. ~. mild 
9. . --10 
I) PlmlicalmsllJu!klllS 
12 u. 
14. 
15.Alop«ia--
l Alopma-mild 
l .~l!r}'tleD,' 
11.Splim!rhHrwmi!a 
:>TlJROPS\ •cmaDJc 
19 A5i!p:ic lll!lringuu 
10.Cermral --
ll.Dml) .. 
l2 MJ!lapldly 
23. Am- cmfnSXINJ SD12 
P5ydlom 
25 Aas- in&mrnmry demytlin,uing ~y 
l6 M~ (.siqle'llmlllpla ) ( 
1 7. Cnmill D!lmlpillhJ ( 
lS ( 
29 PalJ"llll!llnl!imhT ( 
30 Sl'lZ1!R disardff ( 
31.S ( 
32 Catbruvasailll disBif (DDt ID VtiOilitis ) ( 
33. c.o~ dys:6.111,.lian ( 
34.MCM!lll!llldismla" ( 
35 Au!anamic clilCIIM ( 
36 Cm . ('ISO ( 
37 bsd.lcbe - - 111:Rm:DDII.I: ( 
31. BeadK.be fnDI ICbJpe1m.sioa ( 
Ill\mon: 1 00 ) 
) 
) 
) 
) 
) 
) 
) 
i 
) 
) 
) 
) mt miu· s to m:mifi tatio oc,cuning m the 1a.aJ. 
CAJIDlORESl'lRATOltY 
44. Myoanfms -mild c 
4S.M~-Clnli.acfaillm ( 
46. Amrydm:u ( 
47.Nrw\~ ( s Pl!miiy ,Pl!l1cmfiis ( 
9. Cardiac. lllllpOnade ( 
SO. ( 
SL Pulmmw}' ( s ImmitilJ ( 
S3Sbrimq s)'lllllrtmt ( 
S-tAmtim ( 
SS. CGnmlryl ( 
CASTRO ill:STINAL 
SCi. LDpa.s pem .. 
S7 • .Abdmmml saasins ar Bile5 
SI. Lupas l'llll'rim lmJilu 
S9.MallbsofpliDD 
60. Pracen ming emm,pllhJ 
61. ]ISl!lldD-obsmlcaaD 
62. LDpas bepmtis 
63 Aau Jupu dio 
64. Aaft Jupupancr&1ilis 
PfHJJWWf 
65. 0ma.l ~O&is 
66.KIDlil:is-~ 
67. &mlilis • Alll!l:i« .. 
69. POJlmar ~nlillll · !11!11!11! 
0. Posimar muis.ln!in&l · · • mild 
71. f.4iisd!rilis 
2.Sdams-smn 
13. Scl.m!is • mild 
4. R.smal tcbamidal-«.CD.11Wclisase 
7S . ho. mean J (cymid · ) 
76. 0pci.t llellliris 
77. Ammar iscllMlmc optic lll'IRpalhy 
RENAL 
~'5tnlir bJoodpm~ (mm Hg) \\WI! 
9. • b prtS5lft (111111 \'WI' 
80. Aculmt!d lrJpmmsian Yes/No ( 
81. Urin! dipmck (=I. ++cl.+++=] ) ( 
8 UriDI! . . aoo I( u. Urine pm mio ( 
84. ham: llllllt pml!!:iD 00 \'WI! ( 
85. Yesi'No ( 
86. Cretinme {pb!;ma.\sermll) pl!IQL1 ( 
87.GfR(w:w.ac .131111 ( 
81. .Aai\11! !ldimm Yes/No ( 
89. Aaiw aepmUis Yai'No ( 
JWMAIPLOGlfAL 
90. ~m(g 'dl) 
91 Toal · cell caam ( 10'11) 
92. (1. 10'!1) 
93. LyUljlhKJtes (11: 10 II) 
94. ('& 10'11) 
95. TIP 
96. E\!idei:n of ldiw 
97. Coombs ' es1 posuiw (i \ ( 
\'WI! ( 
\lllm ( 
\'WI! ( 
\'WI! ( 
( 
Yts'No ( 
Yes.· ( ) 
) 
) 
) 0 
) 0 
) 0 
) 0 
) 
) 0 
) 0 
) 
) 
) 0 
) 0 
) 0 
) 
) 0 
) 
) 
) 
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 113 21 March 2018Appendix 9. Physician’s Global Assessment of Disease Activity
A horizontal visual analog scale will be used to record the ph ysician’s assessment of the patient’s 
LMN disease activity .
Instructions: 
Place a mark on the line below to indicate the subject’s current LMN disease activity 
(independent of the subject’s self -
assessment):
No LMN disease activity                                                                                 Maximum  LMN disease a ctivity
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 114 21 March 2018Appendix 10. Patient Global Assessment of Disea se Activity
A horizontal, visual analog scale will be used to provide the subject’s overall assessment of 
LMN disease activity .
Instructions:
Place a mark on the line below to indicate how active your lupus has been over the 
last
week:
I have no lupus                                 I have the worst lupus
GS-9876/Filgotinib
Protocol GS -US-437-4093 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 115 21 March 2018Appendix 11. 36- Item Short Form Health Survey
 
SF-36v2® Health Survey © 1992, 1996, 2000 Medical Outcomes Trust and Quality Metric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey Standard , United States (English))  
 
Your Health and Well-Being 
 
 
This survey asks for your views about you r health.  This information will help 
keep track of how you feel and how well you  are able to do your usual activities. 
Thank you for completing this survey!  
 
For each of the following questions, please mark an  in the one box that best 
describes your answer. 
 
1. In general, would you say your health is: 
Excellent Very good Good Fair Poor      
   1    2    3    4    5 
 
 
 
2. Compared to one year ago , how would you rate your health in general 
now? 
Much better 
now than one 
year ago Somewhat 
better  
now than one 
year ago About the 
same as  
one year ago Somewhat 
worse  
now than one 
year ago Much worse 
now than one 
year ago 
     
   1    2    3    4    5 
 
 
SF-36v2® Health Survey © 1992, 1996, 2000 Medical Outcomes Trust and Quality Metric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey Standard , United States (English)) 3. The following questions are about activities you might do during a typical 
day.  Does your health now limit you  in these activities?  If so, how much?  
 
  Yes,  
limited  
a lot Yes, 
limited  
a little No, not 
limited  
at all 
   
 a Vigorous activities , such as running, lifting  
heavy objects, participating in strenuous sports ......................  1 .............  2 .............  3 
 b Moderate activities , such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf ............................ 1 .............  2 ............. 3
 c Lifting or carrying groceries ....................................................  1 .............  2 .............  3 
 d Climbing several  flights of stairs .............................................  1 .............  2 .............  3 
 e Climbing one  flight of stairs ....................................................  1 .............  2 .............  3 
 f Bending, kneeling, or stooping ................................................  1 .............  2 .............  3 
 g Walking more than a mile  ........................................................  1 .............  2 .............  3 
 h Walking several hundred yards  ...............................................  1 .............  2 .............  3 
 i Walking one hundred yards  .....................................................  1 .............  2 .............  3 
 j Bathing or dressing yourself ....................................................  1 .............  2 .............  3 
 
SF-36v2® Health Survey © 1992, 1996, 2000 Medical Outcomes Trust and Quality Metric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey Standard , United States (English)) 4. During the past 4 weeks , how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health ? 
 All of  
the time Most of 
the time Some of  
the time A little of 
the time None of 
the time 
      
 a Cut down on the amount of   
time you spent on work or  
other activities .................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 b Accomplished less  than you  
would like ........................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 c Were limited in the kind  of  
work or other activities ....................  1 ..............  2 ..............  3 ..............  4 .............  5 
 d Had difficulty  performing the  
work or other activities (for  
example, it took extra effort) ...........  1 ..............  2 ..............  3 ..............  4 .............  5 
 
 5. During the past 4 weeks
, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems  (such as feeling depressed or anxious)? 
 All of  
the time Most of 
the time Some of  
the time A little of 
the time None of 
the time 
      
 a Cut down on the amount of   
time you spent on work or  
other activities .................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 b Accomplished less  than you  
would like ........................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 c Did work or other activities  
less carefully than usual  ...................  1 ..............  2 ..............  3 ..............  4 .............  5 
 
SF-36v2® Health Survey © 1992, 1996, 2000 Medical Outcomes Trust and Quality Metric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey Standard , United States (English)) 6. During the past 4 weeks , to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbors, or groups? 
Not at all Slightly Moderately Quite a bit Extremely      
   1    2  3  4    5 
     7. How much bodily
 pain have you had during the past 4 weeks ? 
None Very mild Mild Moderate Severe Very severe       
   1    2  3  4  5    6 
     8. During the past 4 weeks
, how much did pain  interfere with your normal 
work (including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely      
   1    2  3  4    5 
 
SF-36v2® Health Survey © 1992, 1996, 2000 Medical Outcomes Trust and Quality Metric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey Standard , United States (English)) 9. These questions are about how you feel and how things have been with you 
during the past 4 weeks .  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time 
during the past 4 weeks … 
  
10. During the past 4 weeks
, how much of the time has your physical health or 
emotional problems  interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
All of  
the time Most of  
the time Some of  
the time A little of  
the time None of  
the time      
   1    2  3  4    5  All of  
the time Most of  
the time Some of 
the time A little of the 
time None of 
the time 
      
 a Did you feel full of life? ..................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Have you been very nervous? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Have you felt so down in the  
dumps that nothing could  cheer you up? ...................................
 1 ..............  2 ..............  3 ..............  4 ..............  5
 d Have you felt calm and   peaceful? ..........................................
 1 ..............  2 ..............  3 ..............  4 ..............  5
 e Did you have a lot of energy? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 f Have you felt downhearted  and depressed? .................................
 1 ..............  2 ..............  3 ..............  4 ..............  5
 g Did you feel worn out? ....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 h Have you been happy? .....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 i Did you feel tired? ...........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 
SF-36v2® Health Survey © 1992, 1996, 2000 Medical Outcomes Trust and Quality Metric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey Standard , United States (English)) 11. How TRUE or FALSE is each  of the following statements for you? 
 Definitely 
true Mostly  
true Don’t  
know Mostly  
false Definitely 
false      
 a I seem to get sick a little 
easier than other people ..................  1 ..............  2 .............  3 ..............  4 ..............  5
 b I am as healthy as  
anybody I know ..............................  1 ..............  2 .............  3 ..............  4 ..............  5
 c I expect my health to  get worse ......................................... 
 1 ..............  2 .............  3 ..............  4 ..............  5 
 d My health is excellent .....................  1 ..............  2 .............  3 ..............  4 ..............  5
 
      
Thank you for completing these questions!  